Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.5.1.98 - histone deacetylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type fatty-acyl-coa transporter deficiency
Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.
Aberrant Crypt Foci
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
Abortion, Spontaneous
Downregulation of HDAC8 expression decreases CD163 levels and promotes the apoptosis of macrophages by activating the ERK signaling pathway in recurrent spontaneous miscarriage.
Acanthamoeba Keratitis
Application of histone deacetylase inhibitors MPK472 and KSK64 as a potential treatment option for Acanthamoeba keratitis.
Achondroplasia
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Acidosis
Sodium butyrate attenuated iE-DAP induced inflammatory response in the mammary glands of dairy goats fed high-concentrate diet.
Acne Vulgaris
Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes.
Acquired Immunodeficiency Syndrome
Establishment and application of a flow cytometry-based method for detecting histone acetylation levels.
Passport control for foreign integrated DNAs: An unexpected checkpoint by class II HDAC4 revealed by amino acid starvation.
Acrocephalosyndactylia
A contiguous gene deletion neighboring TWIST1 identified in a patient with Saethre-Chotzen syndrome associated with neurodevelopmental delay: possible contribution of HDAC9.
ACTH-Secreting Pituitary Adenoma
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Acute Coronary Syndrome
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Acute Kidney Injury
2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
2-methylquinazoline derivative F7 as a potent and selective HDAC6 inhibitor protected against rhabdomyolysis-induced acute kidney injury.
A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.
Acute Kidney Injury Results in Long-Term Diastolic Dysfunction That Is Prevented by Histone Deacetylase Inhibition.
Alpha-2 adrenoceptor agonist-dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5.
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
Downregulation of miR-29b-3p aggravates podocyte injury by targeting HDAC4 in LPS-induced acute kidney injury.
HDAC inhibitors in kidney development and disease.
Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-? and EGFR signaling pathways in obstructive nephropathy.
Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells.
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury.
The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury.
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Time-dependent effects of histone deacetylase inhibition in sepsis-associated acute kidney injury.
Acute Lung Injury
Cigarette Smoke Disrupted Lung Endothelial Barrier Integrity and Increased Susceptibility to Acute Lung Injury via Histone Deacetylase 6.
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Histone Deacetylase 7 In Murine Gram-Negative Acute Lung Injury.
Histone Deacetylase 7 Inhibition in A Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.
Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice.
Histone Deacetylase Inhibitors Attenuate Acute Lung Injury During Cecal Ligation and Puncture-Induced Polymicrobial Sepsis.
Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.
miR-23b Attenuates LPS-Induced Inflammatory Responses in Acute Lung Injury via Inhibition of HDAC2.
Adenocarcinoma
(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC?1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
2,4?Di?tert?butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells.
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors.
Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.
Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics.
Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line.
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.
Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.
Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.
Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Predicting chemotherapeutic drug combinations through gene network profiling.
RAR? acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Adenocarcinoma of Lung
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways.
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.
HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.
Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells.
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Retraction.
SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women.
Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Up-regulation of IRF-3 expression through GATA-1 acetylation by histone deacetylase inhibitor in lung adenocarcinoma A549 cells.
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
[Relationship between expression of HDAC2, IL-8, TNF-? in lung adenocarcinoma tissues and smoking].
Adenocarcinoma, Follicular
Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.
Adenoma
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Regulation of prostaglandin transporters in colorectal neoplasia.
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Adenomatous Polyposis Coli
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Histone deacetylase expression in white matter oligodendrocytes after stroke.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Adenomyosis
Elevated Immunoreactivity against Class I Histone Deacetylases in Adenomyosis.
Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent.
Adenoviridae Infections
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
The adenovirus-2 E1B-55K protein interacts with a mSin3A/histone deacetylase 1 complex.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Adrenal Gland Neoplasms
Management of patients with adrenal cancer: recommendations of an international consensus conference.
Adrenocortical Carcinoma
Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells.
Adrenoleukodystrophy
HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
African Swine Fever
Analysis of HDAC6 and BAG3-aggresome pathways in African swine fever viral factory formation.
Agenesis of Corpus Callosum
De novo satellited 2q associated with corpus callosum dysgenesis, short stature, mental retardation and developmental delay.
Albuminuria
HDAC6-mediated ?-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy.
Alexander Disease
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant.
Alopecia
Disrupted Ectodermal Organ Morphogenesis in Mice with a Conditional Histone Deacetylase 1, 2 Deletion in the Epidermis.
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.
alpha-Thalassemia
The expanding phenotypes of cohesinopathies: one ring to rule them all!
alpha-tubulin n-acetyltransferase deficiency
MEC-17 Deficiency Leads to Reduced ?-Tubulin Acetylation and Impaired Migration of Cortical Neurons.
Alveolar Bone Loss
Histone deacetylase inhibitors and periodontal bone loss.
Alzheimer Disease
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
3,4-Dihydroxyphenylethanol Assuages Cognitive Impulsivity in Alzheimer's Disease by Attuning HPA-Axis via Differential Crosstalk of ?7 nAChR with MicroRNA-124 and HDAC6.
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Action of trichostatin A on Alzheimer's disease-like pathological changes in SH-SY5Y neuroblastoma cells.
An epigenetic blockade of cognitive functions in the neurodegenerating brain.
Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression.
Bioinformatics methods in drug repurposing for Alzheimer's disease.
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Discovery of in-vivo chemical probes for treating Alzheimer´s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitors.
Effect of C-phycocyanin on HDAC3 and miRNA-335 in Alzheimer's disease.
Effects of velvet antler polypeptides on Alzheimer's disease cell model via miR-613 HDAC6 pathway.
Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against A? toxicity in a mouse model of Alzheimer's disease.
Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer's disease.
HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.
HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
HDAC6 regulates mitochondrial transport in hippocampal neurons.
Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Histone Deacetylase Inhibitor Alleviates the Neurodegenerative Phenotypes and Histone Dysregulation in Presenilins-Deficient Mice.
Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner.
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.
Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A?-induced impaired axonal transport.
Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer's Disease in vitro Model.
Jatrorrhizine can improve nerve cell injury induced by A? 25-35, acting through miR-223-3p/HDAC4 axis.
L1CAM Beneficially Inhibits Histone Deacetylase 2 Expression under Conditions of Alzheimer's Disease.
Loss of HDAC5 Impairs Memory Function: Implications for Alzheimer's Disease.
MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration.
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model.
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric A?25-35 -induced anxiety and cognitive deficits in a mouse model.
Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease.
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Novel Histone Deacetylase 6 Inhibitors for Treating Alzheimer's Disease and Cancer.
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.
Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.
PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6.
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Re-exploring the core genes and modules in the human frontal cortex during chronological aging: insights from network-based analysis of transcriptomic studies.
Recent studies on cellular and molecular mechanisms in Alzheimer's disease: focus on epigenetic factors and histone deacetylase.
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease.
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Sirtuin 3 mRNA Expression is Downregulated in the Brain Tissues of Alzheimer's Disease Patients: A Bioinformatic and Data Mining Approach.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression.
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Targeting Class I Histone Deacetylases in a "Complex" Environment.
Targeting HDACs: a promising therapy for Alzheimer's disease.
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
The glial-specific hypermethylated 3' untranslated region of histone deacetylase 1 may modulates several signal pathways in Alzheimer's disease.
The role of ATM and DNA damage in neurons: upstream and downstream connections.
The Role of HDAC6 in Alzheimer's Disease.
The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons.
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Treatment with Histone Deacetylase Inhibitor Attenuates Peripheral Inflammation-Induced Cognitive Dysfunction and Microglial Activation: The Effect of SAHA as a Peripheral HDAC Inhibitor.
Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
[Epigenetics and etiology of neurodegenerative diseases].
Amyloidosis
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Amyotrophic Lateral Sclerosis
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence.
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis.
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
HDAC6 is a Bruchpilot deacetylase that facilitates neurotransmitter release.
HDAC6 maintains mitochondrial connectivity under hypoxic stress by suppressing MARCH5/MITOL dependent MFN2 degradation.
Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis.
Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis.
Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes.
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.
Therapeutic potential of HDAC6 in amyotrophic lateral sclerosis.
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Anaphylaxis
DNA methyl transferase I acts as a negative regulator of allergic skin inflammation.
Fc?RI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein.
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Anemia
Assessing new therapies and their overall impact in myelofibrosis.
Role of stem cell factor in the reactivation of human fetal hemoglobin.
Anemia, Hemolytic
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
Anemia, Refractory
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Refractory, with Excess of Blasts
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Sickle Cell
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Role of stem cell factor in the reactivation of human fetal hemoglobin.
Aneurysm
An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm.
Aneurysm, Dissecting
Downregulation of HDAC1 suppresses media degeneration by inhibiting the migration and phenotypic switch of aortic vascular smooth muscle cells in aortic dissection.
HDAC6 is associated with the formation of aortic dissection in human.
Anhedonia
Valproic acid administration exerts protective effects against stress-related anhedonia in rats.
Anthrax
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.
Inhibition of IL-1? Expression by Anthrax Lethal Toxin is Reversed by HDAC8 Inhibition in Murine Macrophages.
Inhibition of interleukin 1? (IL-1?) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages.
Aortic Aneurysm, Abdominal
A Novel Histone Deacetylase Inhibitor Reduces Abdominal Aortic Aneurysm Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice.
Aortic Valve Stenosis
Histone deacetylase 6 reduction promotes aortic valve calcification via an endoplasmic reticulum stress-mediated osteogenic pathway.
Apnea
Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure.
Arrhythmias, Cardiac
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
Arteriosclerosis
Epigenetics in Vascular Disease - Therapeutic Potential of New Agents.
Arthritis
A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.
Epigenetics of inflammatory arthritis.
Genome-wide expression and methylation profiling reveal candidate genes in osteoarthritis.
HDACi and Nrf2: not from alpha to omega but from acetylation to OA.
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis.
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice.
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Histone deacetylases in RA: epigenetics and epiphenomena.
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors.
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Suberoylanilide Hydroxamic Acid Attenuates Autoimmune Arthritis by Suppressing Th17 Cells through NR1D1 Inhibition.
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
Arthritis, Experimental
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis.
Histone deacetylase 1 is increased in rheumatoid arthritis synovium and promotes synovial cell hyperplasia and synovial inflammation in the collagen-induced arthritis mouse model via the microRNA-124-dependent MARCKS-JAK/STAT axis.
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Arthritis, Juvenile
Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors.
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Arthritis, Rheumatoid
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
AAA-ATPase p97 suppresses apoptotic and autophagy-associated cell death in rheumatoid arthritis synovial fibroblasts.
Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.
Histone deacetylase 1 is increased in rheumatoid arthritis synovium and promotes synovial cell hyperplasia and synovial inflammation in the collagen-induced arthritis mouse model via the microRNA-124-dependent MARCKS-JAK/STAT axis.
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-{kappa}B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients.
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.
Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
Largazole, a class I histone deacetylase inhibitor, enhances TNF-?-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.
MicroRNA-449 targets histone deacetylase 1 to regulate the proliferation, invasion, and apoptosis of synovial fibroblasts in rheumatoid arthritis.
miR-138 activates NF-?B signaling and PGRN to promote rheumatoid arthritis via regulating HDAC4.
Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
Reduced Activity of HDAC3 and Increased Acetylation of Histones H3 in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis.
Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells.
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
Trichostatin A cooperates with fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts.
Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling.
Aspergillosis
Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.
Asthma
Activation of AMPK inhibits TGF-?1-induced airway smooth muscle cells proliferation and its potential mechanisms.
Asthma in smokers: challenges and opportunities.
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management.
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
CpG oligodeoxynucleotides attenuate ROR?t-mediated Th17 response by restoring histone deacetylase-2 in cigarette smoke-exposure asthma.
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.
Effects of Macrolide and Corticosteroid in Neutrophilic Asthma Mouse Model.
Epigenetic regulation of airway inflammation.
Epigenetics and chromatin remodeling play a role in lung disease.
Epigenetics in asthma and other inflammatory lung diseases.
Expression and activity of histone deacetylases in human asthmatic airways.
Genome-wide interaction study reveals age-dependent determinants of responsiveness to inhaled corticosteroids in individuals with asthma.
Glucocorticoid receptor ? and histone deacetylase 1 and 2 expression in the airways of severe asthma.
HDAC4 induces the development of asthma by increasing Slug-upregulated CXCL12 expression through KLF5 deacetylation.
HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization.
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice.
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma.
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Histone deacetylase inhibitors: can we consider potent anti-neoplastic agents for the treatment of asthma?
Histone deacetylase-2 and airway disease.
Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions.
Histone deacetylation: an important mechanism in inflammatory lung diseases.
How corticosteroids control inflammation: Quintiles Prize Lecture 2005.
Identification of differentially expressed genes associated with asthma in children based on the bioanalysis of the regulatory network.
Impact of gene expression associated with glucocorticoid-induced transcript 1 (GLCCI1) on severe asthma and future exacerbation.
Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma.
Inflammation 2005 - Seventh World Congress. Respiratory inflammation.
Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma.
Low-level laser therapy suppresses the oxidative stress-induced glucocorticoids resistance in U937 cells: relevance to cytokine secretion and histone deacetylase in alveolar macrophages.
MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2.
Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
Pathogenesis of severe asthma.
PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma.
PM2.5 exposure and cold stress exacerbates asthma in mice by increasing histone acetylation in IL-4 gene promoter in CD4+ T cells.
Potential non-oncological applications of histone deacetylase inhibitors.
Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease.
Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma.
Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma.
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma.
Soluble fibre supplementation with and without a probiotic in adults with asthma: A 7-day randomised, double blind, three way cross-over trial.
Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma.
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease.
The influence of smoking on the treatment response in patients with asthma.
The role of HDAC2 in cigarette smoke-induced airway inflammation in a murine model of asthma and the effect of intervention with roxithromycin.
The role of histone deacetylases in asthma and allergic diseases.
Theophylline.
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Therapeutic effects of histone deacetylase inhibitors in a murine asthma model.
Treating patients with respiratory disease who smoke.
Treatment with 1,25(OH)2D3 induced HDAC2 expression and reduced NF-?B p65 expression in a rat model of OVA-induced asthma.
Trichostatin A Abrogates Airway Constriction, but not Inflammation in Mouse and Human Asthma Models.
Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models.
USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation.
[Characteristics of histone deacetylase 9 in peripheral blood of patients with bronchial asthma].
[Roles of histone acetyltransferase and histone deacetylase in the pathogenesis of bronchial asthma].
[Therapeutic effects of histone deacetylase inhibitor givinostat on air inflammation and high airway resistance in a murine asthma model].
[Therapeutic effects of Tubastatin A Hcl on airway inflammation in acute mice asthma model].
Astrocytoma
Abnormal methylation of histone deacetylase genes: implications on etiology and epigenetic therapy of astrocytomas.
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours.
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.
The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Ataxia
Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
The double dealing of cyclin D1.
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Ataxia Telangiectasia
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response.
DDIT4 gene expression is switched on by a new HDAC4 function in ataxia telangiectasia.
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.
Modulation of chromatin conformation by the histone deacetylase inhibitor trichostatin A promotes the removal of radiation-induced lesions in ataxia telangiectasia cell lines.
Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia.
Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.
Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia.
Atherosclerosis
ApoE-/- PGC-1?-/- Mice Display Reduced IL-18 Levels and Do Not Develop Enhanced Atherosclerosis.
Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort.
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Endothelial-Specific Overexpression of Histone Deacetylase 2 Protects Mice against Endothelial Dysfunction and Atherosclerosis.
Enhancing PPAR? by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice.
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1.
Estrogen-SIRT1 Axis Plays a Pivotal Role in Protecting Arteries Against Menopause-Induced Senescence and Atherosclerosis.
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS.
HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter.
HDAC1-mediated deacetylation of HIF1? prevents atherosclerosis progression by promoting miR-224-3p-mediated inhibition of FOSL2.
HDAC1: an environmental sensor regulating endothelial function.
HDAC3 inhibitor suppresses endothelial-to-mesenchymal transition via modulating inflammatory response in atherosclerosis.
HDAC3 protects against atherosclerosis through inhibition of inflammation via the microRNA-19b/PPAR?/NF-?B axis.
HDAC9 regulates ox-LDL-induced endothelial cell apoptosis by participating in inflammatory reactions.
HDAC9: An Inflammatory Link in Atherosclerosis.
Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow.
Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype.
Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development.
Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation.
Inhibition of miR?34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis.
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
Interfering microRNA-410 attenuates atherosclerosis via the HDAC1/KLF5/IKB?/NF-?B axis.
Involvement of the Antioxidant Effect and Anti-inflammatory Response in Butyrate-Inhibited Vascular Smooth Muscle Cell Proliferation.
Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations.
LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6.
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
MicroRNA-200b-3p promotes endothelial cell apoptosis by targeting HDAC4 in atherosclerosis.
miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.
New role for histone deacetylase 9 in atherosclerosis and inflammation.
Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis.
Protein kinase B mediates insulin-like growth factor 1-induced phosphorylation and nuclear export of histone deacetylase 5 via NADPH oxidase 4 activation in vascular smooth muscle cells.
Role of histone deacetylase Sirt3 in the development and regression of atherosclerosis.
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Ionomycin.
Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice.
Atrial Fibrillation
Chronic HDAC6 Activation Induces Atrial Fibrillation Through Atrial Electrical and Structural Remodeling in Transgenic Mice.
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes.
Genetic Risk Factors for Ischemic and Hemorrhagic Stroke.
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Atrioventricular Block
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Atypical Squamous Cells of the Cervix
MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.
Autoimmune Diseases
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus.
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Effects of trichostatin A in a rat model of acute graft-versus-host disease after liver transplantation.
Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review.
Global expression and CpG methylation analysis of primary endothelial cells before and after TNFa stimulation reveals gene modules enriched in inflammatory and infectious diseases and associated DMRs.
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Histone Deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant Natural Killer T Cells.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice.
Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Autoimmune Lymphoproliferative Syndrome
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Bacteremia
Histone Deacetylase 6 Inhibition Improves Survival in a Swine Model of Lethal Hemorrhage, Polytrauma and Bacteremia.
Bacterial Infections
Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections.
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
beta-Thalassemia
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Bicuspid Aortic Valve Disease
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Biliary Tract Neoplasms
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Blast Crisis
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia.
Blindness
HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Selective Histone Deacetylase 6 Inhibitors Restore Cone Photoreceptor Vision or Outer Segment Morphology in Zebrafish and Mouse Models of Retinal Blindness.
Blister
Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid.
Bloom Syndrome
Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor.
Bone Diseases
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Bone Diseases, Metabolic
Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells.
Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion.
miR-4286 functions in osteogenesis and angiogenesis via targeting histone deacetylase 3 and alleviates alcohol-induced bone loss in mice.
Bone Marrow Failure Disorders
Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.
Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.
Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development.
Bone Neoplasms
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring ?-opioid receptor in spinal cord.
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
[Early intervention of bone-nearby acupuncture combined with electroacupuncture on morphine tolerance in bone cancer pain rats and its effect on the expression of HDAC and MOR in dorsal root ganglia].
Bone Resorption
Blueberry juice protects osteocytes and bone precursor cells against oxidative stress partly through SIRT1.
Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro.
Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.
HDAC2 Regulates FOXO1 during RANKL-Induced Osteoclastogenesis.
Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.
HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered ?-catenin switch.
HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPAR?/RANKL Signaling.
Histone deacetylase 3 is required for maintenance of bone mass during aging.
SIKs control osteocyte responses to parathyroid hormone.
Brachydactyly
Dose dependent expression of HDAC4 causes variable expressivity in a novel inherited case of brachydactyly mental retardation syndrome.
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.
Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4.
Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.
The first familial case of inherited 2q37.3 interstitial deletion with isolated skeletal abnormalities including brachydactyly type E and short stature.
Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.
[Analysis of clinical phenotypes and genetic variations in a Chinese family affected with craniofacial and skeletal deformities].
Bradycardia
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome.
Brain Concussion
Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats.
Brain Diseases
A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests.
Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target.
Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy.
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats.
Targeting the correct HDAC(s) to treat cognitive disorders.
Brain Edema
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
[Protective effect of the histone deacetylase inhibitor ACY1215 against brain edema in mice with acute liver failure].
Brain Infarction
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of ?-tubulin acetylation and FGF-21 up-regulation.
Brain Injuries
Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.
Early Histone Deacetylase Inhibition Mitigates Ischemia/Reperfusion Brain Injury by Reducing Microglia Activation and Modulating Their Phenotype.
HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.
HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1.
Histone deacetylase 6 interference protects mice against experimental stroke-induced brain injury via activating Nrf2/HO-1 pathway.
Inhibition of HDAC4 Attenuated JNK/c-Jun-Dependent Neuronal Apoptosis and Early Brain Injury Following Subarachnoid Hemorrhage by Transcriptionally Suppressing MKK7.
Inhibition of HDAC6 expression decreases brain injury induced by APOE4 and A? co?aggregation in rats.
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Magnolol attenuates the inflammation and apoptosis through the activation of SIRT1 in experimental stroke rats.
Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury.
Protective effects of histone deacetylase inhibition by Scriptaid on brain injury in neonatal rat models of cerebral ischemia and hypoxia.
The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia.
Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats.
[Regulatory mechanism of MS275 on the p38 MAPK signaling pathway in rats with convulsion in the developmental stage].
Brain Injuries, Traumatic
Brain proteomic changes by histone deacetylase inhibition after traumatic brain injury.
Corrigendum: HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Development of a novel neuroprotective strategy: combined treatment with hypothermia and valproic acid improves survival in hypoxic hippocampal cells.
Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage.
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.
Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
Modulation of Brain Transcriptome By Combined Histone Deacetylase Inhibition and Plasma Treatment Following Traumatic Brain Injury and Hemorrhagic Shock.
Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway : scriptaid protects against TBI via AKT.
Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock.
Brain Ischemia
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke.
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia.
HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis.
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Molecular switching from ubiquitin-proteasome to autophagy pathways in mice stroke model.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Neuroprotective effects of histone deacetylase inhibitors in brain ischemia.
Overexpressed microRNA-539-5p inhibits inflammatory response of neurons to impede the progression of cerebral ischemic injury by histone deacetylase 1.
Protective effects of ex-527 on cerebral ischemia-reperfusion injury through necroptosis signaling pathway attenuation.
Protective effects of histone deacetylase inhibition by Scriptaid on brain injury in neonatal rat models of cerebral ischemia and hypoxia.
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
The Emerging Role of Epigenetics in Cerebral Ischemia.
The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain.
The role of histone deacetylase inhibitors in regulation of Akt/GSK-3? signaling pathway in mice following transient focal cerebral ischemia.
Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Brain Neoplasms
A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis resistant mammary and brain cancer stem cells thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex.
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity.
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.
NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells.
Novel histone deacetylase inhibitors for the treatment of pediatric brain tumors.
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Breast Neoplasms
17?AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA?MB?231 breast cancer cells.
18F-Fluoroestradiol (18F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
?-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382.
A genomic approach to predict synergistic combinations for breast cancer treatment.
A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells.
A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
A role for paralog-specific sumoylation in histone deacetylase 1 stability.
A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy.
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex.
Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin-An Isobolographic Analysis in Breast Cancer In Vitro Models.
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Aromatase inhibitors and xenograft studies.
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.
ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion.
Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.
Bioimpedance rise in response to histone deacetylase inhibitor is a marker of mammary cancer cells within a mixed culture of normal breast cells.
Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER? coinhibition.
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex.
Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene.
CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Co-exposure to BPA and DEHP enhances susceptibility of mammary tumors via up-regulating Esr1/HDAC6 pathway in female rats.
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
Combination of Histone Deacetylase Inhibitor with Cu(II) 5,5-diethylbarbiturate Complex Induces Apoptosis in Breast Cancer Stem Cells: A Promising Novel Approach.
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells.
Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor.
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Decrease in Cell Viability of Breast Cancer Cells by a Di-Hydroxylated Derivative of N-(2-hydroxyphenyl)-2-Propylpentanamide.
Defining the Role of Histone Deacetylases in the Inhibition of Mammary Carcinogenesis by Dietary Energy Restriction (DER): Effects of Suberoylanilide Hydroxamic Acid (SAHA) and DER in a Rat Model.
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1? synthesis, and decreases breast cancer metastasis.
Dietary polyphenols may affect DNA methylation.
Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin.
Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.
Differential Regulation of Estrogen Receptor ? Expression in Breast Cancer Cells by Metastasis-Associated Protein 1.
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells.
Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells.
Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells.
Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
EFFECTS OF THE PESTICIDE CHLORPYRIFOS ON BREAST CANCER DISEASE. IMPLICATION OF EPIGENETIC MECHANISMS.
Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells.
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells.
Endocrine resistant breast cancer cells with loss of ER? expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-propylpentanamide, a Valproic Acid Aryl Derivative with activity against HeLa cells.
Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells.
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Epigenetic silencing of the tumor suppressor klotho in human breast cancer.
Epigenetic targeting in breast cancer: therapeutic impact and future direction.
Epigenetic Therapy in Breast Cancer.
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer.
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Function of Histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR.
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells.
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8.
HDAC1 was involved in placental breast cancer resistance protein regulation in vitro: A preliminary study.
HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
HDAC3 increases HMGB3 expression to facilitate the immune escape of breast cancer cells via down-regulating microRNA-130a-3p.
HDAC3 regulates stability of estrogen receptor ? mRNA.
HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
HDAC6 deacetylates survivin for its nuclear export in breast cancer.
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.
HDAC6 expression is correlated with better survival in breast cancer.
HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration.
HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3?/Snail signals.
HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human breast cancer cells.
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Histone deacetylase inhibitor- and PMA-induced upregulation of PMCA4b enhances Ca2+ clearance from MCF-7 breast cancer cells.
Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells.
Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines.
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties.
Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells through WNT/?-catenin Signaling.
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Histone deacetylase inhibitors: the Abbott experience.
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.
Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.
Hyaluronate synthase-2 overexpression alters estrogen dependence and induces histone deacetylase inhibitor-like effects on ER-driven genes in MCF7 breast tumor cells.
Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line.
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor.
Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1.
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells.
Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
Isolation, purification and characterization of naturally derived Crocetin beta-d-glucosyl ester from Crocus sativus L. against breast cancer and its binding chemistry with ER-alpha/HDAC2.
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.
Methylation of C/EBP? by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Methylomics of breast cancer: Seeking epimarkers in peripheral blood of young subjects.
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells.
MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression.
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression.
Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.
Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells.
Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.
Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Moscatilin Suppresses the Breast Cancer Both In Vitro and In Vivo by Inhibiting HDAC3.
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7.
NEDD9 Regulates Actin Dynamics through Cortactin Deacetylation in an AURKA/HDAC6-dependent Manner.
Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cells.
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Novel hybrid conjugates with dual estrogen receptor ? degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells.
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.
p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells.
Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Phthalates Stimulate the Epithelial to Mesenchymal TransitionThrough an HDAC6-Dependent Mechanism in Human BreastEpithelial Stem Cells.
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells.
Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence.
Pubertal supplementation of lipotropes in female rats reduces mammary cancer risk by suppressing histone deacetylase 1.
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin a on the energy metabolism of breast cancer cells.
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
Regulation of estrogen receptor ?1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer.
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
Retraction Note: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
Retraction: Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines.
Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Shear stress stimulates integrin ?1 trafficking and increases directional migration of cancer cells via promoting deacetylation of microtubules.
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
SMAR1 repression by pluripotency factors and consequent chemoresistance in breast cancer stem-like cells is reversed by aspirin.
SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation.
Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Sp1-mediated TRAIL induction in chemosensitization.
SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment.
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Sulforaphane Decrease of SERTAD1 Expression Triggers G1/S Arrest in Breast Cancer Cells.
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Synergistic epigenetic reactivation of estrogen receptor-? (ER?) by combined green tea polyphenol and histone deacetylase inhibitor in ER?-negative breast cancer cells.
Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
Targeting triple negative breast cancer with histone deacetylase inhibitors.
Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1.
The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells.
The clinical significance of histone deacetylase-8 in human breast cancer.
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor ? expression.
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.
The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer.
The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
The hopeful anticancer role of oleuropein in breast cancer through histone deacetylase modulation.
The Immunohistochemical Expression and Potential Prognostic Value of HDAC6, AR in Invasive Breast Cancer.
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ER? expression and enhances hormonal therapy for breast cancer.
The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
The role of HDAC6 in cancer.
The role of histone deacetylase inhibitors in metastatic breast cancer.
The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression.
The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2.
The Tumor Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the Beta-catenin Coactivator BCL9-2 in Breast Cancer Cells.
The ZNF750-RAC1 axis as potential prognostic factor for breast cancer.
Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor.
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.
Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.
Trichostatin A enhances acetylation as well as protein stability of ER alpha through induction of p300 protein.
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer.
Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells.
Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect.
Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
WITHDRAWN: Cross-talk between Wnt and hypoxia signaling pathways in breast cancer cells: Dual role of HDAC1 and beta-catenin.
ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
[Expression of melanoma-associated antigen-C2 in breast cancers and mechanism].
[In vitro study about the inhibitory effect of CDAII in combination with sodium butyrate on breast cancer cells.]
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
[Sodium valproate enhances doxorubicin cytotoxicity in breast cancer cells in vitro].
Bronchitis
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Bronchopulmonary Dysplasia
Lipopolysaccharide Induces Up-Regulation of TGF-? through HDAC2 in a Rat Model of Bronchopulmonary Dysplasia.
Burkitt Lymphoma
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation.
HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle.
Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.
Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Camurati-Engelmann Syndrome
The new bone biology: pathologic, molecular, and clinical correlates.
Canavan Disease
Acetate supplementation induces growth arrest of NG2/PDGFR?-positive oligodendroglioma-derived tumor-initiating cells.
Candidiasis
Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.
Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Carcinogenesis
A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer.
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chromatin remodeling, cancer and chemotherapy.
Cloning, purification, crystallization and preliminary crystallographic analysis of the human histone deacetylase sirtuin 1.
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer.
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter.
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1.
Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model.
Epigenetic actions of environmental factors and promising drugs for cancer therapy.
Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction.
Epigenetic therapy in human choriocarcinoma.
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Expression profile of histone deacetylase 1 in gastric cancer tissues.
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Functional analysis of a histone deacetylase-like protein of Thermus caldophilus GK24 in mammalian cell.
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.
Genome-wide characterization of lncRNAs in acute myeloid leukemia.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and ?-tubulin acetylation.
HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
HDAC2 links ubiquitination to tumor suppression in synovial sarcoma.
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2.
HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer.
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.
HDAC6 and Ovarian Cancer.
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
HDAC8 drives spindle organization during meiotic maturation of porcine oocytes.
HDAC8: a multifaceted target for therapeutic interventions.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Histone deacetylase 1 phosphorylation at S421 and S423 is constitutive in vivo, but dispensable in vitro.
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1.
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Histone deacetylase 8 in neuroblastoma tumorigenesis.
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis.
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Immune modulation underpins the anti-cancer activity of HDAC inhibitors.
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis.
Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy.
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Induction of a novel histone deacetylase 1/c-Myc/Mnt/Max complex formation is implicated in parity-induced refractoriness to mammary carcinogenesis.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.
Integrated analysis of lncRNA and mRNA repertoires in Marek's disease infected spleens identifies genes relevant to resistance.
Investigation of sirtuin 1 polymorphisms in relation to the risk of colorectal cancer by molecular subtype.
Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway.
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation.
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
miR-543 promotes gastric cancer cell proliferation by targeting SIRT1.
miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth.
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges.
Never in mitosis gene A-related kinase 6 and aurora kinase A: New gene biomarkers in the conversion from ulcerative colitis to colorectal cancer.
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2.
Pin1 Is Involved in HDAC6-mediated Cancer Cell Motility.
Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy.
Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Regulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders.
Role of SIRT1 in homologous recombination.
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis.
Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cell.
Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
SIRT1 regulates UV-induced DNA repair through deacetylating XPA.
SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer.
SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression.
Sirtuin 1 promotes autophagy and proliferation of endometrial cancer cells by reducing acetylation level of LC3.
SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation.
Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo.
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma.
The biology of HDAC in cancer: the nuclear and epigenetic components.
The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage.
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression.
The role of butyrate in surgical and oncological outcomes in colorectal cancer.
The role of HDAC6 in cancer.
The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer.
The therapeutic properties of resminostat for hepatocellular carcinoma.
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.
Transcription factors as therapeutic targets in lymphoid malignancies.
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Carcinoid Tumor
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors.
Suberoyl bishydroxamic Acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Carcinoma
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
?Np63? promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
A histone deacetylase inhibitor, trichostatin a, enhances radiosensitivity by abrogating g2/m arrest in human carcinoma cells.
A novel long noncoding RNA, LOC440173, promotes the progression of esophageal squamous cell carcinoma by modulating the miR-30d-5p/HDAC9 axis and the epithelial-mesenchymal transition.
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Activation of PAR4 Upregulates p16 through Inhibition of DNMT1 and HDAC2 Expression via MAPK Signals in Esophageal Squamous Cell Carcinoma Cells.
Activation of the gamma-glutamyltransferase promoter 2 in the rat colon carcinoma cell line CC531 by histone deacetylase inhibitors is mediated through the Sp1 binding motif.
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity.
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
BORIS in human cancers - A review.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.
Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer.
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid.
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.
Conjugate of Pt (IV)-Histone Deacetylase Inhibitor as Prodrug for Cancer Chemotherapy.
Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Differential protein acetylation induced by novel histone deacetylase inhibitors.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor.
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line
Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Effect of histone deacetylase on prostate carcinoma.
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.
Effective and new potent drug combination: Histone deacetylase and Wnt/?-catenin pathway inhibitors in lung carcinoma cells.
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Effects of Down-regulation of HDAC6 Expression on Proliferation, Cell Cycling and Migration of Esophageal Squamous Cell Carcinoma Cells and Related Molecular Mechanisms.
Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: A systematic review and meta-analysis.
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Epigenetic control of HNF-4? in colon carcinoma cells affects MUC4 expression and malignancy.
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation.
Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression.
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
HDAC1 regulates the chemosensitivity of laryngeal carcinoma cells via modulation of interleukin-8 expression.
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression.
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism.
HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer.
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5?2 signaling pathway.
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase in chronic lymphocytic leukemia.
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma.
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Histone deacetylase inhibitor for NUT midline carcinoma.
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Histone deacetylase inhibitor OBP?801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1?dependent apoptosis.
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression.
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.
Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo.
Histone deacetylase inhibitors: the Abbott experience.
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors.
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells.
Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).
Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression.
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma.
Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.
L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatins.
Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells.
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number.
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells.
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Rapid detection of apoptosis through real-time reverse transcriptase polymerase chain reaction measurement of the small cytoplasmic RNA Y1.
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Retracted: Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro.
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response.
Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA).
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Sumoylation of HDAC2 promotes NF-?B-dependent gene expression.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells.
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
[Effect of down-regulation of histone deacetylase 2 protein expression on cell proliferation and cell cycle in cervical carcinoma].
[Effect of HDAC6 down-regulation on the growth of xenografted human laryngeal carcinoma cell line Hep-2 in nude mice and underlying mechanism].
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
[Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780]
[Linkage of Drug Resistance and Metabolome Shift in Renal Cell Carcinoma Cells].
[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
[Role of histone deacetylase in inhibiting invasion of human gastric carcinoma cell line SGC-7901 by PPARgamma-mediated pathway.]
Carcinoma, Basal Cell
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Carcinoma, Ductal
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas.
The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ.
Carcinoma, Embryonal
A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells.
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment.
Carcinoma, Hepatocellular
1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression.
A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF-?B-dependent pathway in hepatocellular carcinoma.
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid.
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2.
Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3? activation.
Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model.
C/EBP? negatively regulates SIRT7 expression via recruiting HDAC3 to the upstream-promoter of hepatocellular carcinoma cells.
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells.
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Clinical significance of HDAC9 in hepatocellular carcinoma.
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.
Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients.
Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate.
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.
Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.
Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells.
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Enrichment of Nur77 mediated by retinoic acid receptor ? leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.
Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Erratum: LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Expression of HDAC4 in Stage B Hepatocellular Carcinoma and Its Influence on Survival.
Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells.
HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
Hdac3 is essential for the maintenance of chromatin structure and genome stability.
HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression.
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
HDAC9 Is Preferentially Expressed in Dedifferentiated Hepatocellular Carcinoma Cells and Is Involved in an Anchorage-Independent Growth.
Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.
Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1? under hypoxia condition.
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: Chemoimmunotherapeutic perspective and prospects.
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells.
Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression.
Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1.
HOXD3 was negatively regulated by YY1 recruiting HDAC1 to suppress progression of hepatocellular carcinoma cells via ITGA2 pathway.
Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells.
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Identification of a TGF-?-miR-195 positive feedback loop in hepatocytes and its deregulation in hepatoma cells.
Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
IFN-? inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver.
IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a.
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Inhibition of autophagy signi?cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Inhibitory effects of 1,25(OH)2D3 on the proliferation of hepatocellular carcinoma cells through the downregulation of HDAC2.
Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells.
Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation.
lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity.
LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells.
lncRNA-SNHG15 accelerates the development of hepatocellular carcinoma by targeting miR-490-3p/ histone deacetylase 2 axis.
LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.
miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[(18)F]-fluorothymidine PET.
mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells.
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Network pharmacology predicted HDAC6 as a potential target of flavones from Daphne giraldii on hepatocellular carcinoma.
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II? degradation in hepatocellular carcinoma cells.
Nuclear distribution of histone deacetylase: a marker enzyme for the internal nuclear matrix.
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma.
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Pharmacological inhibition of HDAC1/3-interacting proteins induced morphological changes, and hindered the cell proliferation and migration of hepatocellular carcinoma cells.
Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation.
PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction.
Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors.
Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
Radiosensitizing Effect of a Phenylbutyrate-derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma.
Repression of the miR-627-5p by histone deacetylase 3 contributes to hypoxia-induced hepatocellular carcinoma progression.
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Retraction: Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma.
RGFP966 Suppresses Tumor Growth and Migration Through Inhibition of EGFR Expression in Hepatocellular Carcinoma Cells in vitro.
Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components.
Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells.
Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells.
Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Targeting HDAC6 Reprograms TH 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
The Effects of 5-Aza-2'-Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line.
The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling.
The ménage à trois of autophagy, lipid droplets and liver disease.
The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines.
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Trichostatin A sensitizes hepatoma cells to Taxol more than 5-Aza-dC and dexamethasone.
Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex.
Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma.
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
[Inhibition of curcumin on histone deacetylase and expression promotion of P21 (WAF1/CIP1) in HepG2 cells]
[RNA interference of HDAC7 expression in hepatocellular carcinoma.]
Carcinoma, Intraductal, Noninfiltrating
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ.
Carcinoma, Large Cell
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Carcinoma, Merkel Cell
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Carcinoma, Mucoepidermoid
Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells.
Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas.
Carcinoma, Non-Small-Cell Lung
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells.
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer.
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Pax5 Re-Expression In H460 Cells Treated With The Combination Of Demethylating Agent And Histone Deacetylase Inhibitor Is Associated With The Enhancement Of P53 Binding To Pax5 Promoter Region.
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells.
Sodium Valproate Sensitizes Non-Small Lung Cancer A549 Cells to ?? T-Cell-Mediated Killing through Upregulating the Expression of MICA.
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells.
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.
Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.
Carcinoma, Renal Cell
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Combining Histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: A systematic review and meta-analysis.
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors.
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
[Linkage of Drug Resistance and Metabolome Shift in Renal Cell Carcinoma Cells].
Carcinoma, Small Cell
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Carcinoma, Squamous Cell
?Np63? promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells.
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Carcinoma, Transitional Cell
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Retracted: Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro.
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Cardio-Renal Syndrome
Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress.
Cardiomegaly
Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
CaMKII exacerbates heart failure progression by activating class I HDACs.
CAMTA in cardiac hypertrophy.
Casein Kinase-2 Interacting Protein-1 Regulates Physiological Cardiac Hypertrophy via Inhibition of Histone Deacetylase 4 Phosphorylation.
Casein kinase-2?1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.
CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A.
Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes.
Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.
Dichotomy of Ca in the heart: contraction versus intracellular signaling.
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Effect of the angiotensin II receptor blocker valsartan on cardiac hypertrophy and myocardial histone deacetylase expression in rats with aortic constriction.
Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts.
Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.
HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage.
HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity.
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.
Histone Deacetylase Inhibition Attenuates Cardiac Hypertrophy and Fibrosis through Acetylation of Mineralocorticoid Receptor in Spontaneously Hypertensive Rats.
Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.
Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy.
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2.
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Integrated mechanisms of CaMKII-dependent ventricular remodeling.
Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy.
Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice.
Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Overexpression of peptidase inhibitor 16 attenuates angiotensin II-induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts.
Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3? signaling pathway.
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
Potential non-oncological applications of histone deacetylase inhibitors.
PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.
Regulation of Acetylation of Histone Deacetylase 2 by p300/CBP-Associated Factor/Histone Deacetylase 5 in the Development of Cardiac Hypertrophy.
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway.
Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.
Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats.
STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.
Suppression of HDAC Nuclear Export and Cardiomyocyte Hypertrophy by Novel Irreversible Inhibitors of CRM1.
The black sheep of class IIa: HDAC7 SIKens the heart.
The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin.
The role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
[The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
Cardiomyopathies
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Diet-induced lethality due to loss of HDAC3 in heart and skeletal muscle.
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes.
The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.
Cardiomyopathy, Dilated
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Cardiotoxicity
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.
Cardiovascular Diseases
Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1.
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells.
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Hdac9 inhibits medial artery calcification through down-regulation of Osterix.
Histone deacetylase 5 interacts with Krüppel-like factor 2 and inhibits its transcriptional activity in endothelium.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats under Pressure Overload.
Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.
Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment.
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3? signaling pathway.
Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway.
SIRT3 attenuates AngII-induced cardiac fibrosis by inhibiting myofibroblasts transdifferentiation via STAT3-NFATc2 pathway.
Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells.
Sirtuin 1 rs1467568 and rs7895833 in South African Indians with early-onset coronary artery disease.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.
Carotid Artery Diseases
Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort.
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Cataract
Effects of microRNA-211 on proliferation and apoptosis of lens epithelial cells by targeting SIRT1 gene in diabetic cataract mice.
MiR-22-3p inhibits fibrotic cataract through inactivation of HDAC6 and increase of ?-tubulin acetylation.
Cell Transformation, Neoplastic
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Central Nervous System Diseases
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Cerebral Hemorrhage
HDAC inhibition reduces white matter injury after intracerebral hemorrhage.
Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice.
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice.
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Cerebral Infarction
Extracellular Vesicle-Derived microRNA-410 From Mesenchymal Stem Cells Protects Against Neonatal Hypoxia-Ischemia Brain Damage Through an HDAC1-Dependent EGR2/Bcl2 Axis.
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Cerebrovascular Disorders
Correlation between Histone Deacetylase 9 and Regulatory T Cell in Patients with Chronic Heart Failure.
Histone deacetylase 9 inhibition upregulates microRNA-92a to repress the progression of intracranial aneurysm via silencing Bcl-2-like protein 11.
Charcot-Marie-Tooth Disease
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT.
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Cheilitis
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Chickenpox
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Cholangiocarcinoma
Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1? for Intrahepatic Cholangiocarcinoma.
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth.
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells.
Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
SPRR2a enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity.
Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
TGF-?1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.
Choledochal Cyst
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Cholestasis
Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.
Cholestasis, Intrahepatic
Effect of Histone Deacetylase HDAC3 on Cytokines IL-18, IL-12 and TNF-? in Patients with Intrahepatic Cholestasis of Pregnancy.
Chondrocalcinosis
The new bone biology: pathologic, molecular, and clinical correlates.
Chondrosarcoma
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair.
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Effects of HDAC4 on IL-1?-induced matrix metalloproteinase expression regulated partially through the WNT3A/?-catenin pathway.
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia.
Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
MicroRNA?10b suppresses the migration and invasion of chondrosarcoma cells by targeting brain?derived neurotrophic factor.
Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
Chordoma
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis.
Choriocarcinoma
A new approach combining LC-MS and multivariate statistical analysis for revealing changes in histone modification levels.
Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
Epigenetic therapy in human choriocarcinoma.
Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines.
Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours.
Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells.
Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma.
Choroidal Neovascularization
Attenuation of choroidal neovascularization by histone deacetylase inhibitor.
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.
Chronic Kidney Disease-Mineral and Bone Disorder
Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice.
Chronic Periodontitis
Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.
Ciliopathies
Ciliopathies: Does HDAC6 Represent a New Therapeutic Target?
Cleidocranial Dysplasia
The new bone biology: pathologic, molecular, and clinical correlates.
Colitis
A Highly Potent and Selective Histone Deacetylase 6 Inhibitor Prevents DSS-induced Colitis in Mice.
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
CaM kinase II in colonic smooth muscle contributes to dysmotility in murine DSS-colitis.
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Distinct Roles for Intestinal Epithelial Cell-Specific Hdac1 and Hdac2 in the Regulation of Murine Intestinal Homeostasis.
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.
Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3.
Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.
HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGF?1 signalling in inflammation.
HDAC6 and HSP90 Control The Functions Of Foxp3+ T-Regulatory Cells.
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.
Novel Histone Deacetylase 6 Inhibitor CKD-506 Inhibits NF-?B Signaling in Intestinal Epithelial Cells and Macrophages and Ameliorates Acute and Chronic Murine Colitis.
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
SUMOylation of ROR-?t inhibits IL-17 expression and inflammation via HDAC2.
The acetylome regulators Hdac1 and Hdac2 differently modulate intestinal epithelial cell dependent homeostatic responses in experimental colitis.
The HDAC Inhibitor, SAHA, Prevents Colonic Inflammation by Suppressing Pro-inflammatory Cytokines and Chemokines in DSS-induced Colitis.
Colitis-Associated Neoplasms
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Colonic Neoplasms
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.
9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells.
A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.
Aceroside VIII is a New Natural Selective HDAC6 Inhibitor that Synergistically Enhances the Anticancer Activity of HDAC Inhibitor in HT29 Cells.
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines.
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.
Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study.
Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells.
Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.
Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.
Carbamazepine, a Histone Deacetylase Inhibitor Induces Apoptosis in Human Colon Adenocarcinoma Cell Line HT-29.
CBP Activity Mediates Effects of the Histone Deacetylase Inhibitor Butyrate on WNT Activity and Apoptosis in Colon Cancer Cells.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
Colonic health: fermentation and short chain fatty acids.
Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm.
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
Effect of 5-Aza-2'-Deoxycytidine in Comparison to Valproic Acid and Trichostatin A on Histone Deacetylase 1, DNA Methyltransferase 1, and CIP/KIP Family (p21, p27, and p57) Genes Expression, Cell Growth Inhibition, and Apoptosis Induction in Colon Cancer SW480 Cell Line.
Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine.
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells.
Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells.
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer.
G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer.
Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells.
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
HDAC4 promotes growth of colon cancer cells via repression of p21.
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs.
Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer.
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway.
Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.
Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A.
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells.
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells.
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.
Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of growth and induction of differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon cancer cells.
Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/ Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line.
Making sense of HDAC2 mutations in colon cancer.
Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins.
MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling.
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators.
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry.
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
RAR? acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Selenium-binding protein 1 is associated with the degree of colorectal cancer differentiation and is regulated by histone modification.
SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6.
Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.
Sp1 is a transcription repressor to stanniocalcin-1 expression in TSA-treated human colon cancer cells, HT29.
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation.
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.
Sumoylation of HDAC2 promotes NF-?B-dependent gene expression.
Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer in vitro.
Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
The Australian fruit Illawarra plum (Podocarpus elatus Endl., Podocarpaceae) inhibits telomerase, increases histone deacetylase activity and decreases proliferation of colon cancer cells.
The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
The Effects of 5-Aza-2'-Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line.
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner.
The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.
The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.
Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?
Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
[Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines]
Colorectal Neoplasms
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKC? and E-cadherin.
A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
A novel HDAC1 inhibitor, CBUD?1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Anti-Tumor Effects of Paeoniflorin on Epithelial-To-Mesenchymal Transition in Human Colorectal Cancer Cells.
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells.
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Butyrate production from high-fiber diet protects against lymphoma tumor.
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
Carcinoembryonic Antigen Expression and Resistance to Radiation and 5-Fluorouracil-Induced Apoptosis and Autophagy.
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies.
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy.
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction.
Effect of Sodium Butyrate on LHX1 mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines.
Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Efficacy of butyrate analogues in HT-29 cancer cells.
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.
Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma.
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.
FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression.
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 controls CIP2A transcription in human colorectal cancer cells.
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGF? axis.
HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail.
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Histone deacetylase inhibitors and colorectal cancer: what is new?
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization.
Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
Hypothesis: Sam68 and Pygo2 mediate cell type-specific effects of the modulation of CBP-Wnt and p300-Wnt activities in Colorectal Cancer Cells.
In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Increased transforming growth factor ? and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Integrative Transcriptomic Network Analysis of Butyrate Treated Colorectal Cancer Cells.
Ku70 is essential for histone deacetylase inhibitor trichostatin A-induced apoptosis.
Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619-5p activity and facilitating HDAC3 expression.
Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation.
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1.
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Mutational analysis of mononucleotide repeats in HDAC4, 5, 6, 7, 9 and 11 genes in gastric and colorectal carcinomas with microsatellite instability.
Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1.
Novel ?-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer.
OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells.
Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.
Regulation of prostaglandin transporters in colorectal neoplasia.
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
Sodium Butyrate as a Histone Deacetylase Inhibitor Affects Toll-Like Receptor 4 Expression in Colorectal Cancer Cell Lines.
SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study.
Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
TCF7L1 recruits CtBP and HDAC1 to repress DICKKOPF4 gene expression in human colorectal cancer cells.
The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.
The contribution of activating transcription factor 3 to apoptosis of human colorectal cancer cells by protocatechualdehyde, a naturally occurring phenolic compound.
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells.
The HDAC6 inhibitor ACY?1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
The histone deacetylase HDAC1 activates HIF1?/VEGFA signal pathway in colorectal cancer.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
The microbiome and its potential as a cancer preventive intervention.
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment.
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.
The roles of microbial products in the development of colorectal cancer: a review.
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Untangling the fiber yarn: butyrate feeds Warburg to suppress colorectal cancer.
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer.
USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.
Valproic acid protects intestinal organoids against radiation via NOTCH signaling.
Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer.
ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Colorectal Neoplasms, Hereditary Nonpolyposis
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Communicable Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
HDAC inhibitors in parasitic diseases.
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Modulation of cathelicidin and defensins by histone deacetylase inhibitors: A potential treatment for multi-drug resistant infectious diseases.
Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies.
Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease.
Congenital Abnormalities
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs).
Connective Tissue Diseases
[Effect of histone deacetylase 2 and 4 activity on connective tissue disease associated pulmonary fibrosis in mice].
Corneal Neovascularization
Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model.
Coronary Artery Disease
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Genetic Risk Factors for Ischemic and Hemorrhagic Stroke.
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
COVID-19
A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-? signalling in COVID-19 survivors.
The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.
Craniocerebral Trauma
[INVOLVEMENT OF EPIGENETIC REGULATION IN CEREBRAL CELL DEATH FOLLOWING TRAUMATIC BRAIN INJURY IN A RAT MODEL].
Craniofacial Abnormalities
Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression.
Craniosynostoses
The new bone biology: pathologic, molecular, and clinical correlates.
Cryptorchidism
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Cushing Syndrome
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome.
Cystic Fibrosis
Alleviation of depression-like behavior in a cystic fibrosis mouse model by Hdac6 depletion.
Clinical and experimental applications of sodium phenylbutyrate.
CTCF regulates positioning of the human cystic fibrosis gene in association with a histone deacetylase.
HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge.
HDAC7: a viable target in the treatment of cystic fibrosis.
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Improved Growth Patterns in Cystic Fibrosis Mice after Loss of Histone Deacetylase 6.
Perinuclear positioning of the inactive human cystic fibrosis gene depends on CTCF, A-type lamins and an active histone deacetylase.
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
Regulation of the Coxsackie and adenovirus receptor expression is dependent on cystic fibrosis transmembrane regulator in airway epithelial cells.
Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease.
Small-Molecule Screening for Genetic Diseases.
The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation.
Cystitis
Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis.
Cysts
Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
CCAAT/Enhancer-Binding Protein ? Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis.
Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models.
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Deletion of ADP Ribosylation Factor-Like GTPase 13B Leads to Kidney Cysts.
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
Therapeutic Targets In Polycystic Liver Disease.
De Lange Syndrome
A commentary on exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
A Functional Mutation in HDAC8 Gene as Novel Diagnostic Marker for Cornelia De Lange Syndrome.
A novel de novo HDAC8 missense mutation causing Cornelia de Lange syndrome.
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
Biochemical and structural characterization of HDAC8 mutants associated with Cornelia de Lange syndrome spectrum disorders.
Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders.
Cornelia de Lange syndrome in diverse populations.
Exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Molecular characterization of HDAC8 deletions in individuals with atypical Cornelia de Lange syndrome.
Molecular characterization of two novel intronic variants of NIPBL gene detected in unrelated Cornelia de Lange syndrome patients.
Mutant cohesin affects RNA polymerase II regulation in Cornelia de Lange syndrome.
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.
Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation.
Structural analysis of histone deacetylase 8 mutants associated with Cornelia de Lange Syndrome spectrum disorders.
Structural aspects of HDAC8 mechanism and dysfunction in Cornelia de Lange syndrome spectrum disorders.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
[Clinical and genetic analysis of a neonate with Cornelia de Lange syndrome 5 caused by HDAC8 gene mutation].
[NIPBL gene mutations in two children with Cornelia de Lange syndrome].
Deafness
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness.
Dehydration
AhHDA1-mediated AhGLK1 promoted chlorophyll synthesis and photosynthesis regulates recovery growth of peanut leaves after water stress.
Dementia
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Arsenic toxicity induced endothelial dysfunction and dementia: Pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors.
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Turning back the clock on neurodegeneration.
Dementia, Vascular
Donepezil attenuates vascular dementia in rats through increasing BDNF induced by reducing HDAC6 nuclear translocation.
Demyelinating Diseases
Epigenetic in Multiple Sclerosis: Molecular mechanisms and dietary intervention.
Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm.
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Dermatitis
The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice.
Dermatitis, Contact
Entinostat, a histone deacetylase inhibitor, increases the population of IL-10+ regulatory B cells to suppress contact hypersensitivity.
Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors.
Dermatitis, Phototoxic
Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
Diabetes Complications
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Diabetes Mellitus
Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Histone Deacetylase 3 Aggravates Type 1 Diabetes Mellitus by Inhibiting Lymphocyte Apoptosis Through the microRNA-296-5p/Bcl-xl Axis.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.
Diabetes Mellitus, Type 1
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Histone Deacetylase 3 Aggravates Type 1 Diabetes Mellitus by Inhibiting Lymphocyte Apoptosis Through the microRNA-296-5p/Bcl-xl Axis.
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.
Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
Novel methods of type 1 diabetes treatment.
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
Diabetes Mellitus, Type 2
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice.
HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells.
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Histone deacetylase 3 inhibition alleviates type 2 diabetes mellitus-induced endothelial dysfunction via Nrf2.
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats.
Histone deacetylase 6 regulates insulin signaling in pancreatic ? cells.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Histone deacetylase regulates insulin signaling via two pathways in pancreatic ? cells.
Histone modifications and skeletal muscle metabolic gene expression.
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.
MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues ?-cell dysfunction caused by Hdac7 upregulation.
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing ?-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors.
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells.
Diabetic Cardiomyopathies
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
Diabetic Nephropathies
Cyclo-RGD Truncated Polymeric Nanoconstruct with Dendrimeric Templates for Targeted HDAC4 Gene Silencing in a Diabetic Nephropathy Mouse Model.
Glomerular mesangial cell and podocyte injuries in diabetic nephropathy.
HDAC4 blocks autophagy to trigger podocyte injury: non-epigenetic action in diabetic nephropathy.
HDAC6-mediated ?-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy.
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Histone deacetylase inhibitor valproic acid attenuates high glucose?induced endoplasmic reticulum stress and apoptosis in NRK?52E cells.
Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
Mesenchymal Stem Cell-Derived Exosomes Carry MicroRNA-125a to Protect Against Diabetic Nephropathy by Targeting Histone Deacetylase 1 and Downregulating Endothelin-1.
Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment.
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Diabetic Retinopathy
Dynamic Expression of HDAC3 in db/db Mouse RGCs and Its Relationship with Apoptosis and Autophagy.
Epigenetic control of early neurodegenerative events in diabetic retinopathy by the histone deacetylase SIRT6.
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy.
Overexpression of histone deacetylase SIRT1 exerts an anti-angiogenic role in diabetic retinopathy via miR-20a elevation and YAP/HIF1?/VEGFA depletion.
The anti-angiogenesis role of FBXW7 in diabetic retinopathy by facilitating the ubiquitination degradation of c-Myc to orchestrate the HDAC2.
Diffuse Intrinsic Pontine Glioma
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Diphtheria
Clinical Trials and Treatment of ATL.
[Adult T cell leukemia-lymphoma (ATL)].
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Double Outlet Right Ventricle
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Down Syndrome
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Ductus Arteriosus, Patent
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Dwarfism
Study on pathogenic genes of dwarfism disease by next-generation sequencing.
Dyskinesias
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study.
Dyslipidemias
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Polyphenols: Novel Signaling Pathways.
Embolic Stroke
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration.
Encephalitis
Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice.
Encephalitis, Japanese
Histone deacetylase inhibition by Japanese encephalitis virus in monocyte/macrophages: a novel viral immune evasion strategy.
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Encephalomyelitis
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
Epigenetics of Multiple Sclerosis: An Updated Review.
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Endocrine Gland Neoplasms
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Endocrine System Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Endometrial Neoplasms
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation.
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
Antioxidants impair anti-tumoral effects of vorinostat, but not anti-neoplastic effects of vorinostat and caspase-8 downregulation.
CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells.
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.
DNMT Inhibitors and HDAC Inhibitors Regulate E-Cadherin and Bcl-2 Expression in Endometrial Carcinoma in vitro and in vivo.
Endometrial cancer stem cells: a new target for cancer therapy.
Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues.
Retraction notice to "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells" [Gynecol. Oncol. 101 (2006) 108-113].
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
The role of glycodelin in cell differentiation and tumor growth.
[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells]
Endometrial Stromal Tumors
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Endometriosis
Aberrant histone modification in endometriosis.
Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
CCAAT/Enhancer-Binding Protein ? Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis.
Constitutive and Tumor Necrosis Factor-Alpha-Stimulated Activation of Nuclear Factor-KappaB in Immortalized Endometriotic Cells and Their Suppression by Trichostatin A.
Epigenetics of endometriosis.
HDAC1 and HDAC2 are Differentially Expressed in Endometriosis.
Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription.
KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.
Loss of HDAC3 results in nonreceptive endometrium and female infertility.
The Expression of Histone Deacetylase 1, But Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis.
Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.
Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice.
Valproic Acid and Progestin Inhibit Lesion Growth and Reduce Hyperalgesia in Experimentally Induced Endometriosis in Rats.
Endotoxemia
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
DNMT and HDAC inhibitors together abrogate endotoxemia mediated macrophage death by STAT3-JMJD3 signaling.
HDAC6 inhibition prevents TNF-?-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.
HDAC6 Mediates Macrophage iNOS Expression and Excessive Nitric Oxide Production in the Blood During Endotoxemia.
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model.
Novel pharmacologic treatment attenuates septic shock and improves long-term survival.
Enteritis
Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation.
Enzootic Bovine Leukosis
Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.
Ependymoma
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models.
Ongoing Response in a Multiply Relapsed Metastatic Posterior Fossa Ependymoma A After Vorinostat and Concomitant Irradiation.
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Epilepsy
A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard.
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation.
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Epigenetic Histone Deacetylation Inhibition Prevents the Development and Persistence of Temporal Lobe Epilepsy.
Epigenetic Suppression of GADs Expression is Involved in Temporal Lobe Epilepsy and Pilocarpine-Induced Mice Epilepsy.
HDAC4 gene silencing alleviates epilepsy by inhibition of GABA in a rat model.
HEF1-dependent Aurora A activation induces disassembly of the primary cilium.
High content analysis of histone acetylation in human cells and tissues.
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.
Increased expression of histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and rat models.
Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.
Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease.
miR-485 inhibits histone deacetylase HDAC5, HIF1? and PFKFB3 expression to alleviate epilepsy in cellular and rodent models.
Myocardin-related transcription factor and serum response factor regulate cilium turnover by both transcriptional and local mechanisms.
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Primary cilia in stem cells and neural progenitors are regulated by neutral sphingomyelinase 2 and ceramide.
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Seizures and gliomas - towards a single therapeutic approach.
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Valproate reduces collagen and osteonectin in cultured bone cells.
Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.
Valproic acid increases NO production via the SH-PTP1-CDK5-eNOS-Ser(116) signaling cascade in endothelial cells and mice.
Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity.
Valproic acid induces neuronal cell death through a novel calpain-dependent necroptosis pathway.
Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions.
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Epilepsy, Absence
Pain Modulation in WAG/Rij Epileptic Rats (A Genetic Model of Absence Epilepsy): Effects of Biological and Pharmacological Histone Deacetylase Inhibitors.
Epilepsy, Temporal Lobe
Epigenetic Histone Deacetylation Inhibition Prevents the Development and Persistence of Temporal Lobe Epilepsy.
Increased expression of histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and rat models.
Esophageal Neoplasms
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Genome-Wide Profiling of the Toxic Effect of Bortezomib on Human Esophageal Carcinoma Epithelial Cells.
Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
Induction of MAGE-3 expression in lung and esophageal cancer cells.
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells.
Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.
Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
Activation of PAR4 Upregulates p16 through Inhibition of DNMT1 and HDAC2 Expression via MAPK Signals in Esophageal Squamous Cell Carcinoma Cells.
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Effects of Down-regulation of HDAC6 Expression on Proliferation, Cell Cycling and Migration of Esophageal Squamous Cell Carcinoma Cells and Related Molecular Mechanisms.
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Esophagitis
Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma.
Familial Primary Pulmonary Hypertension
Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension.
Fanconi Anemia
VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression.
Fatty Liver
An HDAC3-PROX1 corepressor module acts on HNF4? to control hepatic triglycerides.
Binge Alcohol-Induced Microvesicular Liver Steatosis and Injury are Associated with Down-Regulation of Hepatic Hdac 1, 7, 9, 10, 11 and Up-Regulation of Hdac 3.
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR?.
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
The loss of histone deacetylase 4 in macrophages exacerbates hepatic and adipose tissue inflammation in male but not in female mice with diet-induced non-alcoholic steatohepatitis.
The ménage à trois of autophagy, lipid droplets and liver disease.
Fetal Death
Growth regulation, imprinting, and epigenetic transcription-related gene expression differs in lung of deceased transgenic cloned and normal goats.
Fibroadenoma
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
RHEB expression in fibroadenomas of the breast.
Fibrosarcoma
A new role for histone deacetylase 5 in the maintenance of long telomeres.
Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line.
Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.
Histone deacetylase inhibitors: the Abbott experience.
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression.
Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells.
The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
Fibrous Dysplasia, Polyostotic
The new bone biology: pathologic, molecular, and clinical correlates.
Food Hypersensitivity
Flagellin modulates IgE expression in B cells to initiate food allergy in mice.
Fragile X Syndrome
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.
Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Friedreich Ataxia
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Epigenetic therapy for Friedreich ataxia.
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.
Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.
Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia.
Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.
Targeting Class I Histone Deacetylases in a "Complex" Environment.
Frontotemporal Dementia
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
Frontotemporal Lobar Degeneration
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Gallbladder Neoplasms
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Gastritis
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Gastritis, Atrophic
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Gastrointestinal Neoplasms
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress.
Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
[Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
Gaucher Disease
Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.
Genetic Diseases, Inborn
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Analysis of post-transcriptional regulation using the FunREG method.
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
The new bone biology: pathologic, molecular, and clinical correlates.
Giant Cell Tumors
Discovery research to clinical trial: a ten year journey.
Glaucoma
An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with Mitomycin-C and a histone deacetylase inhibitor.
Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery.
Integrated microarray analysis provided novel insights to the pathogenesis of glaucoma.
Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid.
Targeting HDAC3 in the DBA/2J spontaneous mouse model of glaucoma.
Glaucoma, Open-Angle
The relationship between HDAC6, CXCR3, and SIRT1 genes expression levels with progression of primary open-angle glaucoma.
Glioblastoma
(P039) outcomes of patients with glioblastoma receiving concurrent radiation treatment and antiepileptic agents with histone deacetylase inhibitor activity.
A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Epigenetic targeting of SLC30A3 by HDAC1 is related to the malignant phenotype of glioblastoma.
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
FBXW7 induces apoptosis in glioblastoma cells by regulating HDAC7.
HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.
HDAC inhibitors and their potential applications to glioblastoma therapy.
HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin.
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.
HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling.
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.
Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells.
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-?B-Dependent Transcription in Glioblastoma Cell Lines.
Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells.
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells.
Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells.
Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.
Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation.
Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy.
Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide.
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Molecular dissection of the valproic acid effects on glioma cells.
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition.
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the ?-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A.
Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520.
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Optimizing antiepileptic drug treatment in tumoral epilepsy.
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Radiosensitisation of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays.
Regulation of Glioblastoma Stem-like Cells by Id proteins and Olig transcription factors.
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines.
Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells.
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.
Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells.
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.
The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.
The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide?induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival.
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Glioma
A combination of BRD4 and HDAC3 inhibitors synergistically suppresses glioma stem cell growth by blocking GLI1/IL-6/STAT3 signaling axis.
A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling.
A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis.
ARID4B Knockdown Suppresses PI3K/AKT Signaling and Induces Apoptosis in Human Glioma Cells.
Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Chromatin structure and expression of the AMPA receptor subunit Glur2 in human glioma cells: major regulatory role of REST and Sp1.
Clinical relevance of lysyl oxidase-like 2 and functional mechanisms in glioma.
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3.
Correction to: ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway.
Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-? signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118].
Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Effects of caffeine on cell viability and activity of histone deacetylase 1 and histone acetyltransferase in glioma cells.
Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor.
Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours.
Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review.
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5.
Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
Growth Suppression of Glioma Cells Using HDAC6 Inhibitor, Tubacin.
HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.
HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.
HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells.
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5?2 signaling pathway.
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1.
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.
Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells.
Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells.
Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells.
Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8- but not caspase-9-dependent apoptosis in human malignant glioma cells.
Histone deacetylase SIRT6 inhibits glioma cell growth through down-regulating NOTCH3 expression.
Histone-deacetylase 8 drives the immune response and the growth of glioma.
Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas.
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
IIp45 inhibits cell migration through inhibition of HDAC6.
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity.
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Inhibition of tribbles protein-1 attenuates radioresistance in human glioma cells.
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas.
Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma.
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.
Novel histone deacetylase inhibitor N25 exerts anti-tumor effects and induces autophagy in human glioma cells by inhibiting HDAC3.
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Phosphorylated SATB1 is associated with the progression and prognosis of glioma.
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.
Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Promoter hypomethylation regulates CD133 expression in human gliomas.
Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene.
Regulation of histone acetylation by NDRG2 in glioma cells.
RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-? signaling via SMAD7.
SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
Seizures and gliomas - towards a single therapeutic approach.
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress.
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.
Targeting post-translational histone modifying enzymes in glioblastoma.
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma.
The possible prognostic role of histone deacetylase and transforming growth factor ?/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study.
The transglutaminase 2 gene is aberrantly hypermethylated in glioma.
Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma.
Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells.
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3.
Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease.
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.
ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway.
[Effect of monoamine oxidase inhibitor on the differentiation of malignant glioma cell].
[Studies on the target cells and molecules with sodium valproate induced differential of human glioma cells]
[The Mechanism Study on Histone Acetylation Activating Glioblastoma-derived Neurotrophic Factor Transcription].
Glomerulonephritis
Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice.
Glomerulonephritis, IGA
Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.
Glucose Intolerance
Conditional ablation of HDAC3 in islet beta cells results in glucose intolerance and enhanced susceptibility to STZ-induced diabetes.
Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through ?-cell protection.
Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-? in human adipose tissue.
Gout
Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.
Graft vs Host Disease
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.
Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.
Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets.
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Low-dose chidamide restores immune tolerance in ITP in mice and humans.
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.
Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Granulomatosis with Polyangiitis
Dysregulation of histone deacetylase and histone acetyltransferase in development of Wegener's granulomatosis.
Gynecomastia
Methylation Profile of X-Chromosome-Related Genes in Male Breast Cancer.
Head and Neck Neoplasms
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells.
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Headache Disorders, Secondary
HDAC3 role in medication consumption in medication overuse headache patients: a pilot study.
Hearing Loss
Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide.
Elucidation of the Hdac2/Sp1/miR-204-5p/Bcl-2 axis as a modulator of cochlear apoptosis via in vivo/in vitro models of acute hearing loss.
Histone deacetylase inhibitor sodium butyrate attenuates gentamicin-induced hearing loss in vivo.
Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.
The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs.
Hearing Loss, Noise-Induced
Histone deacetylase 2 polymorphisms associated with noise-induced hearing loss in Chinese workers.
The histone deacetylase inhibitor sodium butyrate protects against noise-induced hearing loss in Guinea pigs.
Hearing Loss, Sensorineural
Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide.
Elucidation of the Hdac2/Sp1/miR-204-5p/Bcl-2 axis as a modulator of cochlear apoptosis via in vivo/in vitro models of acute hearing loss.
Histone Deacetylase 2 in Sudden Sensorineural Hearing Loss Patients in Response to Intratympanic Methylprednisolone Perfusion.
Response of Glucocorticoid Receptor Alpha and Histone Deacetylase 2 to Glucocorticoid Treatment Predicts the Prognosis of Sudden Sensorineural Hearing Loss.
Theophylline alleviates gentamicin-induced cytotoxicity to sensory hair cells by maintaining HDAC2 expression.
Heart Defects, Congenital
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice.
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Diseases
5-Fluoronicotinamide Derivatives as HDAC6 Inhibitors for Treating Heart Diseases.
Exogenous Hydrogen Sul?de Postconditioning Protects Isolated Rat Hearts From Ischemia/Reperfusion Injury Through Sirt1/PGC-1? Signaling Pathway.
HDAC2 is required by the physiological concentration of glucocorticoid to inhibit inflammation in cardiac fibroblasts.
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
Histone deacetylase inhibition in the treatment of heart disease.
Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Therapeutic effects of histone deacetylase inhibitors on heart disease.
Heart Failure
Acute ?-adrenergic activation triggers nuclear import of histone deacetylase 5 and delays G(q)-induced transcriptional activation.
Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.
Antithetical regulation of ?-myosin heavy chain between fetal and adult heart failure though shuttling of HDAC5 regulating YY-1 function.
Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure.
CaMKII and PKA-dependent phosphorylation co-regulate nuclear localization of HDAC4 in adult cardiomyocytes.
Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Chromatin modifications remodel cardiac gene expression.
Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.
Correlation between Histone Deacetylase 9 and Regulatory T Cell in Patients with Chronic Heart Failure.
Curcumin: a natural pan-HDAC inhibitor in cancer.
Dichotomy of Ca in the heart: contraction versus intracellular signaling.
DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure.
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.
HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
HDAC4 controls histone methylation in response to elevated cardiac load.
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Histone deacetylase 2-dependent ventricular electrical remodeling in a porcine model of early heart failure.
Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure.
Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.
Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure.
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.
Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition.
Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats.
Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart.
Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure.
Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction.
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors.
The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model.
YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
Heart Septal Defects, Atrial
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Septal Defects, Ventricular
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Hematologic Diseases
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Targeting apoptosis proteins in hematological malignancies.
Hematologic Neoplasms
10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells.
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Approaches to target the genome and its epigenome in cancer.
Assessment of HDACi-Induced Protein Cleavage by Caspases.
Belinostat for the treatment of peripheral T-cell lymphomas.
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Could valproic acid be an effective anticancer agent? The evidence so far.
Current limitations and future opportunities for epigenetic therapies.
Decitabine and its role in the treatment of hematopoietic malignancies.
Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Dual targeting of epigenetic therapy in cancer.
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Enhanced expression of the nuclear envelope LAP2 transcriptional repressors in normal and malignant activated lymphocytes.
Epigenetic biomarkers for human cancer: The time is now.
Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis.
Epigenetic therapy and chemosensitization in solid malignancy.
Epigenetic therapy of hematological malignancies: where are we now?
Epigenetics as a Therapeutic Target in Breast Cancer.
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
Functional interplay between histone demethylase and deacetylase enzymes.
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
HDAC expression and clinical prognosis in human malignancies.
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia.
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.
Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes.
Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Histone deacetylase inhibitors in cancer treatment.
Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
Histone deacetylase inhibitors in the treatment of hematological malignancies.
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Histone deacetylase inhibitors: clinical implications for hematological malignancies.
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.
JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity.
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies.
Panobinostat inhibits the proliferation of CD34+ CD38- cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Pharmacogenomics and histone deacetylase inhibitors.
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies.
Potential non-oncological applications of histone deacetylase inhibitors.
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.
Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells.
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage.
The aggresome pathway as a target for therapy in hematologic malignancies.
The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.
The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.
The histone deacetylase 9 gene encodes multiple protein isoforms.
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade.
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
The rationale and use of hypomethylation agents in adult acute myeloid leukemia.
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development.
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Valproic acid treatment is associated with altered leukocyte subset development.
Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression.
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance.
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Hemoglobinopathies
Clinical and experimental applications of sodium phenylbutyrate.
Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo.
The effect of histone deacetylase inhibitors on AHSP expression.
Hemolytic-Uremic Syndrome
Butyrate upregulates endogenous host defense peptides to enhance disease resistance in piglets via histone deacetylase inhibition.
Hepatitis
Potential non-oncological applications of histone deacetylase inhibitors.
Sodium butyrate potentiates carbon tetrachloride-induced acute liver injury in mice.
Hepatitis B
Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.
Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest.
miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Modulation of hepatitis B virus pregenomic RNA stability and splicing by histone deacetylase 5 enhances viral biosynthesis.
Hepatitis B, Chronic
Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B.
Hepatitis C
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity.
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Hydroxamic acids block replication of hepatitis C virus.
Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors.
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines.
Role of HDAC9-FoxO1 Axis in the Transcriptional Program Associated with Hepatic Gluconeogenesis.
Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes.
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Hepatoblastoma
Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
Hepatomegaly
New synthetic conjugates of ursodeoxycholic acid inhibit cystogenesis in experimental models of polycystic liver disease.
Herpes Simplex
Epigenetic Regulation of Histone H3 Serine 10 Phosphorylation Status by HCF-1 Proteins in C. elegans and Mammalian Cells.
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript-independent manner in neuronal cells.
Histone Deacetylase Inhibitors Reduce the Number of Herpes Simplex Virus-1 Genomes Initiating Expression in Individual Cells.
Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist.
Trichostatin-A enhances adaptive immune responses to DNA vaccination.
Viral-encoded enzymes that target host chromatin functions.
Herpes Zoster
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Hirschsprung Disease
Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders.
histone deacetylase deficiency
A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program.
Conditional deletion of histone deacetylase-4 in the central nervous system has no major effect on brain architecture or neuronal viability.
Correction: HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Dopaminergic abnormalities in Hdac6-deficient mice.
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids.
HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer's disease.
HDAC2 deficiency and histone acetylation.
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
HDAC2 negatively regulates memory formation and synaptic plasticity.
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells.
HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.
HDAC3 Is Required for Posterior Lateral Line Development in Zebrafish.
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.
HDAC4 regulates vascular inflammation via activation of autophagy.
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy.
HDAC6 deficiency induces apoptosis in mesenchymal stem cells through p53 K120 acetylation.
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
HDAC6 regulates aggresome-autophagy degradation pathway of ?-synuclein in response to MPP(+) -induced stress.
HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies.
HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
Histone Deacetylase 1 Deficiency Impairs Differentiation and Electrophysiological Properties of Cardiomyocytes Derived from Induced Pluripotent Cells.
Histone deacetylase 3 controls lung alveolar macrophage development and homeostasis.
Histone deacetylase 6 modulates macrophage infiltration during inflammation.
Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability.
Histone Deacetylase 9 Deficiency Protects against Effector T Cell-mediated Systemic Autoimmunity.
Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency.
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Neural Differentiation in HDAC1-Depleted Cells Is Accompanied by Coilin Downregulation and the Accumulation of Cajal Bodies in Nucleoli.
Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction.
Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity.
Repression of Somatic Genes by Selective Recruitment of HDAC3 by BLIMP1 Is Essential for Mouse Primordial Germ Cell Fate Determination.
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc.
HIV Infections
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection.
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Marbostat 100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors.
Novel Histone Deacetylase Inhibitors for Treating HIV Infection.
Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Targeting Class I Histone Deacetylases in a "Complex" Environment.
The search for an HIV cure: tackling latent infection.
Hodgkin Disease
Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
Drug development for recurrent and refractory classical Hodgkin lymphoma.
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Histone deacetylase inhibitors and Hodgkin's lymphoma.
Histone deacetylase inhibitors in Hodgkin lymphoma.
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Modern treatment of Hodgkin lymphoma.
PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-{kappa}B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells.
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
Huntington Disease
A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Correction: Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease.
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease.
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.
Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease.
Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.
Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease.
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice.
Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2.
Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.
Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors.
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Post-translational modifications of tubulin in the nervous system.
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice; implications for the ubiquitin-proteasomal and autophagy systems.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington's Disease Mice.
[Epigenetics and etiology of neurodegenerative diseases].
Hyperalgesia
Activation of HDAC4 and GR signaling contributes to stress-induced hyperalgesia in the medial prefrontal cortex of rats.
Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats.
Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy.
Effect of Histone Deacetylase Inhibitor on Ethanol Withdrawal-Induced Hyperalgesia in Rats.
Epigenetic suppression of liver X receptor ? in anterior cingulate cortex by HDAC5 drives CFA-induced chronic inflammatory pain.
GluN2B/CaMKII mediates CFA-induced hyperalgesia via HDAC4-modified spinal COX2 transcription.
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription.
Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antinociceptive effect in a rat of neuropathic pain.
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice.
Hyperandrogenism
A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.
Hypereosinophilic Syndrome
Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Hyperglycemia
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Histone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia.
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction.
Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats.
Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon.
Sodium butyrate mitigates type 2 diabetes by inhibiting PERK-CHOP pathway of endoplasmic reticulum stress.
Targeting Oxidative Stress Reduction and Inhibition of HDAC1, MECP2, and NF-kB Pathways in Rats With Experimentally Induced Hyperglycemia by Administration of Thymus marshallianus Willd. Extracts.
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Hyperhomocysteinemia
Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system.
Hyperinsulinism
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Hypersensitivity
Arabidopsis Paired Amphipathic Helix Proteins SNL1 and SNL2 Redundantly Regulate Primary Seed Dormancy via Abscisic Acid-Ethylene Antagonism Mediated by Histone Deacetylation.
Complex regulation of the regulator of synaptic plasticity histone deacetylase 2 in the rodent dorsal horn after peripheral injury.
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition.
Epigenetic modulation of chronic anxiety and pain by histone deacetylation.
EXPRESS: Histone hyperacetylation modulates spinal type II metabotropic glutamate receptor alleviating stress-induced visceral hypersensitivity in female rats.
Functional and physical interactions between yeast 14-3-3 proteins, acetyltransferases, and deacetylases in response to DNA replication perturbations.
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats.
HDAC4 is required for inflammation-associated thermal hypersensitivity.
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery.
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Histone deacetylase inhibitors prevent persistent hypersensitivity in an orofacial neuropathic pain model.
Integrin engagement increases histone H3 acetylation and reduces histone H1 association with DNA in murine lung endothelial cells.
MiR-34a affects dexmedetomidine-inhibited chronic inflammatory visceral pain by targeting to HDAC2.
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.
Selective class I histone deacetylase inhibitors suppress persistent spontaneous nociception and thermal hypersensitivity in a rat model of bee venom-induced inflammatory pain.
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
The WD40 Domain Protein MSI1 Functions in a Histone Deacetylase Complex to Fine-Tune Abscisic Acid Signaling.
Valproate Prevents Dysregulation of Spinal Glutamate and Reduces the Development of Hypersensitivity in Rats After Peripheral Nerve Injury.
[Epigenetic regulation of abiotic stress response in plants to improve the stress tolerance].
Hypertelorism
Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance.
Hypertension
Altered expression of norepinephrine transporter participate in hypertension and depression through regulated TNF-? and IL-6.
Angiotensin II-induced overexpression of sirtuin 1 contributes to enhanced expression of Gi? proteins and hyperproliferation of vascular smooth muscle cells.
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Chronic HDAC6 Activation Induces Atrial Fibrillation Through Atrial Electrical and Structural Remodeling in Transgenic Mice.
Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension.
Expression and localization of calmodulin-related proteins in brain, heart and kidney from spontaneously hypertensive rats.
Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2.
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity.
HDAC4 and GATA6 Regulate Arterial Remodeling in Angiotensin II-Induced Hypertension.
HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats.
HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model.
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells.
Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine ?-lyase protein degradation.
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension.
Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension.
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic Acid and suberoylanilide hydroxamic Acid.
Human GRK4?142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.
Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology.
Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition.
Renal mechanisms of salt-sensitive hypertension: contribution of two steroid receptor-associated pathways.
Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.
Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium.
Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice.
Sirtuin-1 contributes to the overexpression of Gi? proteins and hyperproliferation of vascular smooth muscle cells from spontaneously hypertensive rats.
Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension.
Hypertension, Pulmonary
Expression of Class I and Class II a/b Histone Deacetylase is Dysregulated in Hypertensive Animal Models.
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Hyperthyroidism
MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone.
Hypertrophy, Left Ventricular
Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities.
S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction.
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.
Hypertrophy, Right Ventricular
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.
Hypesthesia
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Hypogonadism
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
Hypopigmentation
ITAC induces the melanocytic migration and hypopigmentation through destabilizing p53 via HDAC5: A possible role of ITAC in pigment-related disorders.
Hypothyroidism
A histone deacetylase inhibitor improves hypothyroidism caused by a TR?1 mutant.
Histone deacetylase inhibition reduces hypothyroidism-induced neurodevelopmental defects in rats.
[Analysis of genes related to hypothyroidism during pregnancy].
Hypoxia-Ischemia, Brain
Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats.
Idiopathic Pulmonary Fibrosis
Abrogation of TGF-{beta}1-induced Fibroblast-Myofibroblast Differentiation by Histone Deacetylase (HDAC) Inhibition.
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors.
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Immune System Diseases
Autoantigenic nuclear proteins of a clinically atypical renal vasculitis.
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Histone deacetylase 6 modulates macrophage infiltration during inflammation.
Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Infarction, Middle Cerebral Artery
HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation.
HDAC3 Downregulation Improves Cerebral Ischemic Injury via Regulation of the SDC1-Dependent JAK1/STAT3 Signaling Pathway Through miR-19a Upregulation.
HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1.
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
Nuclear translocation of histone deacetylase 4 induces neuronal death in stroke.
Opposite effects of HDAC5 and p300 on MRTF-A-related neuronal apoptosis during ischemia/reperfusion injury in rats.
Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.
Stroke Induces Nuclear Shuttling of Histone Deacetylase 4.
Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of ?-tubulin acetylation and FGF-21 up-regulation.
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Infections
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors.
Adenovirus transforming protein E1A induces c-Myc in quiescent cells by a novel mechanism.
Agonist-induced nuclear export of GFP-HDAC5 in isolated adult rat ventricular myocytes.
Alterations of Nuclear Architecture and Epigenetic Signatures during African Swine Fever Virus Infection.
Anaplasma phagocytophilum increases the levels of histone modifying enzymes to inhibit cell apoptosis and facilitate pathogen infection in the tick vector Ixodes scapularis.
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Aspergillus fumigatus phospholipase D may enhance reactive oxygen species production by accumulation of histone deacetylase 6.
Bovine herpesvirus 1 immediate-early protein (bICP0) interacts with the histone acetyltransferase p300, which stimulates productive infection and gC promoter activity.
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.
Components of the REST/CoREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells.
Control of cytomegalovirus lytic gene expression by histone acetylation.
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
Effects of ?TAT1 and HDAC5 on axonal regeneration in adult neurons.
Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of Caenorhabditis elegans.
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Epigenetic regulation of defense genes by histone deacetylase1 in human cell line-derived macrophages promotes intracellular survival of Leishmania donovani.
Epigenetic Regulation of Matrix Metalloproteinase-1 and -3 Expression in Mycobacterium tuberculosis Infection.
Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum.
Epithelial Histone Deacetylase 3 Instructs Intestinal Immunity by Coordinating Local Lymphocyte Activation.
Equine herpesvirus type 1 replication is delayed in CD172a+ monocytic cells and controlled by histone deacetylases.
Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1.
Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts.
HDAC1 controls CD8+ T cell homeostasis and antiviral response.
HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.
HDAC5 promotes Mycoplasma pneumoniae-induced inflammation in macrophages through NF-?B activation.
HDAC6 at Crossroads of Infection and Innate Immunity.
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge.
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
HDAC6, A Novel Cargo for Autophagic Clearance of Stress Granules, Mediates the Repression of the Type I Interferon Response During Coxsackievirus A16 Infection.
HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages.
HDAC8 drives spindle organization during meiotic maturation of porcine oocytes.
HDAC8: a multifaceted target for therapeutic interventions.
Helicobacter pylori inhibits autophagic flux and promotes its intracellular survival and colonization by down-regulating SIRT1.
Histone acetylation and flagellin are essential for Legionella pneumophila-induced cytokine expression.
Histone deacetylase 1 interacts with HIV-1 Integrase and modulates viral replication.
Histone Deacetylase 2 Is a Component of Influenza A Virus-Induced Host Antiviral Response.
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice.
Histone Deacetylase 6 Inhibits Influenza A Virus Release by Downregulating the Trafficking of Viral Components to the Plasma Membrane via Its Substrate, Acetylated Microtubules.
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection.
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry.
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.
Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.
Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection.
Histone deacetylase inhibitors suppress RSV infection and alleviate virus-induced airway inflammation.
HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection.
Host gene expression analysis in Sri Lankan melioidosis patients.
Host sirtuin 2 as an immunotherapeutic target against tuberculosis.
ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression.
Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection.
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Influenza A virus uses the aggresome processing machinery for host cell entry.
Inhibiting Histone Deacetylases in Human Macrophages Promotes Glycolysis, IL-1?, and T Helper Cell Responses to Mycobacterium tuberculosis.
Inhibition of Viral Pathogenesis and Promotion of the Septic Shock Response to Bacterial Infection by IRF-3 Are Regulated by the Acetylation and Phosphorylation of Its Coactivators.
Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.
Lessons from Anaplasma phagocytophilum: chromatin remodeling by bacterial effectors.
microRNA-34a aggravates coxsackievirus B3-induced apoptosis of cardiomyocytes through the SIRT1-p53 pathway.
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.
Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells.
Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages.
NF-?Bp50 and HDAC1 Interaction Is Implicated in the Host Tolerance to Infection Mediated by the Bacterial Quorum Sensing Signal 2-Aminoacetophenone.
NKG2D Signaling: The Immune Subversive Side of HDAC3.
Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Overexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.
Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.
Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.
Phosphoinositide 3-kinase ? (PI3K?) in respiratory disease.
PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and ?-catenin.
Porcine Epidemic Diarrhea Virus Inhibits HDAC1 Expression To Facilitate Its Replication via Binding of Its Nucleocapsid Protein to Host Transcription Factor Sp1.
Positive role of promyelocytic leukemia protein in type I interferon response and its regulation by human cytomegalovirus.
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Protein acetylation derepresses Serotonin Synthesis to potentiate Pancreatic Beta-Cell Function through HDAC1-PKA-Tph1 signaling.
Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist.
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.
Recurrent Herpes Simplex Virus Type 1 (HSV-1) Infection Modulates Neuronal Aging Marks in In Vitro and In Vivo Models.
Regulation of disease-responsive genes mediated by epigenetic factors: interaction of Arabidopsis-Pseudomonas.
Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.
RFXB and its splice variant RFXBSV mediate the antagonism between IFNgamma and TGFbeta on COL1A2 transcription in vascular smooth muscle cells.
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Sargassum polysaccharide inhibits inflammatory response in PCV2 infected-RAW264.7 cells by regulating histone acetylation.
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Selective HDAC inhibition for the disruption of latent HIV-1 infection.
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Sodium butyrate: a chemical inducer of in vivo reactivation of herpes simplex virus type 1 in the ocular mouse model.
Suppression of complement component 2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.
The CDK inhibitor p21Cip1/WAF1 is induced by Fc{gamma}R activation and restricts the replication of HIV-1 and related primate lentiviruses in human macrophages.
The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
The Major Capsid Protein, VP1, of the Mouse Polyomavirus Stimulates the Activity of Tubulin Acetyltransferase 1 by Microtubule Stabilization.
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
Transcription Repressor Protein ZBTB25 Associates with HDAC1-Sin3a Complex in Mycobacterium tuberculosis-Infected Macrophages, and Its Inhibition Clears Pathogen by Autophagy.
Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection.
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis.
Vesicular Stomatitis Virus Infection Promotes Immune Evasion by Preventing NKG2D-Ligand Surface Expression.
ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.
Infertility
HDAC3 controls male fertility through enzyme-independent transcriptional regulation at the meiotic exit of spermatogenesis.
Histone Deacetylase 2 (HDAC2) Regulates Chromosome Segregation and Kinetochore Function via H4K16 Deacetylation during Oocyte Maturation in Mouse.
Loss of HDAC3 results in nonreceptive endometrium and female infertility.
SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.
The C. elegans histone deacetylase HDA-1 is required for cell migration and axon pathfinding.
Infertility, Female
Blocking histone deacetylation in Arabidopsis induces pleiotropic effects on plant gene regulation and development.
Loss of HDAC3 results in nonreceptive endometrium and female infertility.
Infertility, Male
In vivo application of histone deacetylase inhibitor trichostatin-a impairs murine male meiosis.
Inflammatory Bowel Diseases
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
Cinnamyl Sulfonamide Hydroxamate Derivatives Inhibited LPS-Stimulated NF-kB Expression in RAW 264.7 Cells in In Vitro and Mitigated Experimental Colitis in Wistar Rats in In Vivo.
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Novel Histone Deacetylase 6 Inhibitor CKD-506 Inhibits NF-?B Signaling in Intestinal Epithelial Cells and Macrophages and Ameliorates Acute and Chronic Murine Colitis.
Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
The roles of microbial products in the development of colorectal cancer: a review.
Inflammatory Breast Neoplasms
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells.
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Influenza, Human
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
Histone Deacetylase 1 Plays an Acetylation-Independent Role in Influenza A Virus Replication.
Histone Deacetylase 2 Is a Component of Influenza A Virus-Induced Host Antiviral Response.
Histone Deacetylase 6 Inhibits Influenza A Virus Release by Downregulating the Trafficking of Viral Components to the Plasma Membrane via Its Substrate, Acetylated Microtubules.
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry.
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Influenza A virus-induced caspase-3 cleaves the histone deacetylase 6 in infected epithelial cells.
Influenza A virus-induced host caspase and viral PA-X antagonize the antiviral host factor, histone deacetylase 4.
Small RNA Profiling of Influenza A Virus-Infected Cells Identifies miR-449b as a Regulator of Histone Deacetylase 1 and Interferon Beta.
TRIM28 functions as a negative regulator of aggresome formation.
Insulin Resistance
A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice.
A Review of Mitochondrial-derived Fatty Acids in Epigenetic Regulation of Obesity and Type 2 Diabetes.
Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation.
Adipose tissue mRNA expression of HDAC1, HDAC3 and HDAC9 in obese women in relation to obesity indices and insulin resistance.
Afadin is a scaffold protein repressing insulin action via HDAC6 in adipose tissue.
Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes.
Co-activator binding protein PIMT mediates TNF-? induced insulin resistance in skeletal muscle via the transcriptional down-regulation of MEF2A and GLUT4.
Conditional deletion of Hdac3 in osteoprogenitor cells attenuates diet-induced systemic metabolic dysfunction.
Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3 depletion.
DNA methylation and histone deacetylation regulating insulin sensitivity due to chronic cold exposure.
FoxO1 mediates an autofeedback loop regulating SIRT1 expression.
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.
Genetic networks in Parkinson's and Alzheimer's disease.
Haplotypes of the Mutated SIRT2 Promoter Contributing to Transcription Factor Binding and Type 2 Diabetes Susceptibility.
HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage.
HDAC9 knockout mice are protected from adipose tissue dysfunction and systemic metabolic disease during high fat feeding.
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration.
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Histone modifications and skeletal muscle metabolic gene expression.
Induction of Dbp by a histone deacetylase inhibitor is involved in amelioration of insulin sensitivity via adipocyte differentiation in ob/ob mice.
Inhibition of HDAC3 promotes ligand-independent PPAR? activation by protein acetylation.
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes.
Loss of Hdac3 in osteoprogenitors increases bone expression of osteoprotegerin, improving systemic insulin sensitivity.
Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity.
Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression.
Silencing insulin resistance through SIRT1.
The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells.
The histone deacetylase inhibitor sodium butyrate improves insulin signalling in palmitate-induced insulin resistance in L6 rat muscle cells through epigenetically-mediated up-regulation of Irs1.
Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2.
Upregulation of skeletal muscle inflammatory genes links inflammation with insulin resistance in women with the metabolic syndrome.
Intellectual Disability
Confirmed rare copy number variants implicate novel genes in schizophrenia.
De novo satellited 2q associated with corpus callosum dysgenesis, short stature, mental retardation and developmental delay.
Dose dependent expression of HDAC4 causes variable expressivity in a novel inherited case of brachydactyly mental retardation syndrome.
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.
HDAC4 governs a transcriptional program essential for synaptic plasticity and memory.
HDAC8: a multifaceted target for therapeutic interventions.
Increased long-term potentiation at medial-perforant path-dentate granule cell synapses induced by selective inhibition of histone deacetylase 3 requires Fragile X mental retardation protein.
Loss of function of NCOR1 and NCOR2 impairs memory through a novel GABAergic hypothalamus-CA3 projection.
Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome.
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.
The clinical and molecular features of three Turkish patients with a rare genetic disorder: 2q37 deletion syndrome.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
The first familial case of inherited 2q37.3 interstitial deletion with isolated skeletal abnormalities including brachydactyly type E and short stature.
The Mendelian disorders of the epigenetic machinery.
Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
[Analysis of clinical phenotypes and genetic variations in a Chinese family affected with craniofacial and skeletal deformities].
Intervertebral Disc Degeneration
Inhibition of HDAC4 by GSK3? leads to downregulation of KLF5 and ASK1 and prevents the progression of intravertebral disc degeneration.
Intestinal Pseudo-Obstruction
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Intracranial Aneurysm
Associations among Genetic Variants and Intracranial Aneurysm in a Chinese Population.
Histone deacetylase 9 inhibition upregulates microRNA-92a to repress the progression of intracranial aneurysm via silencing Bcl-2-like protein 11.
Rs10230207 genotype confers changes in HDAC9 and TWIST1, but not FERD3L in lymphoblasts from patients with intracranial aneurysm.
Intracranial Hemorrhages
Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and Its Neuroprotective Effects in Mice After Intracranial Hemorrhage.
Invasive Fungal Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Iron Overload
Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate.
Ischemic Attack, Transient
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia.
Ischemic Stroke
APOL1, CDKN2A/CDKN2B, and HDAC9 polymorphisms and small vessel ischemic stroke.
Association between Histone Deacetylase 9 Gene Polymorphism and Stroke in Chinese Han Population.
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Association of a Multigenetic Pro-Inflammatory Profile with Ischaemic Stroke.
Association of GWAS-supported loci rs2107595 in HDAC9 gene with ischemic stroke in southern Han Chinese.
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke.
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Expression of Histone Deacetylases HDAC1 and HDAC2 and Their Role in Apoptosis in the Penumbra Induced by Photothrombotic Stroke.
Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
Genetic Risk Factors for Ischemic and Hemorrhagic Stroke.
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.
HDAC4 in ischemic stroke: mechanisms and therapeutic potential.
HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke.
HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury.
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization.
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
OCT4B-190 protects against ischemic stroke by modulating GSK-3?/HDAC6.
Role of Phosphorylated HDAC4 in Stroke-Induced Angiogenesis.
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke.
The Emerging Role of Epigenetics in Cerebral Ischemia.
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
The relationship between the prognosis of children with acute arterial stroke and polymorphisms of CDKN2B, HDAC9, NINJ2, NAA25 genes.
Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
[Expression of HDAC9 in different brain regions in mice with cerebral ischemic stroke].
[Research progress of histone deacetylase 6 inhibitors in the therapy of ischemic stroke].
Keloid
CUDC?907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
Histone deacetylase 2 is upregulated in normal and keloid scars.
Keratitis
Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice.
Ketosis
The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis.
Kidney Diseases
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.
HDAC inhibitors in kidney development and disease.
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.
Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
Histone Deacetylases Take Center Stage on Regulation of Podocyte Function.
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Podocyte histone deacetylase activity regulates murine and human glomerular diseases.
Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Therapeutic effects of histone deacetylase inhibitors on kidney disease.
Trichostatin A ameliorates renal tubulointerstitial fibrosis through modulation of the JNK-dependent Notch-2 signaling pathway.
Up-Regulation of SIRT1 Reduces Endoplasmic Reticulum Stress and Renal Fibrosis.
Kidney Diseases, Cystic
Cytosolic HDAC6 is accumulated in cystic kidneys.
Deletion of ADP Ribosylation Factor-Like GTPase 13B Leads to Kidney Cysts.
Kidney Neoplasms
17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells.
Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment.
HDAC4 protein regulates HIF1? protein lysine acetylation and cancer cell response to hypoxia.
Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1?.
Laryngeal Neoplasms
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells.
Latent Infection
An HIV-1 replication pathway utilizing reverse transcript products that fail to integrate.
Blood-brain barrier pericytes as a target for HIV-1 infection.
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
HSV carrying WT REST establishes latency but reactivates only if the synthesis of REST is suppressed.
Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy.
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
Latent Tuberculosis
Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection.
Leiomyoma
Histone Deacetylase 6 Regulates Estrogen Receptor {alpha} in Uterine Leiomyoma.
The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Leiomyosarcoma
The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Leishmaniasis
Epigenetic regulation of defense genes by histone deacetylase1 in human cell line-derived macrophages promotes intracellular survival of Leishmania donovani.
KH-TFMDI, a novel sirtuin inhibitor, alters the cytoskeleton and mitochondrial metabolism promoting cell death in Leishmania amazonensis.
Leishmaniasis, Cutaneous
Leishmania amazonensis downregulates macrophage iNOS expression via Histone Deacetylase 1 (HDAC1): a novel parasite evasion mechanism.
Leishmaniasis, Visceral
A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis.
Lentivirus Infections
A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.
HDAC2 Regulates FOXO1 during RANKL-Induced Osteoclastogenesis.
HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury.
Leprosy
Effect of dialyzable leukocyte extract, sodium butyrate, and valproic acid in the development of anergy in murine leprosy.
Leukemia
8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1.
A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines.
A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.
A Novel Class of Small Molecule Inhibitors of HDAC6.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Active repression by unliganded retinoid receptors in development: less is sometimes more.
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Analysis of class I and II histone deacetylase gene expression in human leukemia.
Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells.
Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells.
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.".
C/EBP? and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Crystal structure of the BTB domain from PLZF.
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1-arrest,ROS-dependent apoptosis and differentiation in human leukemia cells.
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Dynamic analysis of proviral induction and De Novo methylation: implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression.
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation.
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
Effects of trichostatin A on HDAC8 expression, proliferation and cell cycle of molt-4 cells.
Epigallocatechin-3-gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PML-RAR? and HDAC1.
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.
Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
Erratum to Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4- phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis.
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines.
Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia.
HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human ??T Cells.
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
HDAC1 Is a Required Cofactor of CBF?-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A.
HDAC3 is essential for DNA replication in hematopoietic progenitor cells.
HDAC3: taking the SMRT-N-CoRrect road to repression.
HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
HDAC9 regulates the alternative lengthening of telomere (ALT) pathway via the formation of ALT-associated PML bodies.
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein.
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
Histone deacetylase in chronic lymphocytic leukemia.
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?
Histone deacetylase inhibitors activate NF-?B in human leukemia cells through an ATM/NEMO-related pathway.
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
Histone deacetylase inhibitors induce leukemia gene expression in cord blood hematopoietic stem cells expanded ex vivo.
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein.
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity.
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Histone deacetylase inhibitors: A new perspective for the treatment of leukemia.
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Histone deacetylases and transcriptional therapy with their inhibitors.
Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease.
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi).
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR{alpha} blockade in the pathogenesis of acute promyelocytic leukemia.
In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression.
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival.
Indole: A privileged scaffold for the design of anti-cancer agents.
Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha.
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
Neutrophilic differentiation modulates the apoptotic response of HL-60 cells to sodium butyrate and sodium valproate.
New approaches to the treatment of myelodysplasia.
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells.
Novel targeted drug therapies for the treatment of childhood acute leukemia.
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate.
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL.
Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity.
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.
Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).
Re: Dasmahapatra G, Almenara JA, and Grant S, "Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells that Overexpress Bcl-2." Mol Pharmacol January 2006 69:288-298; doi:10.1124/mol.105.016154.
Re: Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, and Grant S, "The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide." Mol Pharmacol January 2006 69:216-225; doi:10.1124/mol.105.017145.
Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells.
Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Role of histone deacetylases in acute leukemia.
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.
Searching for the magic bullet against cancer: the butyrate saga.
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cell.
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies.
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells.
Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.
Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3.
Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.
Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest.
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells.
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
The gene signature in CCAAT-enhancer-binding protein ? dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming.
The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.
The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia.
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines.
Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia.
Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells.
Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression.
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
[Acute promyelocytic leukemia, histone deacetylase, and response to retinoids]
[Dexamethasone and vorinostat cooperatively promote differentiation and apoptosis in Kasumi-1 leukemia cells through ubiquitination and degradation of AML1-ETO.]
[Down-regulation of HDAC6 Expression Can Influence KG1? Cell Proliferation by Inhibiting ERK Pathway].
[Down-regulation of HDAC6 Expression Promotes Apoptosis of Human Leukemia K562 Cells].
[Effect of downregulation the expression of HDAC1 on cells differentiation of HL-60 cells].
[Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]
[Effects of histone deacetylase inhibitor on the expression of angiogenesis related factors in Kasumi-1 leukemic cell line.]
[Effects of tributyrin on SHI-1 leukemia cells in vitro.]
[Mechanism of Leukemia Cell Apoptosis Induced by Sodium Butyrate activating TRAIL pathway.]
[Molecular diagnosis of and molecular targeting therapy for leukemia]
[Phenol butyrate inhibits cell cycle of leukemia cell lines through up-regulation of p21WAF1/CIP1 gene]
[Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in molt-4 cells]
[The re-expression of p15(INK4B) gene in leukemia cells induced by in vitro DNA methyltransferase and histone deacetylase inhibition]
Leukemia, B-Cell
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.
Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
Leukemia, Erythroblastic, Acute
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation.
Benzo[b]thiophene-based histone deacetylase inhibitors.
Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase.
Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines.
Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells.
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
[Regulatory effect of ginsenoside Rh2 on HDAC1/2 activity and cyclin in human erythroleukemia K562 cells].
Leukemia, Hairy Cell
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Leukemia, Lymphocytic, Chronic, B-Cell
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Histone deacetylase in chronic lymphocytic leukemia.
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors.
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade.
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.
The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells.
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
Inactivation of HDAC3 and STAT3 is Critically Involved in 1-Stearoyl-sn-Glycero-3-Phosphocholine-Induced Apoptosis in Chronic Myelogenous Leukemia K562 Cells.
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
[Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
Leukemia, Myeloid
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Demethylating agents in myeloid malignancies.
Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Induction of myelogenous leukemia cells with histone deacetylase inhibitors through down-regulating the Daxx protein expression.
MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]
Leukemia, Myeloid, Acute
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
A Novel Class of Small Molecule Inhibitors of HDAC6.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
A phase 2 study of vorinostat in acute myeloid leukemia.
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Avian erythroleukemia: a model for corepressor function in cancer.
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
c-Myc suppresses miR-451?YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Epigenetic modifiers: basic understanding and clinical development.
Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects.
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent.
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
HDAC1 Is a Required Cofactor of CBF?-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.
HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia.
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells.
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia.
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.
In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine.
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
MECHANISMS OF SYNERGISTIC ANTILEUKEMIC INTERACTIONS BETWEEN VALPROIC ACID AND CYTARABINE IN PEDIATRIC ACUTE MYELOID LEUKEMIA.
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
The gene signature in CCAAT-enhancer-binding protein ? dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukemia cells.
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.
[Antitumor activity of histone deacetylase inhibitor suberic bishydroxamate on acute myeloid leukemia cell lines].
[Effect of Valproic Acid against Angiogenesis of Kasumi-1 Xenograft Tumor in Nude Mice].
[Efflect of miR-34a-Tangeted Regulation of HDACI on Apoptosis of AML Cells].
[Histone deacetylase inhibitor SAHA induces inactivation of MAPK signaling and apoptosis in HL-60 cells]
[Molecular diagnosis of and molecular targeting therapy for leukemia]
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Leukemia, Myelomonocytic, Chronic
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leukemia, Plasma Cell
Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
Leukemia, Promyelocytic, Acute
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Active repression by unliganded retinoid receptors in development: less is sometimes more.
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells.
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Epigallocatechin-3-gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PML-RAR? and HDAC1.
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR{alpha} blockade in the pathogenesis of acute promyelocytic leukemia.
In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL.
Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
[Acute promyelocytic leukemia, histone deacetylase, and response to retinoids]
[Molecular diagnosis of and molecular targeting therapy for leukemia]
Leukemia, T-Cell
Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine.
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Retraction. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Journal of Virology, Volume 78, no. 9, p. 4582-90, 2004.
Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat.
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Retraction. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Journal of Virology, Volume 78, no. 9, p. 4582-90, 2004.
The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Lipodystrophy
Inhibition of Glyceroneogenesis by Histone Deacetylase 3 Contributes to Lipodystrophy in Mice with Adipose Tissue Inflammation.
Liposarcoma
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Liver Cirrhosis
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-? and vascular endothelial growth factor signalling.
Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype through Inhibition of Histone Deacetylases 4.
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.
Effect of histone deacetylase inhibitor on epithelial-mesenchymal transition of liver fibrosis.
Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation.
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-?1 signal pathway.
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
HNHA, new histone deacetylase inhibitor, improves liver fibrosis in BDL rats through suppression of hepatic stellate cells.
Relationship between Liver Pathology and Disease Progression in a Murine Model of Amyotrophic Lateral Sclerosis.
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
Sirtuin 6 attenuates epithelial-mesenchymal transition by suppressing the TGF-?1/Smad3 pathway and c-Jun in asthma models.
Sodium valproate, a histone deacetylase inhibitor, with praziquantel ameliorates Schistosoma mansoni-induced liver fibrosis in mice.
The miR-455-3p/HDAC2 axis plays a pivotal role in the progression and reversal of liver fibrosis and is regulated by epigenetics.
Liver Cirrhosis, Biliary
Histone deacetylase 9 plays a role in the antifibrogenic effect of astaxanthin in hepatic stellate cells.
Liver Diseases
Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor.
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Nutrient sensor-mediated programmed nonalcoholic fatty liver disease in low birthweight offspring.
Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats.
Regulation of P300 and HDAC1 on endoplasmic reticulum stress in isoniazid-induced HL-7702 hepatocyte injury.
Role of histone deacetylase on nonalcoholic fatty liver disease.
The ménage à trois of autophagy, lipid droplets and liver disease.
Liver Diseases, Alcoholic
Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury.
Liver Failure
Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B.
Liver Failure, Acute
HDAC2 inhibitor CAY10683 reduces intestinal epithelial cell apoptosis by inhibiting mitochondrial apoptosis pathway in acute liver failure.
HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.
Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site.
Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-?B pathway.
Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice.
Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure.
Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure.
Modulations of Histone Deacetylase 2 Offer a Protective Effect through the Mitochondrial Apoptosis Pathway in Acute Liver Failure.
Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice.
The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway.
Liver Neoplasms
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2.
Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period.
Clinical significance of HDAC9 in hepatocellular carcinoma.
Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer.
Correction: HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate.
Epigenetic targets in hepatocellular carcinoma cells: identification of chaperone protein complexes with histone deacetylases.
Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Hdac3 is essential for the maintenance of chromatin structure and genome stability.
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.
Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.
Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells.
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis.
Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells.
lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity.
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression.
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor.
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo.
Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The role of CUGBP1 in age-dependent changes of liver functions.
Transcriptional and translational regulation of C/EBP?-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1? proteins at the early and late stages of liver cancer.
Liver Neoplasms, Experimental
Activity of histone deacetylase in rat liver and Novikoff hepatoma.
Loeys-Dietz Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Lung Diseases
Activation and overexpression of Sirt1 attenuates lung fibrosis via P300.
Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/GSH-dependent manner.
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
HDAC8 inhibition ameliorates pulmonary fibrosis.
Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?
Lung Diseases, Interstitial
Expression of GR-? and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease.
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Lung Injury
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
FoxF1 protects rats from paraquat-evoked lung injury following HDAC2 inhibition via the microRNA-342/KLF5/I?B/NF-?B p65 axis.
Foxp1/2/4-NuRD interactions regulate gene expression and epithelial injury response in the lung via regulation of interleukin-6.
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model.
Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2.
Lung Neoplasms
2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity.
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.
A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
AMPK-Dependent Phosphorylation of HDAC8 Triggers PGM1 Expression to Promote Lung Cancer Cell Survival under Glucose Starvation.
Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells.
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer.
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells.
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer.
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase.
Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis.
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles.
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells.
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor.
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Energy metabolism in h460 lung cancer cells: effects of histone deacetylase inhibitors.
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Epigenetic regulation of RhoB loss of expression in lung cancer.
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.
Epigenetic-Based Biomarkers in the Malignant Transformation of BEAS-2B Cells Induced by Coal Tar Pitch Extract.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Fentanyl Inhibits Lung Cancer Viability and Invasion via Upregulation of miR-331-3p and Repression of HDAC5.
Genetic blockade of IGF-1R via recombinant adenovirus in lung cancer can be enhanced by histone deacetylase inhibitor, vorinostat.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression.
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.
Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Histone deacetylase 1 mRNA expression in lung cancer.
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression.
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells.
Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Histone deacetylase inhibitors in non-small-cell lung cancer.
Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer.
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.
Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer.
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis.
Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling.
Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay.
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Impacts of HDAC2 inhibition on lung cancer treatment.
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer.
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of non?small?cell lung cancer by sponging microRNA?509?3p and competitively upregulating HDAC9 expression.
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Lung cancer chemotherapy, new treatment and related patents.
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
miR-30a suppresses lung cancer progression by targeting SIRT1.
MiR-520b restrains cell growth by targeting HDAC4 in lung cancer.
miRNA-mRNA Interaction Network in Non-small Cell Lung Cancer.
miRNA-mRNA interaction network in non-small-cell lung cancer.
NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer.
Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.
Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells.
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression.
Osthole extracted from a citrus fruit that affects apoptosis on A549 cell line by histone deacetylasese inhibition (HDACs).
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Pax5 Re-Expression In H460 Cells Treated With The Combination Of Demethylating Agent And Histone Deacetylase Inhibitor Is Associated With The Enhancement Of P53 Binding To Pax5 Promoter Region.
PFN2a Suppresses C2C12 Myogenic Development by Inhibiting Proliferation and Promoting Apoptosis via the p53 Pathway.
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Quercetin enhances the antitumor activity of trichostatin A through up-regulation of p300 protein expression in p53 null cancer cells.
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small-Cell Lung Cancer.
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.
Requirement of HDAC6 for activation of Notch1 by TGF-?1.
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
Retraction: Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis.
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagy.
Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells.
Sodium Valproate Sensitizes Non-Small Lung Cancer A549 Cells to ?? T-Cell-Mediated Killing through Upregulating the Expression of MICA.
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells.
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Sulforaphane suppresses in vitro and in vivo lung tumorigenesis through downregulation of HDAC activity.
Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9.
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model.
Targeting the epigenome for the treatment and prevention of lung cancer.
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells.
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
The potential of histone deacetylase inhibitors in lung cancer.
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.
Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA.
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Up-regulation of BRAF activated non-coding RNA is associated with radiation therapy for lung cancer.
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
[Effects of trichostatin A on human lung cancer cell strains A549]
[Protein expressions of HDAC1 and DNMT1 in non-small-cell lung cancer and its clinical significance].
[Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism]
Lupus Erythematosus, Systemic
Downregulation of microRNA-101-3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9.
HDAC1 potentiates CD4 + T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus.
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Methylation and gene expression of histone deacetylases 6 in systemic lupus erythematosus.
Potential non-oncological applications of histone deacetylase inhibitors.
RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1.
Selective HDAC6 inhibition decreases early stage of lupus nephritis by downregulating both innate and adaptive immune responses.
Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice.
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.
Lupus Nephritis
Selective HDAC6 inhibition decreases early stage of lupus nephritis by downregulating both innate and adaptive immune responses.
Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.
Lymphatic Metastasis
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Lymphoma
5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells.
Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin.
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Combination therapies improve the anticancer activities of retinoids in neuroblastoma.
Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation.
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Current status and progress of lymphoma management in China.
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements.
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Epigenetic biomarkers for human cancer: The time is now.
Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
Epigenetic therapy of lymphoma using histone deacetylase inhibitors.
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
HDAC3 is essential for DNA replication in hematopoietic progenitor cells.
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone Deacetylase 3 Is Required for Efficient T Cell Development.
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Histone deacetylase inhibitors in lymphoma.
Histone deacetylase inhibitors in the treatment of lymphoma.
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Histone deacetylase inhibitors promote mice corneal allograft survival through alteration of CD4+ effector T cells and induction of Foxp3+ regulatory T cells.
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Histone deacetylase inhibitors: A new perspective for the treatment of leukemia.
In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box.
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Low-dose spiruchostatin-B, a potent histone deacetylase inhibitor enhances radiation-induced apoptosis in human lymphoma U937 cells via modulation of redox signaling.
Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Novel agents in mantle cell lymphoma.
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Novel targeted therapies of T cell lymphomas.
Novel targets for the treatment of relapsing multiple myeloma.
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis.
Pharmacokinetics and pharmacodynamics of suberoylanilide hydroxamic acid in cats.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells.
Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Targeting BTK through microRNA in chronic lymphocytic leukemia.
Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.
Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity.
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
The double dealing of cyclin D1.
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-?B.
The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.
Vorinostat as potential antiparasitic drug.
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
[Effect of Chidamide on Human B lymphoma Cell Lines and Its Mechanisms].
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
[New treatments of malignant lymphoma--a review].
[Regulatory effect of curcumin on p300 and HDAC1 in B-NHL cells]
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells.]
Lymphoma, B-Cell
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Combined inhibition of Bcl-2 and NF?B synergistically induces cell death in cutaneous T-cell lymphoma.
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Detection of apoptotic cells using immunohistochemistry.
Detection of apoptotic cells using propidium iodide staining.
Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
Emerging therapies for acute myeloid leukemia.
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in hematological tumors.
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL.
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma.
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.
Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.
microRNA-139-5p alleviates neurological deficit in hypoxic-ischemic brain damage via HDAC4 depletion and BCL-2 activation.
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E?-miR-155 transgenic mouse model.
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Novel targets for the treatment of relapsing multiple myeloma.
Paradoxical regulation of hypoxia inducible factor-1? (HIF-1?) by histone deacetylase inhibitor in diffuse large B-cell lymphoma.
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Promising therapies for the treatment of chronic lymphocytic leukemia.
Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues.
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion.
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Lymphoma, Follicular
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Lymphoma, Large B-Cell, Diffuse
8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1.
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL.
HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma.
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E?-miR-155 transgenic mouse model.
Paradoxical regulation of hypoxia inducible factor-1? (HIF-1?) by histone deacetylase inhibitor in diffuse large B-cell lymphoma.
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion.
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Lymphoma, Mantle-Cell
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Novel agents in mantle cell lymphoma.
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Targeting BTK through microRNA in chronic lymphocytic leukemia.
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
The double dealing of cyclin D1.
Lymphoma, Non-Hodgkin
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-{kappa}B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells.
Peptide mass mapping of acetylated isoforms of histone H4 from mouse lymphosarcoma cells treated with histone deacetylase (HDACs) inhibitors.
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
Lymphoma, T-Cell
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.
Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.
Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Hdac1 and Hdac2 are essential for physiological maturation of a Cx3cr1 expressing subset of T-lymphocytes.
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing.
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Kinetic and Thermodynamic Rationale for SAHA Being a Preferential Human HDAC8 Inhibitor as Compared to the Structurally Similar Ligand, TSA.
Kinetically selective and potent inhibitors of HDAC8.
Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma.
Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Romidepsin for peripheral T-cell lymphoma.
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
Switching the Switch: Ligand Induced Disulfide Formation in HDAC8.
Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells.
Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma.
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-?B.
Vorinostat ameliorates IL-1?-induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes.
Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
[Epigenetic therapy for hematologic malignancies].
Lymphoma, T-Cell, Cutaneous
A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.
A histone deacetylase-dependent screen in yeast.
A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice.
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Combination therapies improve the anticancer activities of retinoids in neuroblastoma.
Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Cyclic depsipeptides as potential cancer therapeutics.
Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation.
Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques.
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Factors influencing epigenetic mechanisms and related diseases.
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
HDAC pharmacological inhibition promotes cell death through the eIF2? kinases PKR and GCN2.
Histone Deacetylase 3 Is Required for Efficient T Cell Development.
Histone Deacetylase Inhibition Increases Levels of Choline Kinase ? and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers.
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Histone Deacetylase Inhibitor SAHA Induces Expression of Fatty Acid-Binding Protein 4 and Inhibits Replication of Human Cytomegalovirus.
Histone deacetylase inhibitors as novel anticancer therapeutics.
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level.
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma.
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Low-Dose Electron Beam Radiation and Romidepsin Therapy for Symptomatic Cutaneous T-Cell Lymphoma Lesions.
Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.
Novel agents in mantle cell lymphoma.
Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl.
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma.
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair.
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Potential non-oncological applications of histone deacetylase inhibitors.
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells.
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature.
Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.
Response to hydralazine-valproate in a patient with mycosis fungoides.
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma (October).
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Romidepsin: a novel histone deacetylase inhibitor for cancer.
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
Small-molecule chromatin-modifying agents: therapeutic applications.
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT).
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms.
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy.
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
Vorinostat as potential antiparasitic drug.
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Vorinostat in solid and hematologic malignancies.
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.
Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance.
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
[Application of epigenetics to cancer diagnosis and therapy].
Lymphoma, T-Cell, Peripheral
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Beleodaq approved for rare lymphomas.
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.
Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression.
Belinostat: first global approval.
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Chidamide tablets: HDAC inhibition to treat lymphoma.
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
Current status and progress of lymphoma management in China.
Determination of chidamide in rat plasma and cerebrospinal fluid.
Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Epigenetic modifiers: basic understanding and clinical development.
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Histone deacetylase inhibitors: emerging mechanisms of resistance.
In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes.
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma.
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides.
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications.
Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
Targeting histone deacetylases in T-cell lymphoma.
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Lymphopenia
In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development.
Lymphoproliferative Disorders
Epigenetic biomarkers for human cancer: The time is now.
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Machado-Joseph Disease
Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Macular Degeneration
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Malaria
An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes.
Comparative Gene Expression Profiling of P. falciparum Malaria Parasites Exposed to Three Different Histone Deacetylase Inhibitors.
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Inhibition of Plasmodium falciparum proliferation in vitro by double-stranded RNA directed against malaria histone deacetylase.
Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
Potent antimalarial activity of histone deacetylase inhibitor analogues.
Potential non-oncological applications of histone deacetylase inhibitors.
Malaria, Falciparum
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
Malnutrition
Histone Deacetylase Activity and the Renin-Angiotensin-Aldosterone System: Key Elements in Cardiorenal Alterations Provoked by Chronic Malnutrition in Male Adult Rats.
Variants in the SIRT1 gene may affect diabetes risk in interaction with prenatal exposure to famine.
Malocclusion
Epigenetic influence of KAT6B and HDAC4 in the development of skeletal malocclusion.
Mania
Behavioral and neurochemical effects of sodium butyrate in an animal model of mania.
HDAC inhibitors reverse mania-like behavior and modulate epigenetic regulatory enzymes in an animal model of mania induced by Ouabain.
Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania.
Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain.
Role of epigenetic regulatory enzymes in animal models of mania induced by amphetamine and paradoxical sleep deprivation.
Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an animal model of mania induced by ouabain.
The Effects of Histone Deacetylase Inhibition on the Levels of Cerebral Cytokines in an Animal Model of Mania Induced by Dextroamphetamine.
Treating post-dengue mania: Is role of valproate and quetiapine related to histone deacetylase inhibition?
Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2.
Marfan Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
The new bone biology: pathologic, molecular, and clinical correlates.
Mastocytoma
Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.
Mastocytosis
Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells: Implications for Mastocytosis.
Mastocytosis, Systemic
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Measles
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma.
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma.
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro.
Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway.
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.
Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.
Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma.
Histone Deacetylases 5 and 9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth.
Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma.
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Measuring cytotoxicity: a new perspective on LC50.
Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma.
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells.
Transcriptional profiling of medulloblastoma in children.
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
Megacolon
Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders.
Melanoma
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk.
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
BAP1tism of a tumor suppressor.
Beyond PD-1 Immunotherapy in Malignant Melanoma.
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells.
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma.
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Combining Histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells.
Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1.
Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Epigenetic lesions in malignant melanoma.
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.
Expression and function of CD9 in melanoma cells.
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Green tea polyphenols inhibit malignant melanoma progression via regulating circ_MITF/miR-30e-3p/HDAC2 axis.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells.
HDAC6 interacts with PTPN1 to enhance melanoma cells progression.
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation.
Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway.
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.
Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment.
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Histone deacetylase inhibitors and malignant melanoma.
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Histone Deacetylase Inhibitors Sensitize Murine B16F10 Melanoma Cells to Carbon Ion Irradiation by Inducing G1 Phase Arrest.
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin.
Identification of AP-2-regulated genes by macroarray profiling of gene expression in human A375P melanoma.
Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma.
Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay.
Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines.
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.
In vitro effects of histone deacetylase inhibitors and mitomycin C on tenon capsule fibroblasts and conjunctival melanoma cells.
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-? and valproic acid.
Loss of oncostatin M receptor beta in metastatic melanoma cells.
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
Melanoma senescence: HDAC1 in focus.
miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells.
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma.
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.
Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells.
Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway.
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations.
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.
Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma.
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.
Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.
Selenium-containing histone deacetylase inhibitors for melanoma management.
Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.
SIRT6 histone deacetylase functions as a potential oncogene in human melanoma.
Sirtuin deacetylases: a new target for melanoma management.
Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma.
Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
The 14-3-3sigma gene promoter is methylated in both human melanocytes and melanoma.
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome.
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 alpha in human melanoma cells.
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).
Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.
Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors.
Tumour Expression of Histone Deacetylases in Uveal Melanoma.
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Melanoma, Experimental
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Melioidosis
Host gene expression analysis in Sri Lankan melioidosis patients.
Memory Disorders
Cinnamic acid rescues behavioral deficits in a mouse model of traumatic brain injury by targeting miR-455-3p/HDAC2.
CREB binding protein is required for both short-term and long-term memory formation.
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.
Dual influences of early-life maternal deprivation on histone deacetylase activity and recognition memory in rats.
HDAC2 hyperexpression alters hippocampal neuronal transcription and microglial activity in neuroinflammation-induced cognitive dysfunction.
HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
HDAC7 Ubiquitination by the E3 Ligase CBX4 Is Involved in Contextual Fear Conditioning Memory Formation.
Hippocampal chromatin-modifying enzymes are pivotal for scopolamine-induced synaptic plasticity gene expression changes and memory impairment.
Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models.
Histone deacetylase inhibition prevents the impairing effects of hippocampal gastrin-releasing peptide receptor antagonism on memory consolidation and extinction.
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Lentivirus-Mediated HDAC3 Inhibition Attenuates Oxidative Stress in APPswe/PS1dE9 Mice.
Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.
Long-Term Memory in Drosophila Is Influenced by Histone Deacetylase HDAC4 Interacting with SUMO-Conjugating Enzyme Ubc9.
Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease.
Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats.
Sodium Butyrate Reduces Brain Amyloid-? Levels and Improves Cognitive Memory Performance in an Alzheimer's Disease Transgenic Mouse Model at an Early Disease Stage.
Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function.
The Class IIa histone deacetylase HDAC4 and neuronal function: Nuclear nuisance and cytoplasmic stalwart?
The Role of Histone Deacetylase 6 in Synaptic Plasticity and Memory.
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases.
Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model.
Meningioma
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
New insights into meningioma: from genetics to trials.
Meningitis
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
Meningitis, Bacterial
Sodium Butyrate Prevents Memory Impairment by Re-establishing BDNF and GDNF Expression in Experimental Pneumococcal Meningitis.
Mesothelioma
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
Recent advances in the treatment of malignant pleural mesothelioma.
Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid.
The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.
Translational Advances in Pleural Malignancies.
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
Mesothelioma, Malignant
Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes.
Histone Deacetylase Inhibitors as Potential Therapeutic Agents For The Treatment Of Malignant Mesothelioma.
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Metabolic Diseases
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
HDAC9 knockout mice are protected from adipose tissue dysfunction and systemic metabolic disease during high fat feeding.
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Histone modifications and skeletal muscle metabolic gene expression.
Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice.
Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases.
Role of histone deacetylase 9 in regulating adipogenic differentiation and high fat diet-induced metabolic disease.
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
The mechanism and potential targets of class II HDACs in angiogenesis.
Metabolic Syndrome
Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome.
High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-? and LXR-?-pathways in E3 rats.
Pioglitazone up-regulates long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome.
SAHA induces white fat browning and rectifies metabolic dysfunctions via activation of ZFPs.
Microcephaly
Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression.
Microphthalmos
Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor.
Migraine Disorders
Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
Mitochondrial Diseases
Reduction of Rpd3 suppresses defects in locomotive ability and neuronal morphology induced by the knockdown of Drosophila SLC25A46 via an epigenetic pathway.
The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications.
Mononeuropathies
The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model.
Motor Neuron Disease
Clinical and experimental applications of sodium phenylbutyrate.
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.
Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases.
MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients.
Phase 2 study of sodium phenylbutyrate in ALS.
Mouth Neoplasms
Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells.
Moyamoya Disease
Panobinostat, a histone deacetylase inhibitor, rescues the angiogenic potential of endothelial colony-forming cells in moyamoya disease.
Mucositis
Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis.
Multiple Myeloma
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma.
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality.
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Chidamide, a novel histone deacetylase inhibitor, inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A.
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.
CIK Cells and HDAC Inhibitors in Multiple Myeloma.
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Effect of 5-aza-2'-deoxycytidine combined with trichostatin A on RPMI-8226 cell proliferation, apoptosis and DLC-1 gene expression.
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.
Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials.
Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway.
Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma.
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Histone deacetylase inhibitors in multiple myeloma.
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Histone deacetylase inhibitors in the treatment for multiple myeloma.
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
How I treat: New agents in myeloma.
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-?B- and caspase-8-dependent mechanisms.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4.
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Physiologically-based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions.
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Ricolinostat May Enhance Lenalidomide and Dexamethasone Efficacy.
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS.
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma.
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/STAT3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
The role of HDAC6 in cancer.
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF??B pathway in multiple myeloma cells.
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
[Epigenetic therapy for hematologic malignancies].
[Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
[Inhibitory Effect of Histone Deacetylase Inhibitor SAHA on Proliferation of Mouse Multiple Myeloma Cell Line SP2/0 in vitro and in vivo].
[Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Multiple Sclerosis
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
The use of valproic acid and multiple sclerosis.
Tolerogenic dendritic cells generated by in vitro treatment with SAHA are not stable in vivo.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Multiple System Atrophy
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Muscle Cramp
Role of 4-hydroxybutyrate in increased resistance to surgical site infections associated with surgical meshes.
Muscle Weakness
Reduced HDAC2 in skeletal muscle of COPD patients.
Muscular Atrophy
A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program.
Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Differential expression of HDAC and HAT genes in atrophying skeletal muscle.
HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy.
HDAC4 Knockdown Alleviates Denervation-Induced Muscle Atrophy by Inhibiting Myogenin-Dependent Atrogene Activation.
HDAC4 preserves skeletal muscle structure following long-term denervation by mediating distinct cellular responses.
Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice.
Histone Deacetylase 2 Suppresses Skeletal Muscle Atrophy and Senescence via NF-?B Signaling Pathway in Cigarette Smoke-Induced Mice with Emphysema.
Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Histone Deacetylase 6 Is a FoxO Transcription Factor-dependent Effector in Skeletal Muscle Atrophy.
Immobilization induces nuclear accumulation of HDAC4 in rat skeletal muscle.
Long-term cigarette smoke exposure inhibits histone deacetylase 2 expression and enhances the nuclear factor-?B activation in skeletal muscle of mice.
MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients.
MiR-206 Attenuates Denervation-Induced Skeletal Muscle Atrophy in Rats Through Regulation of Satellite Cell Differentiation via TGF-?1, Smad3, and HDAC4 Signaling.
Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4.
The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging.
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy.
[Effect of electroacupuncture on muscular atrophy and expression of microRNAs and muscle satellite cell proliferation related proteins in denervated gastrocnemius muscle rats].
Muscular Atrophy, Spinal
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy.
Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics.
Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on doi: 10.1111/jnc.14935.
Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy.
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy.
In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy.
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Small-Molecule Screening for Genetic Diseases.
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.
Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition.
The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.
Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients.
Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells.
Muscular Diseases
HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1?, and Hsc70.
Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice.
Muscular Dystrophies
Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease.
Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBP?-regulated atrogin1 expression in cancer cachexia.
Muscular Dystrophies, Limb-Girdle
Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.
Muscular Dystrophy, Duchenne
Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.
MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway.
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
Steroid Responsiveness in Duchenne Muscular Dystrophy - Predictive Value of Epigenetic Regulator Histone Deacetylase 2.
Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
Muscular Dystrophy, Emery-Dreifuss
PCAF Involvement in Lamin A/C-HDAC2 Interplay during the Early Phase of Muscle Differentiation.
Mycosis Fungoides
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome.
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.
Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma.
Myelitis
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Myelodysplastic Syndromes
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Epigenetic biomarkers for human cancer: The time is now.
Epigenetic modifiers: basic understanding and clinical development.
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Histone deacetylase inhibitors in myelodysplastic syndrome.
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?
Myelodysplastic syndrome associated with chronic valproic acid therapy: A case report and review of the literature.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Role of epigenetic therapy in myelodysplastic syndrome.
Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
[Application of epigenetics to cancer diagnosis and therapy].
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line]
Myocardial Infarction
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
CaMKII exacerbates heart failure progression by activating class I HDACs.
Exercise improves cardiac function and glucose metabolism in mice with experimental myocardial infarction through inhibiting HDAC4 and upregulating GLUT1 expression.
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation.
HDAC9 exacerbates myocardial infarction via inactivating Nrf2 pathways.
Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats.
LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis.
Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.
Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs.
Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium.
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model.
[Electroacupuncture for myocardial ischemia injury in rats via AMPK-HDAC5-HIF-1? signaling].
Myocardial Ischemia
Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury.
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
[Electroacupuncture for myocardial ischemia injury in rats via AMPK-HDAC5-HIF-1? signaling].
Myocarditis
Histone deacetylase inhibitors suppress coxsackievirus B3 growth in vitro and myocarditis induced in mice.
Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Myositis Ossificans
The new bone biology: pathologic, molecular, and clinical correlates.
Nasal Polyps
Effects of histone deacetylase inhibitor on extracellular matrix production in human nasal polyp organ cultures.
Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts.
The role of transcriptional factor p63 in regulation of epithelial barrier and ciliogenesis of human nasal epithelial cells.
Nasopharyngeal Carcinoma
Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma.
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression.
Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics.
Essential role of PKC{delta} in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells.
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis.
Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Nasopharyngeal Neoplasms
LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer.
Neonatal Sepsis
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Neoplasm Metastasis
15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29.
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer.
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.
Anticancer Effects of Valproic Acid via Regulation of Epigenetic Mechanisms in Non-small-cell Lung Cancer A549 Cell Line.
AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3? activation.
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Crosstalk between ATF4 and MTA1/HDAC1 promotes osteosarcoma progression.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
DDX23-Linc00630-HDAC1 axis activates the Notch pathway to promote metastasis.
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1? synthesis, and decreases breast cancer metastasis.
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Down-Regulated Expression of HSP70 in Correlation with Clinicopathology of Cholangiocarcinoma.
Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.
Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
EPIGENETIC CHANGES IN MALIGNANT UVEAL MELANOMA AND POSSIBILITIES OF THEIR THERAPEUTIC TARGETING.
Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer.
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A.
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Expression profiles of histone modification genes in gastric cancer progression.
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.
HDAC6 interacts with PTPN1 to enhance melanoma cells progression.
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration.
HIF-1? and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC metastasis.
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1? under hypoxia condition.
Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.
Histone deacetylase 6 in cancer.
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Histone deacetylase 8 in neuroblastoma tumorigenesis.
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane.
Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis.
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy.
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer.
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619-5p activity and facilitating HDAC3 expression.
MAPK phosphatase-1 contributes to trichostatin A inhibition of cyclooxygenase-2 expression in human umbilical vascular endothelial cells exposed to lipopolysaccharide.
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma.
Metastasis-associated Protein 1 Drives Tumor Cell Migration and Invasion through Transcriptional Repression of RING Finger Protein 144A.
Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
MicroRNA-206 suppresses gastric cancer cell growth and metastasis.
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
miR-1236 regulates hypoxia-induced epithelial-mesenchymal transition and cell migration/invasion through repressing SENP1 and HDAC3.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
NEDD9 Regulates Actin Dynamics through Cortactin Deacetylation in an AURKA/HDAC6-dependent Manner.
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
p53 in trichostatin A induced C6 glioma cell death.
PFN2a Suppresses C2C12 Myogenic Development by Inhibiting Proliferation and Promoting Apoptosis via the p53 Pathway.
Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Phthalates Stimulate the Epithelial to Mesenchymal TransitionThrough an HDAC6-Dependent Mechanism in Human BreastEpithelial Stem Cells.
PKC? phosphorylates MIIP and promotes colorectal cancer metastasis through inhibition of RelA deacetylation.
Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex.
Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Radiosynthesis and preliminary evaluation of an 18 F-labeled tubastatin A analog for PET imaging of histone deacetylase 6.
Repression of the Long Noncoding RNA-LET by Histone Deacetylase 3 Contributes to Hypoxia-Mediated Metastasis.
Requirement of HDAC6 for activation of Notch1 by TGF-?1.
RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer.
Runx3 Induces a Cell Shape Change and Suppresses Migration and Metastasis of Melanoma Cells by Altering a Transcriptional Profile.
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells.
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis.
Targeting Histone Modifications in Bone and Lung Metastatic Cancers.
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
TGF-?1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer.
The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases.
The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting SMO expression.
The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.
The Relationship between HDAC3 and Malignant Tumors: A Mini Review.
The role of HDAC6 in cancer.
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer.
v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex.
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
Yixin-Fumai granules improve sick sinus syndrome in aging mice through Nrf-2/HO-1 pathway: A new target for sick sinus syndrome.
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
Neoplasm Micrometastasis
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Neoplasm, Residual
AML in 2017: Advances in clinical practice.
Neoplasms
1,3,4-oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells.
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.
3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90? chaperone activity against prostate cancer.
4sc-202 and Ink-128 cooperate to reverse the epithelial to mesenchymal transition in OSCC.
A Bioluminescent Probe for Simultaneously Imaging Esterase and Histone Deacetylase Activity in a Tumor.
A C-terminus-dependent conformational change is required for HDAC3 activation by nuclear receptor corepressors.
A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy.
A Class 1 Histone Deacetylase with Potential as an Antifungal Target.
A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
A CRISPR-Cas9 repressor for epigenetic silencing of KRAS.
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene.
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.
A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells.
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
A histone deacetylase-dependent screen in yeast.
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
A library of aminoglycoside-derived lipopolymer nanoparticles for delivery of small molecules and nucleic acids.
A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling.
A monoclonal antibody specific for prophase phosphorylation of histone deacetylase 1: a readout for early mitotic cells.
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.
A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
A New Molecular Mechanism Underlying the Antitumor Effect of DNA Methylation Inhibitors via an Antiviral Immune Response.
A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.
A new role for histone deacetylase 5 in the maintenance of long telomeres.
A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells.
A non-isotopic assay for histone deacetylase activity.
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKC? and E-cadherin.
A novel class of anthraquinone-based HDAC6 inhibitors.
A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells.
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells.
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer.
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
A Perspective of Epigenetic Regulation in Radiotherapy.
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
A phase I study of resminostat in Japanese patients with advanced solid tumors.
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.
A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases.
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.
A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.
A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.
A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy.
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
A Prognostic Model for Brain Glioma Patients Based on 9 Signature Glycolytic Genes.
A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression.
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard.
A series of novel, potent, and selective histone deacetylase inhibitors.
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
A spectrophotometric assay for histone deacetylase 8.
A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
A valproic acid-modified platinum diimine complex as potential photosensitizer for photodynamic therapy.
A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells.
A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling.
ABIN1 inhibits HDAC1 ubiquitination and protects it from both proteasome- and lysozyme-dependent degradation.
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation.
Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion.
Acetylation and histone deacetylase inhibitors in cancer.
Acetylation modification regulates GRP78 secretion in colon cancer cells.
Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.
Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.
Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator.
Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer.
Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation.
Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells.
Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.
Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z.
Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C.
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid.
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Adoptive transfer of immature myeloid cells lacking NF-?B p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma.
Advances in epigenetic glioblastoma therapy.
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
AKT activation controls cell survival in response to HDAC6 inhibition.
Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
Alkylating agent methyl methanesulfonate (MMS) induces a wave of global protein hyperacetylation: implications in cancer cell death.
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter.
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
Alterations of epigenetics and microRNA in hepatocellular carcinoma.
Alternative Modes of Binding of Recombinant Human Histone Deacetylase 8 to Colloidal Gold Nanoparticles.
Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
Amino acid derivatives as histone deacetylase inhibitors.
Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1? and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol.
An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms.
An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy.
An epigenetic vaccine model active in the prevention and treatment of melanoma.
An epigenetically altered tumor cell vaccine.
An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.
An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression.
An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis.
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex.
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
An overview on the role of dietary phenolics for the treatment of cancers.
An unbiased approach to identify endogenous substrates of "histone" deacetylase 8.
An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation.
AN-9 (Titan).
Analysis of class I and II histone deacetylase gene expression in human leukemia.
Analysis of Epigenetic Regulation of Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancer Cells by Quantitative Chromatin Immunoprecipitation of Histone Deacetylase 3 (HDAC3).
Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE.
Analysis of post-transcriptional regulation using the FunREG method.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Analysis of the role of DAMTC in lung adenocarcinoma cells based on the DNA microarrays.
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.
Anti-Cancer Effect of 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide in MCF-7 Human Breast Cancer.
Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer.
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents.
Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (-)-Epigallocatechin-3-Gallate (EGCG).
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T- and natural killer- cell lymphoma.
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
Anticancer activity of topical ointments with histone deacetylase inhibitor, trichostatin A.
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Anticancer Effects of Valproic Acid via Regulation of Epigenetic Mechanisms in Non-small-cell Lung Cancer A549 Cell Line.
Anticancer Peptidylarginine Deiminase (PAD) Inhibitors Regulate the Autophagy Flux and the Mammalian Target of Rapamycin Complex 1 Activity.
Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy.
Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1.
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.
Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells.
Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy.
Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
AP-1 confers resistance to anti-cancer therapy by activating XIAP.
Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase C?1- and Ca(2+)-dependent pathway in mouse Neuro-2a neuroblastoma cells.
Apicidin Inhibited Proliferation and Invasion and Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 Cells.
Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.
Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer.
APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.
Apoptotic Effects of N-(2-hydroxyphenyl)-2-propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties.
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression.
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.
Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Array-based approaches for the identification of epigenetic silenced tumor suppressor genes.
Arsenic exposure disrupts epigenetic regulation of SIRT1 in human keratinocytes.
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Arylurea Derivatives: a Class of Potential Cancer Targeting Agents.
Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.
Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Association of a Multigenetic Pro-Inflammatory Profile with Ischaemic Stroke.
Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies.
Astrocytes are HIV reservoirs in the brain: A cell type with poor HIV infectivity and replication but efficient cell-to-cell viral transfer.
ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Autophagy and mTOR pathways in mouse embryonic stem cell, lung cancer and somatic fibroblast cell lines.
Autophagy inhibitor sensitizes MCF-7 breast cancer cells to novel cyclic tetrapeptide CTS203-induced caspase-9-dependent apoptotic cell death.
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKC?-mediated AHR-HDAC interactions.
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients.
Belinostat for the treatment of peripheral T-cell lymphomas.
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
Belinostat suppresses cell proliferation by inactivating Wnt/?-catenin pathway and promotes apoptosis through regulating PKC pathway in breast cancer.
Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1.
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells.
Bicyclic tetrapeptide histone deacetylase inhibitors with methoxymethyl ketone and boronic acid zinc-binding groups.
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
Biological functions of the ING family tumor suppressors.
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death.
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation.
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
BOS is associated with decreased HDAC2 from steroid resistant lymphocytes in the small airways.
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
Brain region-specific regulation of histone acetylation and efflux transporters in mice.
BRCA1 in cancer, cell cycle and genomic stability.
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
BRG1, the ATPase subunit of SWI/SNF chromatin remodeling complex, interacts with HDAC2 to modulate telomerase expression in human cancer cells.
Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways.
Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells.
Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.".
Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells.
Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis.
Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.
Butyrate rich colonic microenvironment is a relevant selection factor for metabolically adapted tumour cells.
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and ?-tubulin hyperacetylation both in vitro and in vivo.
CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis.
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.
Cancer chemopreventive diterpenes from Salvia corrugata.
Cancer epigenetics.
Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat.
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Cancer-testis antigens in haematological malignancies.
Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1? for Intrahepatic Cholangiocarcinoma.
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
Cardio-Hepatic Metabolic Derangements and Valproic Acid.
Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?
Carrier-Free Supramolecular Hydrogel Composed of Dual Drugs for Conquering Drug Resistance.
Caspase-mediated specific cleavage of human histone deacetylase 4.
Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.
CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy.
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A.
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis.
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: Induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Changes in Chromatin Structure in NIH 3T3 Cells Induced by Valproic Acid and Trichostatin A.
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers?
Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells.
Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
Characterization of Histone Deacetylase Mechanisms in Cancer Development.
Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress.
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer.
Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation.
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chemoprotection by sulforaphane: Keep one eye beyond Keap1.
Chemotherapy-induced peripheral neuropathy: where are we now?
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Chidamide in the treatment of peripheral T-cell lymphoma.
Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl?2 pathway.
Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR?33a?5p?LDHA axis.
Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Chidamide, a novel histone deacetylase inhibitor, inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A.
Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling.
Chlorogenic-induced inhibition of non-small cancer cells occurs through regulation of histone deacetylase 6.
Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.
Chromatin modifying agents - the cutting edge of anticancer therapy.
Chromatin remodeling agents for cancer therapy.
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.
Chromatin remodeling, cancer and chemotherapy.
Chromatin-remodelling mechanisms in cancer.
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).
Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9).
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis.
Cinnamaldehyde, Cinnamic Acid, and Cinnamyl Alcohol, the Bioactives of
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis.
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha}.
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Clinical and experimental applications of sodium phenylbutyrate.
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
Clinical Potential of Histone Deacetylase Inhibitors as Stand Alone Therapeutics and in Combination with Other Chemotherapeutics or Radiotherapy for Cancer.
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Clinical significance of HDAC9 in hepatocellular carcinoma.
Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors.
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC.
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor.
Cloning and characterization of a novel human histone deacetylase, HDAC8.
Cloning and characterization of the murine histone deacetylase (HDAC3).
Cloning and structural characterization of the human histone deacetylase 6 gene.
Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter.
CLU blocks HDACI-mediated killing of neuroblastoma.
Clusterin and chemoresistance.
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models.
Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter.
Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies.
Colonic health: fermentation and short chain fatty acids.
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.
Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways.
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Combinatorial
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors.
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma.
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Combining epigenetic and immune therapy to overcome cancer resistance.
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.
Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Comparative epigenomics of human and mouse mammary tumors.
Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.
Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro.
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors.
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells.
Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment.
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression.
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Correction: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Could valproic acid be an effective anticancer agent? The evidence so far.
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Cracking a cancer code histone deacetylation in epigenetic: the implication from molecular dynamics simulations on efficacy assessment of histone deacetylase inhibitors.
Creating zinc monkey wrenches in the treatment of epigenetic disorders.
CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma.
Critical role of deoxynucleotidyl transferase terminal interacting protein 1 in oral cancer.
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Crystal structure of a bacterial class 2 histone deacetylase homologue.
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10.
CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis.
Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis.
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Curcumin as a regulator of epigenetic events.
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells.
Curcumin: a natural pan-HDAC inhibitor in cancer.
Current and emerging treatment strategies for cutaneous T-cell lymphoma.
Current limitations and future opportunities for epigenetic therapies.
Current status of healthy human skin models: can histone deacetylase inhibitors potentially improve the present replacement models?
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
CXCL1/GRO? increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-?B/HDAC1 epigenetic regulation.
Cyclic Disulfides as Functional Mimics of the Histone Deacetylase Inhibitor FK-228.
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.
Deacetylase inhibitors - focus on non-histone targets and effects.
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ?Np73 expression.
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Decoy Receptor 3 Enhances Tumor Progression via Induction of Tumor-Associated Macrophages.
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Defining the chemotherapeutic targets of histone deacetylase inhibitors.
Defining the minimal peptide sequence of the ING1b tumour suppressor capable of efficiently inducing apoptosis.
Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays.
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling?
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Design and conduct of early-phase radiotherapy trials with targeted therapeutics: Lessons from the PRAVO experience.
Design and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics.
Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Design and synthesis of a potent histone deacetylase inhibitor.
Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
Design of N-substituted aminobutyric hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic composition.
Design of novel histone deacetylase inhibitors.
Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
Design, Synthesis and Biological Evaluation of Quinazoline Derivatives as Dual HDAC1 and HDAC6 Inhibitors for the Treatment of Cancer.
Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy.
Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.
Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Design, Synthesis, Structure-Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors.
Detection of apoptotic cells using immunohistochemistry.
Detection of apoptotic cells using propidium iodide staining.
Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Development and optimization of a binding assay for histone deacetylase 4 using surface plasmon resonance.
Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors.
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Development of decision trees to discriminate HDAC8 inhibitors and non-inhibitors using recursive partitioning.
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Development of histone deacetylase inhibitors for cancer treatment.
Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
Development of new therapeutic options for the treatment of uveal melanoma.
Development of novel alkylating drugs as anticancer agents.
Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy.
Development of Tetrahydroisoquinoline-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells.
Developmental programming: Prenatal bisphenol A treatment disrupts mediators of placental function in sheep.
Dietary agents as histone deacetylase inhibitors.
Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.
Dietary Sulforaphane, a Histone Deacetylase Inhibitor for Cancer Prevention.
Differences in Functional Expression of Connexin43 and NaV1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart.
Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements.
Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines.
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?
Differential effects of hydroxamate histone deacetylase inhibitors on cellular functionality and gap junctions in primary cultures of mitogen-stimulated hepatocytes.
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy.
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Differential expression of selected histone modifier genes in human solid cancers.
Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia.
Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.
Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy.
Differential SIRT1 Expression in Hepatocellular Carcinomas and Cholangiocarcinoma of the Liver.
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines.
Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent.
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone.
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic alpha(3)beta-Tetrapeptides.
Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure-Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses.
Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Discovery research to clinical trial: a ten year journey.
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor.
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A.
Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas.
Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
DNA methylation and cancer.
DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression.
DNA Methylation as a Target of Epigenetic Therapeutics in Cancer.
DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability.
DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly.
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
Docking and QSAR studies of aryl-valproic acid derivatives to identify anti-proliferative agents targeting the HDAC8.
Does valproic acid induce neuroendocrine differentiation in prostate cancer?
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.
Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter.
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Downregulation of Ca2+-activated Cl- channel TMEM16A by the inhibition of histone deacetylase in TMEM16A-expressing cancer cells.
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells.
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients.
Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma.
Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin.
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.
Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells.
Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.
Downregulation of SIRT2 Inhibits Invasion of Hepatocellular Carcinoma by Inhibiting Energy Metabolism.
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells.
Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress.
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors.
Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Dual Targeting Strategies On Histone Deacetylase 6 (HDAC6) And Heat Shock Protein 90 (Hsp90).
Dual-acting histone deacetylase-topoisomerase I inhibitors.
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
Dynamic interaction of HDAC1 with a glucocorticoid receptor-regulated gene is modulated by the activity state of the promoter.
Dynamic Structure-Based Pharmacophore Model Development: A New and Effective Addition in the Histone Deacetylase 8 (HDAC8) Inhibitor Discovery.
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress.
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
E3 ligase RCHY1 negatively regulates HDAC2.
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Ectopic expression of activation-induced cytidine deaminase caused by epigenetics modification.
Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis.
Editorial: Epigenetic Therapy With Histone Deacetylase Inhibitors: Implications for Cancer Treatment.
Effect of epigenetic modulation on cancer sphere.
Effect of Genistein in Comparison with Trichostatin A on Reactivation of DNMTs Genes in Hepatocellular Carcinoma.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Effect of histone deacetylase on prostate carcinoma.
Effect of suberoylanilide hydroxamic acid on peripheral blood mononuclear cell cytotoxicity towards tumor cells in canines.
Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Effect of the histone deacetylase inhibitor trichostatin a on the metabolome of cultured primary hepatocytes.
Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.
Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments.
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Effect of valproic acid on the outcome of glioblastoma multiforme.
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Effects of HDACi on Immunological Functions.
Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Effects of the histone deacetylases inhibitors sodium butyrate and trichostatin A on the inhibition of gap junctional intercellular communication by H2O2- and 12-O-tetradecanoylphorbol-13-acetate in rat liver epithelial cells.
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells.
Efficient organic monoliths prepared by ?-radiation induced polymerization in the evaluation of histone deacetylase inhibitors by capillary(nano)-high performance liquid chromatography and ion trap mass spectrometry.
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function.
EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours.
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer.
Elucidating the mechanism of regulation of transforming growth factor ? Type II receptor expression in human lung cancer cell lines.
Emerging roles of calreticulin in cancer: implications for therapy.
Emerging roles of the microbiome in cancer.
Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Emerging Therapies for the Treatment of Relapsed or Refractory Multiple Myeloma.
Endocrine resistant breast cancer cells with loss of ER? expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin.
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
Enhanced activation of NAD(P)H: quinone oxidoreductase 1 attenuates spontaneous hypertension by improvement of endothelial nitric oxide synthase coupling via tumor suppressor kinase liver kinase B1/adenosine 5'-monophosphate-activated protein kinase-mediated guanosine 5'-triphosphate cyclohydrolase 1 preservation.
Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824.
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities.
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action.
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Enhancing the anti-angiogenic action of histone deacetylase inhibitors.
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway.
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells.
Epigenetic alterations and cancer: new targets for therapy.
Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review.
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
EPIGENETIC CHANGES IN MALIGNANT UVEAL MELANOMA AND POSSIBILITIES OF THEIR THERAPEUTIC TARGETING.
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.
Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
Epigenetic control of gene expression: Potential implications for cancer treatment.
Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.
Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis.
Epigenetic information and estrogen receptor alpha expression in breast cancer.
Epigenetic inhibition assisted chemotherapeutic treatment of lung cancer based on artificial exosomes.
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.
Epigenetic modulation of immunotherapy and implications in head and neck cancer.
Epigenetic modulation of immunotherapy cofactors to enhance tumor response in lung cancer.
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6.
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer.
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells.
Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins.
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Epigenetic Silencing of Apoptosis-Inducing Gene Expression Can Be Efficiently Overcome by Combined SAHA and TRAIL Treatment in Uterine Sarcoma Cells.
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Epigenetic Targeting of Transforming Growth Factor beta Receptor II and Implications for Cancer Therapy.
Epigenetic targets in cancer and aging: dietary and therapeutic interventions.
Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Epigenetic therapy for colorectal cancer.
Epigenetic therapy for solid tumors: from bench science to clinical trials.
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia.
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Epigenetic therapy in human choriocarcinoma.
Epigenetic therapy of cancer with histone deacetylase inhibitors.
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Epigenetic transitions: towards therapeutic targets.
Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.
Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors.
Epigenetically active drugs inhibiting DNA methylation and histone deacetylation.
Epigenetics as a Therapeutic Target in Breast Cancer.
Epigenetics of cervical cancer. An overview and therapeutic perspectives.
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Epigenome: a new target in cancer therapy.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer.
Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges.
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A.
Epstein-Barr virus-infected Akata cells are sensitive to histone deacetylase inhibitor TSA-provoked apoptosis.
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
ERK1/2 activation plays important roles in the opposite effects of Trichostatin A in non-cancer and cancer cells.
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
ERRATUM.
Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors.
Essential role of DNA methyltransferase 1-mediated transcription of insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Establishment and characterization of 18 human colorectal cancer cell lines.
Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules.
Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma.
Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells.
ETS gene fusions in prostate cancer.
Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy.
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Exploiting novel cell cycle targets in the development of anticancer agents.
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.
Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma.
Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.
Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.
Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.
Expression of HDAC4 in Stage B Hepatocellular Carcinoma and Its Influence on Survival.
Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis.
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
Expression of SIRT1 in Ocular Surface Squamous Neoplasia.
Expression profile of class I histone deacetylases in human cancer tissues.
Expression profile of histone deacetylase 1 in gastric cancer tissues.
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues.
Expression profiles of histone modification genes in gastric cancer progression.
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
EZH2 Regulates Protein Stability via Recruiting USP7 to Mediate Neuronal Gene Expression in Cancer Cells.
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Factors influencing epigenetic mechanisms and related diseases.
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Fc?RI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.
Fentanyl Inhibits Lung Cancer Viability and Invasion via Upregulation of miR-331-3p and Repression of HDAC5.
Ferritin H induction by histone deacetylase inhibitors.
Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.
Finding a cure for HIV: will it ever be achievable?
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
First non-radioactive assay for in vitro screening of histone deacetylase inhibitors.
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors.
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation.
Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention.
Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases.
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Focus on deacetylation for therapeutic benefit.
Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy.
FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
From Anti-infective Agents to Cancer Therapy: a Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives.
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Functional DNA demethylation is accompanied by chromatin accessibility.
Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Functionalized MoS2 Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy.
Fungus-specific sirtuin HstD coordinates secondary metabolism and development through control of LaeA.
Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome.
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer.
Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4 in vivo footprinting on its promoter region.
Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor.
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.
Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
Gene Ontology-driven transcriptional analysis of CD34+ cell-initiated megakaryocytic cultures identifies new transcriptional regulators of megakaryopoiesis.
Gene Silencing Associated with SWI/SNF Complex Loss during NSCLC Development.
Genes methylated in cancer that are resistant to activation by DNA demethylating agents and histone deacetylase inhibitors.
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Genetic dissection of histone deacetylase requirement in tumor cells.
Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro.
Genomic DNA hypomethylation by HDAC inhibition implicates DNMT1 nuclear dynamics.
Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Grand Rounds at the National Institutes of Health: HDAC Inhibitors as Radiation Modifiers, from Bench to Clinic.
GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis.
Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53.
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
HDAC expression and clinical prognosis in human malignancies.
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy.
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2.
HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.
HDAC inhibitor-based therapies and haematological malignancy.
HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).
HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.
HDAC inhibitors and immunotherapy; a double edged sword?
HDAC Inhibitors and RECK Modulate Endoplasmic Reticulum Stress in Tumor Cells.
HDAC inhibitors and their potential applications to glioblastoma therapy.
HDAC inhibitors as anti-inflammatory agents.
HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy.
HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma.
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action.
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL.
HDAC inhibitors for the treatment of cancer.
HDAC inhibitors in experimental liver and kidney fibrosis.
HDAC inhibitors in parasitic diseases.
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.
HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.
HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression.
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells.
HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics.
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
HDAC inhibitors, trichostatin A and valproic acid, increase E?cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
HDAC inhibitors: Clinical update and mechanism-based potential.
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity.
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.
HDAC is indispensable for IFN-?-induced B7-H1 expression in gastric cancer.
HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.
HDAC pharmacological inhibition promotes cell death through the eIF2? kinases PKR and GCN2.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis.
Hdac1 and Hdac2 are essential for physiological maturation of a Cx3cr1 expressing subset of T-lymphocytes.
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
HDAC1 controls CIP2A transcription in human colorectal cancer cells.
HDAC1 expression and effect of curcumin on proliferation of Raji cells.
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression.
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta.
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
HDAC1 Substrate Profiling using Proteomics-Based Substrate Trapping.
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
HDAC2 links ubiquitination to tumor suppression in synovial sarcoma.
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression.
HDAC2: a critical factor in health and disease.
HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels.
HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGF? axis.
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
HDAC3 mediates smoking-induced pancreatic cancer.
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
HDAC3 regulates stability of estrogen receptor ? mRNA.
HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
HDAC3: taking the SMRT-N-CoRrect road to repression.
HDAC3i-Finder: A Machine Learning-based Computational Tool to Screen for HDAC3 Inhibitors.
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.
HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
HDAC4 promotes growth of colon cancer cells via repression of p21.
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
HDAC4 protein regulates HIF1? protein lysine acetylation and cancer cell response to hypoxia.
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.
HDAC6 and Ovarian Cancer.
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS.
HDAC6 as privileged target in drug discovery: A perspective.
HDAC6 Brain Mapping with [
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.
HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma.
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.
HDAC6 expression is correlated with better survival in breast cancer.
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the E?-TCL1 Model.
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth.
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia.
HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
HDAC6 interacts with PTPN1 to enhance melanoma cells progression.
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization.
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma.
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.
Hdac6 regulates Tip60-p400 function in stem cells.
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
HDAC6 Substrate Discovery Using Proteomics-Based Substrate Trapping: HDAC6 Deacetylates PRMT5 to Influence Methyltransferase Activity.
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models.
HDAC6-Dependent Functions in Tumor Cells: Crossroad with the MAPK Pathways.
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis.
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells.
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.
HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.
HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3?/Snail signals.
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
HDAC8, A Potential Therapeutic Target, Regulates Proliferation and Differentiation of Bone Marrow Stromal Cells in Fibrous Dysplasia.
HDAC8: a multifaceted target for therapeutic interventions.
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
HDAC9 Is Preferentially Expressed in Dedifferentiated Hepatocellular Carcinoma Cells and Is Involved in an Anchorage-Independent Growth.
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.
HDACi: molecular mechanisms and therapeutic implications in the innate immune system.
HDACiDB: a database for histone deacetylase inhibitors.
HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.
High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region.
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.
Histone acetylation and gastrointestinal carcinogenesis.
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Histone acetylation-mediated regulation of genes in leukaemic cells.
Histone acetylation-mediated regulation of the Hippo pathway.
Histone acetyltransferase inhibitors and preclinical studies.
Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.
Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors.
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis.
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Histone deacetylase (HDAC) inhibitory and antiproliferative activities of phenolic-rich extracts derived from the rhizome of Hydnophytum formicarum Jack.: sinapinic acid acts as HDAC inhibitor.
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Histone deacetylase 1 and 2 in mesenchymal tumors.
Histone deacetylase 1 and 2 regulate Wnt and p53 pathways in the ureteric bud epithelium.
Histone deacetylase 1 expression in gastric cancer.
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia.
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway.
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Histone deacetylase 10, a potential epigenetic target for therapy.
Histone Deacetylase 11 Is an ?-N-Myristoyllysine Hydrolase.
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Histone deacetylase 3 controls a transcriptional network required for B cell maturation.
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Histone deacetylase 4 inhibits NF-?B activation by facilitating I?B? sumoylation.
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Histone deacetylase 5 regulates the inflammatory response of macrophages.
Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells.
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer.
Histone deacetylase 6 in cancer.
Histone deacetylase 6 in health and disease.
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.
Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway.
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway.
Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis.
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
Histone deacetylase as a new target for cancer chemotherapy.
Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase HDAC4 participates in the pathological process of myocardial ischemia-reperfusion injury via MEKK1/JNK pathway by binding to miR-206.
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Histone deacetylase inhibition as an anticancer telomerase-targeting strategy.
Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy.
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Histone Deacetylase Inhibition Downregulates Collagen 3A1 in Fibrotic Lung Fibroblasts.
Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Histone Deacetylase Inhibition Increases Levels of Choline Kinase ? and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers.
Histone deacetylase inhibition induces apoptosis in neuroblastoma.
Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes.
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.
Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer.
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.
Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells.
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.
Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy.
Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice.
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor {beta} (TGF{beta}) Receptor II Leading to Cancer Cell Death.
Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.
Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
Histone Deacetylase Inhibitor Induced Radiation Sensitization Effects on Human Cancer Cells after Photon and Hadron Radiation Exposure.
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region.
Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells.
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Histone Deacetylase Inhibitor SAHA Induces Expression of Fatty Acid-Binding Protein 4 and Inhibits Replication of Human Cytomegalovirus.
Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells.
Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.
Histone deacetylase inhibitor stimulates E2 and P4 secretion in sika deer ovarian granulosa cells at a moderate dose.
Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell.
Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.
Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha.
Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing.
Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells.
Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53.
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives.
Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Histone deacetylase inhibitors and anticancer therapy.
Histone deacetylase inhibitors and cancer therapy.
Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Histone deacetylase inhibitors and colorectal cancer: what is new?
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Histone deacetylase inhibitors as cancer therapeutics.
Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Histone deacetylase inhibitors as new cancer drugs.
Histone deacetylase inhibitors as novel anti-inflammatory agents.
Histone deacetylase inhibitors as novel anticancer therapeutics.
Histone deacetylase inhibitors as potent modulators of cellular contacts.
Histone deacetylase inhibitors as potential anti-skin cancer agents.
Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.
Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes.
Histone deacetylase inhibitors block IFN?-induced STAT1 phosphorylation.
Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells.
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells.
Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy.
Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity.
Histone deacetylase inhibitors for cancer therapy.
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success.
Histone deacetylase inhibitors for epigenetic therapy of cancer.
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
Histone deacetylase inhibitors from the rhizomes of Zingiber zerumbet.
Histone deacetylase inhibitors in APL and beyond.
Histone deacetylase inhibitors in cancer therapy.
Histone Deacetylase Inhibitors in Cancer Therapy.
Histone deacetylase inhibitors in cancer therapy. A review.
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.
Histone deacetylase inhibitors in cancer treatment.
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.
Histone deacetylase inhibitors in cancer: What have we learnt?
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.
Histone deacetylase inhibitors in programmed cell death and cancer therapy.
Histone deacetylase inhibitors in the generation of the anti-tumour immune response.
Histone deacetylase inhibitors in the therapy of cancer: much to learn.
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
Histone Deacetylase Inhibitors in Tumor Immunotherapy.
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression.
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.
Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin dependent mechanism.
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Histone deacetylase inhibitors mediate post-transcriptional regulation of p21(WAF1) through novel cis-acting elements in the 3' untranslated region.
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Histone deacetylase inhibitors open new doors in cancer therapy.
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions.
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.
Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET.
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.
Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells.
Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties.
Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis resistant mammary and brain cancer stem cells thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.
Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells.
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells.
Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer.
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity.
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
Histone Deacetylase Inhibitors Suppress the Expression of Inflammatory and Innate Immune Response Genes in Human Microglia and Astrocytes.
Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Histone deacetylase inhibitors through click chemistry.
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8- but not caspase-9-dependent apoptosis in human malignant glioma cells.
Histone deacetylase inhibitors--a new tool to treat cancer.
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Histone deacetylase inhibitors: a review on class-I specific inhibition.
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.
Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy.
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
Histone deacetylase inhibitors: development as cancer therapy.
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.
Histone deacetylase inhibitors: gathering pace.
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
Histone deacetylase inhibitors: novel agents in cancer treatment.
Histone deacetylase inhibitors: novel anticancer agents.
Histone deacetylase inhibitors: potent anti-leukemic agents.
Histone deacetylase inhibitors: Potential in cancer therapy.
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.
Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines
Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Histone deacetylase regulation of immune gene expression in tumor cells.
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers.
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Histone Deacetylases 5 and 9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth.
Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Histone Deacetylases and their Inhibitors in Cancer Epigenetics.
Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane.
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Histone deacetylases in RA: epigenetics and epiphenomena.
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.
Histone Deacetylases Inhibit the Snail2-Mediated EMT During Metastasis of Hepatocellular Carcinoma Cells.
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Histone deacetylases.
Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy.
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair.
Histone hyperacetylation during meiosis interferes with large-scale chromatin remodeling, axial chromatid condensation and sister chromatid separation in the mammalian oocyte.
Histone lysine demethylases as targets for anticancer therapy.
Histone-deacetylase 8 drives the immune response and the growth of glioma.
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors.
Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors.
HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
hsa-miR-20a-5p attenuates allergic inflammation in HMC-1 cells by targeting HDAC4.
Hsp60 and IL-8 axis promotes apoptosis resistance in cancer.
Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.
Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
Hyaluronan binding motifs of USP17 and SDS3 exhibit anti-tumor activity.
Hyaluronic acid butyric esters in cancer therapy.
Hyaluronic acid promotes the expression of progesterone receptor membrane component 1 via epigenetic silencing of miR-139-5p in human and rat granulosa cells.
Hyaluronic Acid-Functionalized Nanomicelles Enhance SAHA Efficacy in 3D Endometrial Cancer Models.
Hybrid mesoporous nanorods with deeply grooved lateral faces toward cytosolic drug delivery.
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
Hydralazine Target: From blood vessels to the epigenoma.
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells.
Hydrogen Sulfide Protects Cardiomyocytes against Apoptosis in Ischemia/Reperfusion through MiR-1-Regulated Histone Deacetylase 4 Pathway.
Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells.
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Hypoxia promotes colorectal cancer cell migration and invasion in a SIRT1-dependent manner.
Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.
Hypoxic microenvironment shapes HIV-1 replication and latency.
I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain.
Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma.
Identification and characterization of the variants of metastasis-associated protein 1 generated following alternative splicing.
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis.
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr virus.
Identification of a novel polyprenylated acylphloroglucinol?derived SIRT1 inhibitor with cancer?specific anti-proliferative and invasion-suppressing activities.
Identification of an intrinsic determinant critical for maspin subcellular localization and function.
Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer.
Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.
Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes.
Identification of Dacinostat as a potential anti-obesity compound through transcriptional activation of adipose thermogenesis in mice.
Identification of epigenetically silenced genes in tumor endothelial cells.
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases.
Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach.
Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.
Identifying Novel Type ZBGs and Nonhydroxamate HDAC Inhibitors Through a SVM Based Virtual Screening Approach.
IFN-? potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study.
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Impact of HDAC inhibitors on dendritic cell functions.
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis.
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme.
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Implantable HDAC-inhibiting chemotherapeutics derived from hydrophobic amino acids for localized anticancer therapy.
Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy.
Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors.
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
In silico Design of Novel Sirtuin 1 Enzyme Activators for Treatment of Age-related Diseases and Life Span.
In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.
In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation.
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells.
Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression.
Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist.
Increase of Hspa1a and Hspa1b genes in the resting B cells of Sirt1 knockout mice.
Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.
Increased Histone Deacetylase Activity Involved in the Suppressed Invasion of Cancer Cells Survived from ALA-Mediated Photodynamic Treatment.
Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice.
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹?F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer.
Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease.
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells.
Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Induction of cell differentiation activates transcription of the Sarco/Endoplasmic Reticulum calcium-ATPase 3 gene (ATP2A3) in gastric and colon cancer cells.
Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box.
Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells.
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Induction of TAp63 by histone deacetylase inhibitors.
Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells.
Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
ING1b-inducible microRNA203 inhibits cell proliferation.
ING2, a tumor associated gene, enhances PAI?1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C?terminal.
Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-I? Expression.
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Inhibition mechanism of SAHA in HDAC: a revisit.
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy.
Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells.
Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.
Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer.
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer.
Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Inhibition of Histone Deacetylase Attenuates Hypoxia-Induced Migration and Invasion of Cancer Cells via the Restoration of RECK Expression.
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells.
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression.
Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.
Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA.
Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors.
Inhibition of store-operated Ca(2+) entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.
Inhibition of tribbles protein-1 attenuates radioresistance in human glioma cells.
Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity.
Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay.
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Inhibitors of histone deacetylase as new anticancer agents.
Inhibitors of histone deacetylases as anti-inflammatory drugs.
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest.
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress.
Inside HDAC with HDAC inhibitors.
Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking.
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.
Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.
Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition.
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.
Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer.
Interstrand Crosslink Repair as a Target for HDAC Inhibition.
Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.
Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors.
Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Involvement of histone deacetylase 1/2 in adrenocorticotropic hormone synthesis and proliferation of corticotroph tumor AtT-20 cells.
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
Isoform-selective histone deacetylase inhibitors.
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Jinwei Tang modulates HDAC2 expression in a rat model of COPD.
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity.
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
KATs in cancer: functions and therapies.
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations.
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ?-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
Kruppel-Like Factor 9 Loss-of-Expression in Human Endometrial Carcinoma Links Altered Expression of Growth-Regulatory Genes with Aberrant Proliferative Response to Estrogen.
L1 retrotransposon and retinoblastoma: molecular linkages between epigenetics and cancer.
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Largazole, a class I histone deacetylase inhibitor, enhances TNF-?-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Leishmania donovani Targets Host Transcription Factor NRF2 To Activate Antioxidant Enzyme HO-1 and Transcriptional Repressor ATF3 for Establishing Infection.
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.
Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors.
Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance.
LIM domain only 4 protein promotes granulocyte colony-stimulating factor-induced signaling in neurons.
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Limited proteolysis of human histone deacetylase 1.
lin-35/Rb and the CoREST ortholog spr-1 coordinately regulate vulval morphogenesis and gonad development in C. elegans.
Lineage of origin in rhabdomyosarcoma informs pharmacological response.
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation.
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.
Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells.
Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110/HDAC2/PLIN1 axis.
Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.
Long-term cigarette smoke exposure inhibits histone deacetylase 2 expression and enhances the nuclear factor-?B activation in skeletal muscle of mice.
Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD).
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation.
Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells.
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival and migration.
Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumour Growth Arrest and Multi-lineage Differentiation of Malignant Rhabdoid Tumours.
Low-dose tubacin promotes BMSCs proliferation and morphological changes through the ERK pathway.
Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis.
Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.
LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Macrocyclic histone deacetylase inhibitors.
Macromolecular crowding effect is critical for maintaining SIRT1's nuclear localization in cancer cells.
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice.
Maintenance of open DNA base pairs through histone acetylated lysine-purine interaction leading to transcriptional activation: a proposed mechanism.
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Manipulation of B-cell responses with histone deacetylase inhibitors.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas.
Marbostat 100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Mass spectrometry in epigenetic research.
Massively multiplex chemical transcriptomics at single-cell resolution.
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
Maternal high-methyl diet suppresses mammary carcinogenesis in female rat offspring.
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma.
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells.
Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.
Mechanism of N-Acylthiourea-mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels.
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor.
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition.
Metabolism as a key to histone deacetylase inhibition.
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.
Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells.
Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.
Metastasis-associated Protein 1 Drives Tumor Cell Migration and Invasion through Transcriptional Repression of RING Finger Protein 144A.
Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
Metastasis-associated Protein 1/Histone Deacetylase 4-Nucleosome Remodeling and Deacetylase Complex Regulates Phosphatase and Tensin Homolog Gene Expression and Function.
Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer.
Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.
Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2.
Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase.
Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line.
Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Methylation of C/EBP? by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors.
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
Microarray study of mechanism of trichostatin a inducing apoptosis of Molt-4 cells.
Microbial butyrate and its role for barrier function in the gastrointestinal tract.
Microbiota and Neurological Disorders: A Gut Feeling.
MicroRNA expression and protein acetylation pattern in respiratory and limb muscles of Parp-1(-/-) and Parp-2(-/-) mice with lung cancer cachexia.
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
MicroRNA-22 negatively regulates LPS-induced inflammatory responses by targeting HDAC6 in macrophages.
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD.
microRNA-34a as a Therapeutic Agent against Human Cancer.
MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors.
Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells.
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
miR-211-5p is down-regulated and a prognostic marker in bladder cancer.
miR-30a suppresses lung cancer progression by targeting SIRT1.
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.
miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway.
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.
miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2.
MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma.
MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1.
Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles.
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.
Modulation of cellular radiation responses by histone deacetylase inhibitors.
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.
Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer.
Modulation of STAT1-Driven Transcriptional Activity by Histone Deacetylases.
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.
Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
Molecular characterization of the grape seeds extract's effect against chemically induced liver cancer: In vivo and in vitro analyses.
Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors.
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer.
Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells.
Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
Molecular Pathways: Targeting ETS Gene Fusions in Cancer.
Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment.
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment.
Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[(18)F]-fluorothymidine PET.
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.
MTBP inhibits migration and metastasis of hepatocellular carcinoma.
MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition.
Multi-targeted histone deacetylase inhibitors in cancer therapy.
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Multiple myeloma: from front-line to relapsed therapies.
Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.
Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Natural chalcones as dual inhibitors of HDACs and NF-?B.
Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer.
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Negative and positive regulation of gene expression by mouse histone deacetylase 1.
Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1.
Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
New anti-cancer strategies: epigenetic therapies and biomarkers.
New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents.
New biomarkers for monitoring the levels of isothiocyanates in humans.
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
New molecular targets of breast cancer therapy.
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.
New Platinum-Based Prodrug Pt(IV)Ac-POA: Antitumour Effects in Rat C6 Glioblastoma Cells.
New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents.
New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors.
NF-?B addiction and its role in cancer: 'one size does not fit all'.
NF?B1 is a suppressor of neutrophil-driven hepatocellular carcinoma.
NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.
Nicotine inhibits the proliferation by upregulation of nitric oxide and increased HDAC1 in mouse neural stem cells.
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor.
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
Non-peptide macrocyclic histone deacetylase inhibitors.
Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth.
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Notch1 binds and induces degradation of Snail in hepatocellular carcinoma.
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.
Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR.
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.
Novel HDAC8 inhibitors: A multi-computational approach.
Novel Histone Deacetylase 6 Inhibitors for Treating Alzheimer's Disease and Cancer.
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Novel histone deacetylase inhibitors and embryo aggregation enhance cloned embryo development and ES cell derivation in pigs.
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Novel methods of type 1 diabetes treatment.
Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019.
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520.
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon.
Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency.
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.
Oncolytic viruses and histone deacetylase inhibitors-A multi-pronged strategy to target tumor cells.
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.
Opposing roles of the two isoforms of ErbB3 binding protein 1 in human cancer cells.
Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes.
Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids.
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors.
Osteoblasts modulate Ca(2+) signaling in bone-metastatic prostate and breast cancer cells.
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma.
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4.
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.
p15(INK4b) in HDAC inhibitor-induced growth arrest.
p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation.
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
p300 promotes differentiation of Th17 cells via positive regulation of the nuclear transcription factor ROR?t in acute respiratory distress syndrome.
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death.
p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y.
Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death.
Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial.
Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Panobinostat for the treatment of multiple myeloma.
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Panobinostat: first global approval.
Paraneoplastic Itch Management.
Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer.
Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma.
PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells.
PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy.
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity.
Peptide-templated gold nanoparticle nanosensor for simultaneous detection of multiple posttranslational modification enzymes.
Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Pharmacologic therapies in endometriosis: a systematic review.
Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds.
Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer.
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors.
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies.
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies.
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Phase II Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Mycosis Fungoides/Sézary Syndrome.
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.
Phenylbutyrate Mouthwash Mitigates Oral Mucositis During Radiotherapy or Chemoradiotherapy in Patients with Head and Neck Cancer.
Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury.
Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice.
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.
Pin1 Is Involved in HDAC6-mediated Cancer Cell Motility.
PIWIL2 suppresses Siah2-mediated degradation of HDAC3 and facilitates CK2?-mediated HDAC3 phosphorylation.
PKC? phosphorylates MIIP and promotes colorectal cancer metastasis through inhibition of RelA deacetylation.
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study.
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells.
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer.
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex.
Polyphotosensitizer nanogels for GSH-responsive histone deacetylase inhibitors delivery and enhanced cancer photodynamic therapy.
Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery.
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma.
Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Potential Epigenetic-Based Therapeutic Targets for Glioma.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Potential use of histone deacetylase inhibitors in cancer therapy.
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2.
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.
Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma.
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells.
Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells.
Profile of panobinostat and its potential for treatment in solid tumors: an update.
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer.
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Promotion of Metastasis-associated Gene Expression in Survived PANC-1 Cells Following Trichostatin A Treatment.
Promyelocytic Leukemia Nuclear Bodies Link the DNA Damage Repair Pathway with Hepatitis B Virus Replication: Implications for Hepatitis B Virus Exacerbation during Chemotherapy and Radiotherapy.
Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.
Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line.
Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.
Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.
Proteomic and Mitochondrial Genomic Analyses of Pediatric Brain Tumors.
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors.
Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry.
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence.
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small-Cell Lung Cancer.
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Radical-Mediated Thiol-Ene Strategy: Photoactivation of Thiol-Containing Drugs in Cancer Cells.
Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A.
Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.
Radiosynthesis and preliminary evaluation of an 18 F-labeled tubastatin A analog for PET imaging of histone deacetylase 6.
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate.
RASSF1A Regulates Spindle Organization by Modulating Tubulin Acetylation via SIRT2 and HDAC6 in Mouse Oocytes.
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Reactivating the expression of methylation silenced genes in human cancer.
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors.
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.
Recent advances in histone deacetylase targeted cancer therapy.
Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy.
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Recent development of novel HDAC6 isoform-selective inhibitors.
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
Recent Update of HDAC Inhibitors in Lymphoma.
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice.
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Reduced HDAC2 in skeletal muscle of COPD patients.
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Regulated Polarization of Tumor-Associated Macrophages by miR-145 via Colorectal Cancer-Derived Extracellular Vesicles.
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Regulation of AURKC expression by CpG island methylation in human cancer cells.
Regulation of CD133 by HDAC6 promotes ?-catenin signaling to suppress cancer cell differentiation.
Regulation of Glioblastoma Stem-like Cells by Id proteins and Olig transcription factors.
Regulation of histone acetylation by NDRG2 in glioma cells.
Regulation of histone deacetylase 4 expression by the SP family of transcription factors.
Regulation of Nuclear Translocation of HDAC3 by I{kappa}B{alpha} Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor {gamma} Function.
Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela.
Regulation of the HIF-1alpha stability by histone deacetylases.
Regulation of the INK4a/ARF locus by histone deacetylase inhibitors.
Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 alpha and chicken ovalbumin upstream promoter transcription factors 1 and 2.
Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1.
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity.
Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Requirement of HDAC6 for activation of Notch1 by TGF-?1.
Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.
Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation.
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential.
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Resveratrol reverses morphine-induced neuroinflammation in morphine-tolerant rats by reversal HDAC1 expression.
Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Retinoids, retinoic acid receptors, and cancer.
Retraction: Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma.
Retraction: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Rewriting the epigenetic code for tumor resensitization: a review.
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Role for histone deacetylase 1 in human tumor cell proliferation.
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.
Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Role of HDAC1 in senescence, aging, and cancer.
Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance.
Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer.
Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1? expression in peripheral blood mononuclear cells.
Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment.
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate.
Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.
Role of primary cilium in pancreatic ductal adenocarcinoma (Review).
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation.
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
ROLE OF Wip1-p53 AXIS IN RESPONSE OF MURINE CELLS TO TREATMENT WITH SODIUM BUTYRATE AND MEK/ERK SIGNALLING PATHWAY INHIBITOR.
Roles of BRCA1 and its interacting proteins.
Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Romidepsin (FK228), An Histone Deacetylase Inhibitor, and its Analogues in Cancer Chemotherapy.
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Romidepsin for the treatment of non-Hodgkin's lymphoma.
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
Romidepsin: a novel histone deacetylase inhibitor for cancer.
RSF1 in cancer: interactions and functions.
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells.
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy.
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
SAHA-based novel HDAC inhibitor design by core hopping method.
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Screening of Novel Histone Deacetylase 7 Inhibitors through Molecular Docking Followed by a Combination of Molecular Dynamics Simulations and Ligand-Based Approach.
Screening of selective histone deacetylase inhibitors by proteochemometric modeling.
Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects.
Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation.
Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.
Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease.
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors.
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors.
Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy.
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1.
Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6.
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Signal Therapy of Breast Cancers by the HDAC Inhibitor FK228 That Blocks the Activation of PAK1 and Abrogates the Tamoxifen-Resistance.
Signal Therapy of NF1-Deficient Tumor Xenograft in Mice by the Anti-PAK1 Drug FK228.
Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies.
Signaling alterations caused by drugs and autophagy.
Signaling Pathways of the ING Proteins in Apoptosis.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines.
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS.
Simultaneous NF-?B inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation.
Single Conformation Spectroscopy of Suberoylanilide Hydroxamic Acid: A Molecule Bites Its Tail.
SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells.
SIRT1 Expression Is Associated With Cell Proliferation in Angiosarcoma.
SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients.
SIRT1 is significantly elevated in mouse and human prostate cancer.
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
SIRT1: roles in aging and cancer.
SIRT2 reduces actin polymerization and cell migration through deacetylation and degradation of HSP90.
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3?/BCL2-associated X protein-dependent apoptotic pathway.
Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing ?-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors.
Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
Sirtuins in dermatology: applications for future research and therapeutics.
Site-specific acetylation of p53 directs selective transcription complex assembly.
Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin.
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
Small-Molecule Screening for Genetic Diseases.
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria.
Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways.
Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1.
Sodium butyrate induces apoptosis in MSN neuroblastoma cells in a calcium independent pathway.
Sodium butyrate induces cell death by autophagy and reactivates a tumor suppressor gene DIRAS1 in renal cell carcinoma cell line UOK146.
Sodium Butyrate Induces Growth Inhibition and Apoptosis in Human Prostate Cancer DU145 Cells by Up-Regulation of the Expression of Annexin A1.
Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner.
Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells.
Sodium butyrate reduces bovine mammary epithelial cell inflammatory responses induced by exogenous lipopolysaccharide, by inactivating NF-?B signaling.
Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Sodium butyrate-dependent sensitization of human colon adenocarcinoma COLO 205 cells to TNF-alpha-induced apoptosis.
Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells.
Solid tumor differentiation therapy - is it possible?
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study.
Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Spectroscopic analysis of the interaction of valproic acid with histone H1 in solution and in chromatin structure.
Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation.
SQAP, an acyl sulfoquinovosyl derivative, suppresses expression of histone deacetylase and induces cell death of cancer cells under hypoxic conditions.
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
SRC gene expression in human cancer: the role of transcriptional activation.
SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors.
Src regulates the activity of the ING1 tumor suppressor.
SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines.
Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells In Vivo.
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment.
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.
Strategies To Design Selective Histone Deacetylase Inhibitors.
Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate.
Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
Suberanilohydroxamic Acid. Aton Pharma.
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Suberoyl bishydroxamic Acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells.
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma.
Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis.
Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.
Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation.
Suberoylanilide hydroxamic acid upregulates histone acetylation and activates endoplasmic reticulum stress to induce apoptosis in HepG2 liver cancer cells.
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.
Sumoylation of HDAC2 promotes NF-?B-dependent gene expression.
Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest.
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells.
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Suppression of HIF-1? by Valproic Acid Sustains Self-Renewal of Mouse Embryonic Stem Cells under Hypoxia In Vitro.
Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.
Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors.
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.
Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer.
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer in vitro.
Synergistic effect of p53 on TSA-induced stanniocalcin 1 expression in human nasopharyngeal carcinoma cells, CNE2.
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors.
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Synergy of hypoxia relief and chromatin remodeling to overcome tumor radiation resistance.
Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Synthesis and antitumor effects of novel 18?-glycyrrhetinic acid derivatives featuring an exocyclic ?,?-unsaturated carbonyl moiety in ring A.
Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors.
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives.
Synthesis and evaluation of N?,N?-diacetyl-l-lysine-inositol conjugates as cancer-selective probes for metabolic engineering of GPIs and GPI-anchored proteins.
Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.
Synthesis, anticancer activity, structure-activity relationship and binding mode of interaction studies of substituted pentanoic acids.
Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers.
Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Targeted histone deacetylase inhibition for cancer prevention and therapy.
Targeted histone deacetylase inhibition for cancer therapy.
Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.
Targeted therapy in the treatment of malignant gliomas.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.
Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Targeting epigenetic machinery: Emerging novel allosteric inhibitors.
Targeting epigenetic misregulation in synovial sarcoma.
Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer.
Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Targeting histone deacetylase in cancer therapy.
Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Targeting Histone Modifications in Bone and Lung Metastatic Cancers.
Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.
Targeting of HDAC8 and investigational inhibitors in neuroblastoma.
Targeting of histone deacetylases in brain tumors.
Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment.
Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Targeting the extracellular signal-regulated kinase pathway in cancer therapy.
Targeting tumor angiogenesis with histone deacetylase inhibitors.
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis.
Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.
TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion.
Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer.
Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner.
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
TGF? Promotes Chemoresistance of Malignant Pleural Mesothelioma.
Thalidomide as a multi-template for development of biologically active compounds.
The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy.
The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair.
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
The application of epigenetic modifiers on the treatment of prostate and bladder cancer.
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors.
The changing face of HDAC inhibitor depsipeptide.
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
The clinical significance of histone deacetylase-8 in human breast cancer.
The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment.
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects.
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
The critical role of the class III histone deacetylase SIRT1 in cancer.
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
The CUG-translated WT1, not AUG-WT1, is an oncogene.
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.
The Deubiquitinase USP38 Promotes NHEJ Repair through Regulation of HDAC1 Activity and Regulates Cancer Cell Response to Genotoxic Insults.
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.
The Effect of 5-Aza-2'-Deoxycytidine in Combination to and in Comparison with Vorinostat on DNA Methyltransferases, Histone Deacetylase 1, Glutathione S-Transferase 1 and Suppressor of Cytokine Signaling 1 Genes Expression, Cell Growth Inhibition and Apoptotic Induction in Hepatocellular LCL-PI 11 Cell Line.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells.
The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.
The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method.
The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line.
The Effect of Vicinal Difluorination on the Conformation and Potency of Histone Deacetylase Inhibitors.
The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats.
The Effects of Histone Deacetylase Inhibition on the Levels of Cerebral Cytokines in an Animal Model of Mania Induced by Dextroamphetamine.
The Effects of Histone Deacetylase Inhibitors on Glioblastoma-Derived Stem Cells.
The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?
The Effects of Molecular Hydrogen and Suberoylanilide Hydroxamic Acid on Paraquat-Induced Production of Reactive Oxygen Species and TNF-? in Macrophages.
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma.
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells.
The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
The epigenetic agents suberoylanilide hydroxamic acid and 5?AZA?2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
The Epigenetic Modifier, Valproic Acid, Enhances Radiation Sensitivity.
The epigenetics of ovarian cancer drug resistance and resensitization.
The estrogen-responsive B box protein is a novel regulator of the retinoid signal.
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
The fission yeast inhibitor of growth (ING) protein PNG1P functions in response to DNA damage.
The future of epigenetic therapy in solid tumours--lessons from the past.
The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation.
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
The histone deacetylase 9 gene encodes multiple protein isoforms.
The histone deacetylase HDAC1 activates HIF1?/VEGFA signal pathway in colorectal cancer.
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
The histone deacetylase inhibitor entinostat enhances polymer-mediated transgene expression in cancer cell lines.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo.
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
The Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiation Sensitivity and Accumulation of gammaH2A.X.
The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells.
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
The histone deacetylase SIRT2 stabilizes Myc oncoproteins.
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells.
The influence of ketogenic therapy on the 5 R's of radiobiology.
The ING1a Tumor Suppressor Regulates Endocytosis to Induce Cellular Senescence Via the Rb-E2F Pathway.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
The mechanism and potential targets of class II HDACs in angiogenesis.
The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells.
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment.
The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukemia cells.
The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytes.
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA.
The novel human endogenous retrovirus related gene, psiTPTE22-HERV, is silenced by DNA methylation in cancers.
The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC.
The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer.
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs.
The potential of RECK inducers as antitumor agents for glioma.
The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation.
The Relationship between HDAC3 and Malignant Tumors: A Mini Review.
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
The role of HDAC6 in cancer.
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc.
The role of histone deacetylase inhibitors in metastatic breast cancer.
The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
The roles of microbial products in the development of colorectal cancer: a review.
The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.
The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
The SIRT3 and SIRT6 Promote Prostate Cancer Progression by Inhibiting Necroptosis-Mediated Innate Immune Response.
The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice.
The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
The therapeutic properties of resminostat for hepatocellular carcinoma.
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53.
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
The Tumor Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the Beta-catenin Coactivator BCL9-2 in Breast Cancer Cells.
The Tumorigenic Properties of EZH2 are Mediated by MiR-26a in Uveal Melanoma.
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases.
Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Therapeutic efficacy of valproic Acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells.
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.
Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.
Therapy of human papillomavirus-related disease.
Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.
Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms.
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.
Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease.
Towards targeted epigenetic therapy of cancer.
Trans-regulation of histone deacetylase activities through acetylation.
Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.
Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma.
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis.
Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells.
Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer.
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Transcriptome screening and verification of genes related to metabolism affected by histone deacetylase inhibitors.
Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors.
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Translational Advances in Pleural Malignancies.
Treatment of tumor cells with histone deacetylase inhibitors results in altered recruitment of methyl-CpG binding proteins to a methylated CpG island.
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy.
Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.
Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells.
Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells.
Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR?375.
Trichostatin A increases the thermosensitivity of human glioblastoma A172 cells.
Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.
Trichostatin A inhibits inflammation in phorbol myristate acetate?induced macrophages by regulating the acetylation of histone and/or non?histone proteins.
Trichostatin a inhibits phenotypic transition and induces apoptosis of the TAF-treated normal colonic epithelial cells through regulation of TGF-? pathway.
Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells.
Trichostatin A protects against intestinal injury in rats with acute liver failure.
Trichostatin A reverses epithelial-mesenchymal transition and attenuates invasion and migration in MCF-7 breast cancer cells.
Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice.
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1).
Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice.
Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1?survivin downregulation at the late phase of treatment.
TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells.
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels.
TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.
TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116.
TSA-induced JMJD2B downregulation is associated with Cyclin B1-dependent survivin degradation and apoptosis in LNCap cells.
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
Tubastatin A, a deacetylase inhibitor, as a tool to study the division, cell cycle and microtubule cytoskeleton of trypanosomatids.
Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs.
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.
Tumor necrosis factor-alpha enhances neutrophil adhesiveness: induction of vascular cell adhesion molecule-1 via activation of Akt and CaM kinase II and modifications of histone acetyltransferase and histone deacetylase 4 in human tracheal smooth muscle cells.
Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
Tumor suppressor maspin as a modulator of host immune response to cancer.
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Tumour Expression of Histone Deacetylases in Uveal Melanoma.
Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2.
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Ubiquitin B in cervical cancer: critical for the maintenance of cancer stem-like cell characters.
UHRF1 Induces Methylation of the TXNIP Promoter and Down-Regulates Gene Expression in Cervical Cancer.
Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.
Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis.
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy.
Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation.
Unique functional roles for class I and class II histone deacetylases in central nervous system development and function.
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Unlocking repression of the human luteinizing hormone receptor gene by trichostatin A-induced cell-specific phosphatase release.
Unprecedented behavior of (9R)-9-hydroxystearic acid loaded keratin nanoparticles on cancer cell cycle.
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.
Upregulation of peroxisome proliferator-activated receptor-? and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer.
Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature.
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Use of polyamine derivatives as selective histone deacetylase inhibitors.
USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.
USP4 inhibits p53 and NF-?B through deubiquitinating and stabilizing HDAC2.
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells.
Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B.
Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers.
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.
Valproic Acid Enhances the Efficacy of Chemotherapy in EBV-Positive Tumors by Increasing Lytic Viral Gene Expression.
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/? Catenin Signalling Activation.
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi?1 leukemia cells.
Valproic acid overcomes hypoxia-induced resistance to apoptosis.
Valproic acid promotes the epithelial-to-mesenchymal transition of breast cancer cells through stabilization of Snail and transcriptional upregulation of Zeb1.
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway.
Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
Vascular endothelial growth factor production is induced by histone deacetylase 1 and suppressed by von Hippel-Lindau protein in HaCaT cells.
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells.
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Vorinostat in cutaneous T-cell lymphoma.
Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake.
Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.
Vorinostat triggers miR-769-5p/3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer.
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Vulnerability of IDH1 mutant cancers to histone deacetylase inhibition via orthogonal suppression of DNA repair.
Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer.
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer.
xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner.
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.
Xenografting of Cancer Cell Lines for In Vivo Screening of the Therapeutic Potential of HDAC Inhibitors.
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
YY1 negatively regulates the XAF1 gene expression in prostate cancer.
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.
Zinc dependent Histone deacetylase inhibitors in cancer therapeutics: Recent update.
ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
[A histone deacetylase inhibitor and tumor suppressing gene p53 induction synergistically induce apoptosis of cancer cells]
[A new target of cancer therapy: advances in the study of histone deacetylase]
[Chromosome arm 17p13.3: could hic1 be the one ?]
[Combination of phenylbutyrate and 5-Aza-2'deoxycytidine inhibits human Kasumi-1 xenograft tumor growth in nude mice.]
[Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]
[Effect of trichostatin A on the osteogenic differentiation potential of periodontal ligament stem cells in inflammatory microenvironment induced by tumor necrosis factor-? stimulation].
[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells]
[Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
[Experimental study on the mechanism of the apoptosis of leukemic cells induced by valproic acid]
[Gene-regulating chemoprevention against cancer--as a model for "molecular-targeting prevention" of cancer]
[Ginsenoside Rh?-induced inhibition of histone deacetylase 6 promotes K562 cells autophagy and apoptosis in vivo].
[HDAC1 expression and effect of TSA on proliferation and apoptosis of A549 cells]
[Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome].
[Histone deacetylases: a new class of efficient anti-tumor drugs.]
[Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
[Legionella pneumophila activates Nrf2-Keap1 pathway to inhibit autophagy of mouse RAW264.7 macrophages].
[Mechanism of apoptosis induced by trichostatin a in leaukemia molt-4 cells analyzed by microarray.]
[Mechanisms of cytotoxic action of a series of directionally synthesized heterocyclic hydroxamic acids].
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
[Molecular mechanisms of parthenolide's action: Old drug with a new face]
[Morphological reversion of tumor cells by histone deacetylase inhibitors and radicicol]
[Novel therapies for higher-risk myelodysplastic syndromes].
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
[Primary skin lymphomas: Current therapy].
[Progress in cancer treatment with histone deacetylase inhibitor].
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line]
[Synergistic effect of DNA methylation inhibitor and histone deacetylase inhibitor on RASSF1A gene expression in U266 cells.]
[Synthesis and anti-tumor activity of novel histone deacetylase inhibitors based on dihydropyridin-2-one scaffold].
[The significance of histone modifications in malignant transformation].
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Neoplasms, Germ Cell and Embryonal
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Neoplasms, Glandular and Epithelial
Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes.
Neoplasms, Squamous Cell
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer.
Neoplastic Cells, Circulating
Expression profile of histone deacetylase 1 in gastric cancer tissues.
Nephritis, Hereditary
CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome.
Nephrotic Syndrome
Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.
Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma.
Nervous System Diseases
3',4'-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.
Chromatin and nuclear architecture in the nervous system.
Cloning and structural characterization of the human histone deacetylase 6 gene.
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors.
HDAC3 inhibition prevents oxygen glucose deprivation/reoxygenation-induced transendothelial permeability by elevating PPAR? activity in vitro.
HDAC6 as privileged target in drug discovery: A perspective.
HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
Histone Deacetylase 2 Inhibition Attenuates Downregulation of Hippocampal Plasticity Gene Expression during Aging.
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.
Histone deacetylase in neuropathology.
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
Neuroprotective effects of valproic acid in a rat model of cauda equina injury.
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Regional and cell-type specific distribution of HDAC2 in the adult mouse brain.
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease.
Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.
Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva.
Valproic acid mitigates spinal nerve ligation-induced neuropathic pain in rats by modulating microglial function and inhibiting neuroinflammatory response.
Neural Tube Defects
Histone deacetylase inhibitor Trichostatin A induces neural tube defects and promotes neural crest specification in the chicken neural tube.
S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
Neuralgia
An integrated review on new targets in the treatment of neuropathic pain.
Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats.
Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats.
Central Endothelin-1 Confers Analgesia by Triggering Spinal Neuronal Histone Deacetylase 5 (HDAC5) Nuclear Exclusion in Peripheral Neuropathic Pain in Mice.
Circulating microRNA Signatures in Rodent Models of Pain.
Complex regulation of the regulator of synaptic plasticity histone deacetylase 2 in the rodent dorsal horn after peripheral injury.
Dual BET/HDAC inhibition to relieve neuropathic pain: recent advances, perspectives, and future opportunities.
Effect of HDAC2/Inpp5f on neuropathic pain and cognitive function through regulating PI3K/Akt/GSK-3? signal pathway in rats with neuropathic pain.
Effect of histone deacetylase inhibitor JNJ-26481585 in pain.
Epigenetic suppression of GAD65 expression mediates persistent pain.
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring ?-opioid receptor in spinal cord.
HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats.
HDAC3 in hippocampus contributes to memory impairment following chronic constriction injury of sciatic nerve in mice.
HDAC6: A Key Link Between Mitochondria and Development of Peripheral Neuropathy.
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain.
Histone deacetylase inhibitor-induced emergence of synaptic ?-opioid receptors and behavioral antinociception in persistent neuropathic pain.
Histone deacetylase inhibitors prevent persistent hypersensitivity in an orofacial neuropathic pain model.
Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
MiR-206-3p alleviates chronic constriction injury-induced neuropathic pain through targeting HDAC4.
Modulation of Nerve Injury-induced HDAC4 Cytoplasmic Retention Contributes to Neuropathic Pain in Rats.
NF-?B p65-dependent transcriptional regulation of histone deacetylase 2 contributes to the chronic constriction injury-induced neuropathic pain via the microRNA-183/TXNIP/NLRP3 axis.
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Pregabalin on Hdac2 and Inpp5f levels in rats with CCI-induced neuropathic pain.
SIRT1 Decreases Emotional Pain Vulnerability with Associated CaMKII? Deacetylation in Central Amygdala.
SIRT1 Mediates Neuropathic Pain Induced by Sciatic Nerve Chronic Constrictive Injury in the VTA-NAc Pathway.
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
The etiological changes of acetylation in peripheral nerve injury-induced neuropathic hypersensitivity.
The HDAC1/c-JUN complex is essential in the promotion of nerve injury-induced neuropathic pain through JNK signaling.
The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model.
[Trichostatin A suppresses up-regulation of histone deacetylase 4 and reverses differential expressions of miRNAs in the spinal cord of rats with chronic constrictive injury].
Neurilemmoma
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Neuritis
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
Neuritis, Autoimmune, Experimental
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
Neurobehavioral Manifestations
Reduction of Tet2 exacerbates early stage Alzheimer's pathology and cognitive impairments in 2?×?Tg-ad mice.
Neuroblastoma
A gastrin-releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: prevention by a histone deacetylase inhibitor.
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
Amide-based derivatives of ?-alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects.
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2.
Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Biological significance of EPHA2 expression in neuroblastoma.
BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells.
CLU blocks HDACI-mediated killing of neuroblastoma.
Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.
Combined sialic acid and HDAC inhibitor treatment upregulates the neuroblastoma antigen GD2.
Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A.
CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene.
De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene.
Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition.
Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines.
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
DNA and histone deacetylases as targets for neuroblastoma treatment.
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Dysbindin-1, a schizophrenia-related protein, interacts with HDAC3.
Effect of low doses of actinomycin D on neuroblastoma cell lines.
Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells.
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.
Expression of DHA-Metabolizing Enzyme Alox15 is Regulated by Selective Histone Acetylation in Neuroblastoma Cells.
Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents.
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma.
GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3.
HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.
HDAC4 inhibits cell-cycle progression and protects neurons from cell death.
HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma.
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Histone deacetylase 10 promotes autophagy-mediated cell survival.
Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas.
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Histone deacetylase 8 in neuroblastoma tumorigenesis.
Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
Histone deacetylase inhibition induces apoptosis in neuroblastoma.
Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.
Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms.
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND).
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Hypoxia-inducible factor-1? mediates up-regulation of neprilysin by histone deacetylase-1 under hypoxia condition in neuroblastoma cells.
Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.
Identification of novel targets for PGC-1alpha and histone deacetylase inhibitors in neuroblastoma cells.
Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
Kinetically selective and potent inhibitors of HDAC8.
Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors.
LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Mechanism of N-Acylthiourea-mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels.
Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells.
miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth.
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
Neuronal apoptosis induced by histone deacetylase inhibitors.
New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
p38/Sp1/Sp4/HDAC4/BDNF Axis Is a Novel Molecular Pathway of the Neurotoxic Effect of the Methylmercury.
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts.
Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression.
Regulation of neuronal nitric oxide synthase exon 1f gene expression by nuclear factor-kappaB acetylation in human neuroblastoma cells.
RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells.
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy.
Switching the Switch: Ligand Induced Disulfide Formation in HDAC8.
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137.
Targeting class I histone deacetylases in cancer therapy.
Targeting of HDAC8 and investigational inhibitors in neuroblastoma.
The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells.
The effect of vorinostat on the development of resistance to Doxorubicin in neuroblastoma.
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
The histone deacetylase SIRT2 stabilizes Myc oncoproteins.
The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells.
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease.
Neurodegenerative Diseases
A novel class of anthraquinone-based HDAC6 inhibitors.
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome.
A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.
Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target.
Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.
An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity.
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Chiral mercaptoacetamides display enantioselective inhibition of histone deacetylase?6 and exhibit neuroprotection in cortical neuron models of oxidative stress.
Cholesterol derivatives induce dephosphorylation of the histone deacetylases Rpd3/HDAC1 to upregulate autophagy.
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Chronic restraint stress impairs cognition via modulating HDAC2 expression.
Cognitive deficits triggered by early life stress: The role of histone deacetylase 1.
Cognitive Function in Health and Disease: The Role of Epigenetic Mechanisms.
Compensatory Motor Neuron Response to Chromatolysis in the Murine hSOD1(G93A) Model of Amyotrophic Lateral Sclerosis.
Complex neuroprotective and neurotoxic effects of histone deacetylases.
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Contribution of Neuroepigenetics to Huntington's Disease.
Creating zinc monkey wrenches in the treatment of epigenetic disorders.
Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10.
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Developmental neurotoxicity in the context of multiple sevoflurane exposures: Potential role of histone deacetylase 6.
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Effects of histone deacetylase inhibition on the survival, proliferation and migration of Schwann cells, as well as on the expression of neurotrophic factors and genes associated with myelination.
Epigenetic therapy for Friedreich ataxia.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Genetic networks in Parkinson's and Alzheimer's disease.
HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells.
HDAC inhibitors and neurodegeneration: At the edge between protection and damage.
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
HDAC3i-Finder: A Machine Learning-based Computational Tool to Screen for HDAC3 Inhibitors.
HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.
HDAC6 ?-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases.
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
HDAC6 at the Intersection of Autophagy, the Ubiquitin-Proteasome System and Neurodegeneration.
HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations.
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.
HDAC6 regulates mitochondrial transport in hippocampal neurons.
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Histone Deacetylase 6 and the Disease Mechanisms of ?-Synucleinopathies.
Histone deacetylase 6 in health and disease.
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux.
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise.
Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.
Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model.
Histone deacetylase-3: Friend and foe of the brain.
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Increased Abundance of Nuclear HDAC4 Impairs Neuronal Development and Long-Term Memory.
Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A?-induced impaired axonal transport.
Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Interplay Between HDAC6 and Its Interacting Partners: Essential Roles in the Aggresome-Autophagy Pathway and Neurodegenerative Diseases.
Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression.
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Knock-Down of HDAC2 in Human Induced Pluripotent Stem Cell Derived Neurons Improves Neuronal Mitochondrial Dynamics, Neuronal Maturation and Reduces Amyloid Beta Peptides.
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Liposomal-formulated curcumin [Lipocurc™] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform.
Lysine deacetylases and mitochondrial dynamics in neurodegeneration.
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model.
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Neuronal Nitric Oxide Synthase in Neural Stem Cells Induces Neuronal Fate Commitment via the Inhibition of Histone Deacetylase 2.
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease.
Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.
Pin1 Is Involved in HDAC6-mediated Cancer Cell Motility.
Post-translational modifications of tubulin in the nervous system.
Potential non-oncological applications of histone deacetylase inhibitors.
Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain.
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Proteomic analysis identifies NPTX1 and HIP1R as potential targets of histone deacetylase-3-mediated neurodegeneration.
Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord.
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia.
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death.
Rosiglitazone Synergizes the Neuroprotective Effects of Valproic Acid Against Quinolinic Acid-Induced Neurotoxicity in Rats: Targeting PPAR? and HDAC Pathways.
SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa.
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease.
Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3.
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
The Contribution of Necroptosis in Neurodegenerative Diseases.
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease.
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.
The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
To prevent neurodegeneration: HDAC6 uses different strategies for different challenges.
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases.
Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: Current targets and future perspective.
Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease.
Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity.
Neuroectodermal Tumors, Primitive
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Neuroendocrine Tumors
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Valproic acid induces Notch1 signaling in small cell lung cancer cells.
Neurofibromatoses
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Neurofibrosarcoma
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: Potential implications for the treatment of a therapeutic-resistant malignancy.
Correction: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
Neuroinflammatory Diseases
Biomarkers in amyotrophic lateral sclerosis: a review of new developments.
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency.
Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression.
HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.
HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice.
HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.
Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-?B Signaling Pathway.
Histone Deacetylase Inhibitor MS-275 Alleviates Postoperative Cognitive Dysfunction in Rats by Inhibiting Hippocampal Neuroinflammation.
Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction.
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Increased transcription of TSPO, HDAC2, and HDAC6 in the amygdala of males with alcohol use disorder.
Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer's Disease in vitro Model.
Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice.
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization.
Opening a New Time Window for Treatment of Stroke by Targeting HDAC2.
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Resveratrol reverses morphine-induced neuroinflammation in morphine-tolerant rats by reversal HDAC1 expression.
Suppression of histone deacetylases by SAHA relieves bone cancer pain in rats via inhibiting activation of glial cells in spinal dorsal horn and dorsal root ganglia.
The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
The Mechanisms by Which the Ketone Body D-?-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease.
Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: Current targets and future perspective.
Neuroma, Acoustic
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
Neuromuscular Diseases
The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.
The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming.
Neutropenia
New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Nevus
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.
Nevus, Pigmented
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi.
Niemann-Pick Disease, Type C
An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease.
Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor.
The Potential of Histone Deacetylase Inhibitors in Niemann-Pick Type C Disease.
Treatment of Niemann-Pick Type C Disease by Histone Deacetylase Inhibitors.
Non-alcoholic Fatty Liver Disease
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR?.
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.
Nutrient sensor-mediated programmed nonalcoholic fatty liver disease in low birthweight offspring.
Role of histone deacetylase on nonalcoholic fatty liver disease.
The ménage à trois of autophagy, lipid droplets and liver disease.
non-specific protein-tyrosine kinase deficiency
Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.
Non-ST Elevated Myocardial Infarction
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Nutritional and Metabolic Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Obesity
A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice.
A Review of Mitochondrial-derived Fatty Acids in Epigenetic Regulation of Obesity and Type 2 Diabetes.
Adaptor protein APPL1 coordinates HDAC3 to modulate brown adipose tissue thermogenesis in mice.
Adipose tissue mRNA expression of HDAC1, HDAC3 and HDAC9 in obese women in relation to obesity indices and insulin resistance.
Association between HDACs and pro-inflammatory cytokine gene expressions in obesity.
Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases.
Deleted in Breast Cancer 1 regulates cellular senescence during obesity.
Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity.
Disruption of Epithelial HDAC3 in Intestine Prevents Diet-Induced Obesity in Mice.
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Genome-wide analysis reveals that altered methylation in specific CpG loci is associated with childhood obesity.
HDAC3-Selective Inhibition Activates Brown and Beige Fat Through PRDM16.
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation.
Histone deacetylase 11 as a key regulator of metabolism and obesity.
Histone Deacetylase 3 Regulates Adipocyte Phenotype at Early Stages of Differentiation.
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Histone modifications and skeletal muscle metabolic gene expression.
Hypothalamic leptin action is mediated by histone deacetylase 5.
Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function.
In silico Design of Novel Sirtuin 1 Enzyme Activators for Treatment of Age-related Diseases and Life Span.
Inhibition of HDAC3 promotes ligand-independent PPAR? activation by protein acetylation.
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Loss of HDAC6 alters gut microbiota and worsens obesity.
MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice.
Obesity alters the ovarian proteomic response to zearalenone exposure†.
Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity.
Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-? in human adipose tissue.
Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.
SAHA induces white fat browning and rectifies metabolic dysfunctions via activation of ZFPs.
Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice.
Sodium Butyrate Protects Against High Fat Diet-induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice.
Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
The intestinal microbiota programs diurnal rhythms in host metabolism through histone deacetylase 3.
The loss of histone deacetylase 4 in macrophages exacerbates hepatic and adipose tissue inflammation in male but not in female mice with diet-induced non-alcoholic steatohepatitis.
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
Obesity, Maternal
A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates.
Ocular Hypertension
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities.
Oligodendroglioma
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Optic Nerve Injuries
Combined HDAC1 and HDAC2 Depletion Promotes Retinal Ganglion Cell Survival After Injury Through Reduction of p53 Target Gene Expression.
HDAC5 promotes optic nerve regeneration by activating the mTOR pathway.
Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury.
Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury.
Targeting HDAC3 in the DBA/2J spontaneous mouse model of glaucoma.
Valproic acid promotes neural regeneration of olfactory epithelium in adult mice after methimazole-induced damage.
Osteoarthritis
Adenovirus-mediated transduction with Histone Deacetylase 4 ameliorates disease progression in an osteoarthritis rat model.
Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis.
Chondrocyte mTORC1 activation stimulates miR-483-5p via HDAC4 in osteoarthritis progression.
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Decreased histone deacetylase 4 is associated with human osteoarthritis cartilage degeneration by releasing histone deacetylase 4 inhibition of runt-related transcription factor-2 and increasing osteoarthritis-related genes: a novel mechanism of human osteoarthritis cartilage degeneration.
HDAC2 interacts with microRNA-503-5p to regulate SGK1 in osteoarthritis.
HDACi and Nrf2: not from alpha to omega but from acetylation to OA.
Histone deacetylase 4 alters cartilage homeostasis in human osteoarthritis.
Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis.
Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1?-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte.
Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1? signaling in osteoarthritis fibroblast-like synoviocytes.
Histone Deacetylase Inhibitory Approaches for the Management of Osteoarthritis.
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Inhibition of HDAC6 by Tubastatin A reduces chondrocyte oxidative stress in chondrocytes and ameliorates mouse osteoarthritis by activating autophagy.
Inhibition of histone deacetylase 6 by Tubastatin A attenuates the progress of osteoarthritis via improving mitochondrial function.
Mechanical and IL-1? Responsive miR-365 Contributes to Osteoarthritis Development by Targeting Histone Deacetylase 4.
MicroRNA-92a-3p regulates the expression of cartilage-specific genes by directly targeting histone deacetylase 2 in chondrogenesis and degradation.
miR-193b-5p regulates chondrocytes metabolism by directly targeting histone deacetylase 7 in interleukin-1?-induced osteoarthritis.
Osteoarthritis: chondroprotection by histone deacetylase inhibition.
Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease.
Osteoarthritis, Knee
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Osteochondroma
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Osteogenesis Imperfecta
The new bone biology: pathologic, molecular, and clinical correlates.
Osteolysis
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Osteopetrosis
The new bone biology: pathologic, molecular, and clinical correlates.
Osteophyte
Adenovirus-mediated transduction with Histone Deacetylase 4 ameliorates disease progression in an osteoarthritis rat model.
Osteoporosis
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.
HDAC6 inactivates Runx2 promoter to block osteogenesis of bone marrow stromal cells in age-related bone loss of mice.
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Impaired autophagy triggered by HDAC9 in mesenchymal stem cells accelerates bone mass loss.
Mechanical stimulation orchestrates the osteogenic differentiation of human bone marrow stromal cells by regulating HDAC1.
MicroRNA-29a mitigates glucocorticoid induction of bone loss and fatty marrow by rescuing Runx2 acetylation.
MiR-206 regulates the progression of osteoporosis via targeting HDAC4.
MiR-29a promotes osteogenic differentiation of mesenchymal stem cells via targeting HDAC4.
miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4.
MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs.
PPAR? forms a bridge between DNA methylation and histone acetylation at the C/EBP? gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells.
Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling.
The new bone biology: pathologic, molecular, and clinical correlates.
[Mechanisms of electroacupuncture underlying treatment of osteoporosis based on HDAC2-mediated osteoblast differentiation pathway].
Osteosarcoma
A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia.
Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells.
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines.
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.
Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.
Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Knockdown of CircCRIM1 Inhibits HDAC4 to Impede Osteosarcoma Proliferation, Migration, and Invasion and Facilitate Autophagy by Targeting miR-432-5p.
Kruppel-Like Factor 9 Loss-of-Expression in Human Endometrial Carcinoma Links Altered Expression of Growth-Regulatory Genes with Aberrant Proliferative Response to Estrogen.
Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells.
Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line.
MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4.
Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.
Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4.
Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma.
Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.
RNA sequencing identifies gene expression profile changes associated with ?-estradiol treatment in U2OS osteosarcoma cells.
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.
Suberoylanilide hydroxamic acid affects ?H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells.
Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.
The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats.
The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases.
Trichostatin A activates FOXO1 and induces autophagy in osteosarcoma.
Tubulin polymerization promoting protein 1 (TPPP1) increases ?-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells.
Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.
Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells.
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
[Histone deacetylase inhibits the growth and migration of human osteosarcoma cells].
Ototoxicity
Histone deacetylase inhibition protects hearing against acute ototoxicity by activating the Nf-?B pathway.
Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity.
The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs.
Theophylline alleviates gentamicin-induced cytotoxicity to sensory hair cells by maintaining HDAC2 expression.
Ovarian Neoplasms
A key HDAC6 dependency of ARID1A-mutated ovarian cancer.
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity.
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study.
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells.
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Association of histone deacetylase expression with histology and prognosis of ovarian cancer.
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.
CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells.
Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins.
Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition.
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells.
DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells.
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells.
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.
Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.
Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues.
From Anti-infective Agents to Cancer Therapy: a Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives.
Genetics Helps to Find Synergy for Immune Checkpoint and Targeted Combination Therapies.
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
HDAC6 and Ovarian Cancer.
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.
HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Histone deacetylase inhibitor trichostatin A modulates cell cycles in A2780 human ovarian cancer cell lines.
Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.
Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing.
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
Impact of the histone deacetylase inhibitor trichostatin A on active uptake, volume-sensitive release of taurine, and cell fate in human ovarian cancer cells.
In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation.
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.
Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1?-mediated regulation of apoptosis and autophagy.
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.
Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
MiRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Overcoming immune suppression with epigenetic modification in ovarian cancer.
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients.
Retraction notice to "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells" [Gynecol. Oncol. 101 (2006) 108-113].
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341.
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.
Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy.
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells.
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression.
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.
Three-Combined Treatment, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil and Paclitaxel, Induces G2-Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells.
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.
Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Overnutrition
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Pancreatic Neoplasms
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
A histone deacetylase inhibitor, panobinostat, enhances chimeric receptor antigen T cell anti-tumor effect against pancreatic cancer.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors.
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.
ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/?-catenin signaling pathway.
Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study.
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
Epigenetic Regulation Affects N-myc Downstream-Regulated Gene 1 Expression Indirectly in Pancreatic Cancer Cells.
Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells.
Epigenetic Silencing of MicroRNA miR-107 Regulates Cyclin-Dependent Kinase 6 Expression in Pancreatic Cancer.
Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer.
FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression.
FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
HDAC3 mediates smoking-induced pancreatic cancer.
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.
Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors.
Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.
Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells.
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer.
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Identification and Characterization of AES-135, a Hydroxamic Acid-based HDAC Inhibitor that Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer.
Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer.
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells.
MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Neuronal pentraxin II (NPTX2) Is Frequently Down-Regulated by Promoter Hypermethylation in Pancreatic Cancers.
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer.
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer.
SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
The histone deacetylase SIRT2 stabilizes Myc oncoproteins.
The role of oxysterol binding protein-related protein 5 in pancreatic cancer.
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.
Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.
Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer.
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
Pancreatitis
ATF4-mediated histone deacetylase HDAC1 promotes the progression of acute pancreatitis.
Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.
Histone Deacetylase Regulates Trypsin Activation, Inflammation, and Tissue Damage in Acute Pancreatitis in Mice.
Pancreatitis, Chronic
Histone deacetylase 2 is involved in µ?opioid receptor suppression in the spinal dorsal horn in a rat model of chronic pancreatitis pain.
Papilloma
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.
Paralysis
Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Paramyxoviridae Infections
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Paraparesis, Spastic
Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.
Paraproteinemias
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Parasitic Diseases
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
HDAC inhibitors in parasitic diseases.
HDAC8: a multifaceted target for therapeutic interventions.
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Toxoplasma gondii Infection Inhibits Histone Crotonylation to Regulate Immune Response of Porcine Alveolar Macrophages.
Parkinson Disease
A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease.
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Acetylation of NDUFV1 induced by a newly synthesized HDAC6 inhibitor HGC rescues dopaminergic neuron loss in Parkinson models.
Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
HDAC6 regulates mitochondrial transport in hippocampal neurons.
HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy.
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity.
Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.
Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson's Disease.
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Targeting HDACs: a promising therapy for Alzheimer's disease.
The Histone Deacetylase Inhibitor Nicotinamide Exacerbates Neurodegeneration in the Lactacystin Rat Model of Parkinson's Disease.
Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease.
[Epigenetics and etiology of neurodegenerative diseases].
Parkinsonian Disorders
A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in LRRK2-G2019S parkinsonism.
Glucocerebrosidase and its relevance to Parkinson disease.
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Sex differences in autophagy-mediated diseases: toward precision medicine.
Pediatric Obesity
Associations between placental CpG methylation of metastable epialleles and childhood body mass index across ages one, two and ten in the Extremely Low Gestational Age Newborns (ELGAN) cohort.
Penile Induration
Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease.
Silencing Histone Deacetylase 7 Alleviates Transforming Growth Factor-?1-Induced Profibrotic Responses in Fibroblasts Derived from Peyronie's Plaque.
Suppression of Cavernosal Fibrosis in a Rat Model.
Pericardial Effusion
Characteristics of pericardial effusions in patients with leukemia.
Pericarditis
Histone deacetylase inhibition attenuates atrial arrhythmogenesis in sterile pericarditis.
Periodontal Diseases
HDAC3 Regulates Gingival Fibroblast Inflammatory Responses in Periodontitis.
MicroRNA-22 Promoted Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Targeting HDAC6.
Periodontitis
HDAC3 Regulates Gingival Fibroblast Inflammatory Responses in Periodontitis.
Peripheral Nerve Injuries
A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration.
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Peripheral Nervous System Diseases
Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Charcot-Marie-Tooth disease: emerging mechanisms and therapies.
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
HDAC6 inhibition promotes ?-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.
HDAC6 Inhibitors Rescued the Defective Axonal Mitochondrial Movement in Motor Neurons Derived from the Induced Pluripotent Stem Cells of Peripheral Neuropathy Patients with HSPB1 Mutation.
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
HDAC6: A Key Link Between Mitochondria and Development of Peripheral Neuropathy.
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Peritoneal Fibrosis
HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal.
Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis.
Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells.
SAHA SUPPRESSES PERITONEAL FIBROSIS IN MICE.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Peritonitis
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Persistent Infection
Dysfunctional gastric emptying with downregulation of muscle-specific microRNAs in Helicobacter pylori-infected mice.
Reactivation of feline foamy virus from a chronically infected feline renal cell line by trichostatin A.
Pheochromocytoma
Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure.
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway.
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹?F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
phosphatidate phosphatase deficiency
Lipin1 is required for skeletal muscle development by regulating MEF2c and MyoD expression.
phosphoribosylaminoimidazole carboxylase deficiency
PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2.
Pituitary ACTH Hypersecretion
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Pituitary Neoplasms
Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells.
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.
Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75).
Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.
Pleural Diseases
Translational Advances in Pleural Malignancies.
Pneumococcal Infections
Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection.
Pneumonia
Carbon black nanoparticle induces HDAC6-mediated inflammatory responses in 16HBE cells.
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
HDAC5 promotes Mycoplasma pneumoniae-induced inflammation in macrophages through NF-?B activation.
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Histone Deacetylase 2 is Phosphorylated, Ubiquitinated and Degraded by Cigarette Smoke.
Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation.
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Histone Deacetylase 7 Inhibition in A Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.
Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection.
Histone Deacetylase Inhibitor Treatment Attenuates MAP Kinase Pathway Activation and Pulmonary Inflammation Following Hemorrhagic Shock in a Rodent Model.
Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction.
Remote Burn Injury Increases Pulmonary Histone Deacetylase 1 and Reduces Histone Acetylation.
Sirt1 protects against thrombomodulin down-regulation and lung coagulation after particulate matter exposure.
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
Trichostatin A attenuates ventilation-augmented epithelial-mesenchymal transition in mice with bleomycin-induced acute lung injury by suppressing the Akt pathway.
Update on Molecular Mechanisms of Corticosteroid Resistance in Chronic Obstructive Pulmonary Disease.
Polycystic Kidney Diseases
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Downregulation of HDAC1 suppresses media degeneration by inhibiting the migration and phenotypic switch of aortic vascular smooth muscle cells in aortic dissection.
HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
Dopamine receptor antagonists as potential therapeutic agents for ADPKD.
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystic Ovary Syndrome
A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.
Polycythemia
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Polycythemia Vera
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Efficacy of vorinostat in a murine model of polycythemia vera.
Polycythemia vera: the current status of preclinical models and therapeutic targets.
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Polydactyly
Polydactyly in mice lacking HDAC9/HDRP.
Porcine Reproductive and Respiratory Syndrome
Overexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.
Pre-Eclampsia
Dysregulation of HDAC9 represses trophoblast cell migration and invasion through TIMP3 activation in preeclampsia.
HDAC4 Knockdown Induces Preeclampsia Cell Autophagy and Apoptosis by miR-29b.
Histone deacetylase 6 negatively regulated microRNA-199a-5p induces the occurrence of preeclampsia by targeting VEGFA in vitro.
Histone deacetylase inhibition disturbs the balance between ACE and chymase expression in endothelial cells: a potential mechanism of chymase activation in preeclampsia.
Reduced mRNA Expression of RGS2 (Regulator of G Protein Signaling-2) in the Placenta Is Associated With Human Preeclampsia and Sufficient to Cause Features of the Disorder in Mice.
Up-regulation of miR-299 suppressed the invasion and migration of HTR-8/SVneo trophoblast cells partly via targeting HDAC2 in pre-eclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1- pre-B-ALL.
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.
Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-?B and autophagy on panobinostat cytotoxicity.
Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.
CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia.
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia.
Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Hyper-activation of WNT/?-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia.
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Prediabetic State
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Preleukemia
Cloning and characterization of human histone deacetylase 8.
Premature Birth
Prostaglandin dehydrogenase is a target for successful induction of cervical ripening.
Primary Myelofibrosis
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Prion Diseases
Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity.
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
Prognathism
Genetic Factors Involved in Mandibular Prognathism.
Prostatic Hyperplasia
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Prostatic Intraepithelial Neoplasia
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
Prostatic Neoplasms
1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90? chaperone activity against prostate cancer.
A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.
A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL).
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.
A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells.
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Acetylation and phosphorylation of high-mobility group A1 proteins in PC-3 human tumor cells.
Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer.
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity.
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.
Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.
Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells.
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Curcumin is an inhibitor of p300 histone acetylatransferase.
Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells.
Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells.
Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.
Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
Dietary histone deacetylase inhibitors: from cells to mice to man.
Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition.
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-?B and HSP90 in castration resistant prostate cancer.
Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Effect of HDAC9 inhibition on epithelial-mesenchymal transition in CD133+ prostate cancer cell lines.
Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells.
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Epigenetic regulation of androgen receptor gene expression in human prostate cancers.
Epigenetic regulation of androgen receptor signaling in prostate cancer.
Epigenetic Regulation of Phosphatidylinositol 3,4,5-Triphosphate-dependent Rac Exchanger 1 Gene Expression in Prostate Cancer Cells.
Epigenetic therapy in urologic cancers: an update on clinical trials.
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
ETS gene fusions in prostate cancer.
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Expression profile of class I histone deacetylases in human cancer tissues.
Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide.
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.
Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis.
HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9.
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Histone deacetylase 3 indirectly modulates tubulin acetylation.
Histone deacetylase and DNA methyltransferase in human prostate cancer.
Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells.
Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer.
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-?B-dependent autophagy.
Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.
Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells.
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
I?B? mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
IFI16 in human prostate cancer.
Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer.
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Inducible expression of cancer-testis antigens in human prostate cancer.
Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.
Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy.
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361.
Long non?coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11.
Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis.
Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model.
Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2.
MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway.
miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2.
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
MRJF4, a novel histone deacetylase inhibitor, induces p21 mediated autophagy in PC3 prostate cancer cells.
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance Between NF-?B and HDAC1.
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Polyphotosensitizer nanogels for GSH-responsive histone deacetylase inhibitors delivery and enhanced cancer photodynamic therapy.
Posttranscription regulation of prostate cancer growth.
Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype.
Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation.
Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
Retraction: Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation.
Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors.
Signal Therapy of NF1-Deficient Tumor Xenograft in Mice by the Anti-PAK1 Drug FK228.
Smad7 Enhances TGF-?-Induced Transcription of c-Jun and HDAC6 Promoting Invasion of Prostate Cancer Cells.
Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells.
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Targeting MTA1/HIF-1? signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Targeting radiation-induced upstream stimulatory factor-1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer.
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.
The development of differentiation agents for the treatment of prostate cancer.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation.
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
The Immunohistochemical Expression and Potential Prognostic Value of HDAC6, AR in Invasive Breast Cancer.
The novel imprinted carboxypeptidase A4 gene ( CPA4) in the 7q32 imprinting domain.
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression.
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Up-regulation of TIF1? by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-?/Smad signaling pathway.
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells.
Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis.
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
[Ca2+-activated K+ channels as cancer therapeutic targets].
[Epigenetics of prostate cancer]
[Expressions of HDAC1 and HDAC2 in prostate cancer and their clinical implications].
protein-tyrosine-phosphatase deficiency
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
Proteinuria
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction.
Podocyte histone deacetylase activity regulates murine and human glomerular diseases.
Proteostasis Deficiencies
HDAC Inhibitors Rescue Multiple Disease-Causing CFTR Variants.
The extracellular HDAC6 ZnF UBP domain modulates the actin network and post-translational modifications of Tau.
Protozoan Infections
Targeting histone acetylation/deacetylation in parasites: an update (2017-2020).
Pseudohypoparathyroidism
The new bone biology: pathologic, molecular, and clinical correlates.
Pseudorabies
Corrigendum to "Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity" [Mol. Immunol. 136 (2021) 55-64].
Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity.
Psoriasis
Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris.
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.
Histone Deacetylase 1 and Sirtuin 1 Expression in Psoriatic Skin: A Comparison between Guttate and Plaque Psoriasis.
Histone deacetylase inhibitors in psoriasis therapy.
Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis.
Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1.
SIRT1, a Class III histone deacetylase, regulates LPS-induced inflammation in human keratinocytes and mediates the anti-inflammatory effects of hinokitiol.
The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches.
Pulmonary Arterial Hypertension
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic Acid and suberoylanilide hydroxamic Acid.
Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model.
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients.
Altered Histone Deacetylase Activity and iNOS Expression in Cells Isolated from Induced Sputum of COPD Patients Treated with Tiotropium.
Alveolar Macrophages as Orchestrators of COPD.
Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2.
Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence.
Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.
Changes in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trial.
Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways.
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Corticosteroid effects on cell signalling.
Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction.
Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Corticosteroids: the drugs to beat.
Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema.
Curcumin modulates the effect of histone modification on the expression of chemokines by type II alveolar epithelial cells in a rat COPD model.
Curcumin: a natural pan-HDAC inhibitor in cancer.
Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD.
Decreased Histone Deacetylase 2 (HDAC2) in Peripheral Blood Monocytes (PBMCs) of COPD Patients.
Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress.
Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
Defect of adaptation to hypoxia in COPD patients due to reduction of histone deacetylase 7.
Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.
Do epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease?
Downregulated Peroxisome Proliferator-activated Receptor ? (PPAR?) in Lung Epithelial Cells Promotes a PPAR? Agonist-reversible Proinflammatory Phenotype in Chronic Obstructive Pulmonary Disease (COPD).
Effect of Quanzhenyiqitang on apoptosis of alveolar macrophages and expression of histone deacetylase 2 in rats with chronic obstructive pulmonary disease.
Epigenetic mechanisms in respiratory muscle dysfunction of patients with chronic obstructive pulmonary disease.
Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review.
Epigenetic regulation of airway inflammation.
Epigenetics and chromatin remodeling play a role in lung disease.
Epigenetics in asthma and other inflammatory lung diseases.
Erythromycin enhances the anti-inflammatory activity of budesonide in COPD rat model.
Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD.
Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases.
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
Genetic ablation of histone deacetylase 2 leads to lung cellular senescence and lymphoid follicle formation in COPD/emphysema.
HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-?B p65 transcriptional activity.
HDAC2 Suppresses IL17A-Mediated Airway Remodeling in Human and Experimental Modeling of COPD.
HDAC6 Activates ERK in Airway and Pulmonary Vascular Remodeling of COPD.
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Histone Deacetylase 2 is Phosphorylated, Ubiquitinated and Degraded by Cigarette Smoke.
Histone Deacetylase 2 Suppresses Skeletal Muscle Atrophy and Senescence via NF-?B Signaling Pathway in Cigarette Smoke-Induced Mice with Emphysema.
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-{kappa}B suppression.
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction.
Histone deacetylase activity and COPD.
Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD.
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease.
Histone deacetylase-2 and airway disease.
Histone deacetylation: an important mechanism in inflammatory lung diseases.
Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulmonary gene expression.
How corticosteroids control inflammation: Quintiles Prize Lecture 2005.
IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-? expression in monocytes: Implications for chronic obstructive pulmonary disease.
IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: Effect of Tiotropium.
Impact of protein acetylation in inflammatory lung diseases.
Inflammation 2005 - Seventh World Congress. Respiratory inflammation.
Inhibition of histone deacetylase causes emphysema.
Jinwei Tang modulates HDAC2 expression in a rat model of COPD.
Long-term effects of acupuncture treatment on airway smooth muscle in a rat model of smoke-induced chronic obstructive pulmonary disease.
Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes.
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD.
Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin.
Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2.
Over-expression of prothymosin-? antagonizes TGF? signalling to promote the development of emphysema.
Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Patterns of Inflammatory Responses in Large and Small Airways in Smokers with and without Chronic Obstructive Pulmonary Disease.
Quadriceps muscle weakness and atrophy are associated with a differential Epigenetic Profile in Advanced COPD.
Reduced HDAC2 in skeletal muscle of COPD patients.
Reduced histone deacetylase in COPD: clinical implications.
Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease.
Retraction: Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.
Role of HDAC2 in the Pathophysiology of COPD.
Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD.
Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.
Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study.
Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production.
Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease.
The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD.
The role of histone deacetylases in asthma and allergic diseases.
The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
Theophylline.
Transcription factors in airway diseases.
Treating patients with respiratory disease who smoke.
Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD.
USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation.
[New development of pharmacotherapy--physiological basis and future possibility]
[Relationship between expression of HDAC2, IL-8, TNF-? in lung adenocarcinoma tissues and smoking].
[The pathogenesis of chronic obstructive pulmonary disease, steroid resistance and the place of theophylline in the treatment]
Pulmonary Edema
Selective HDAC6 inhibition prevents TNF-?-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
Pulmonary Fibrosis
Effects of dynamic changes in histone acetylation and deacetylase activity on pulmonary fibrosis.
HDAC8 inhibition ameliorates pulmonary fibrosis.
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo.
Inhibiting HDAC3 (Histone Deacetylase 3) Aberration and the Resultant Nrf2 (Nuclear Factor Erythroid-Derived 2-Related Factor-2) Repression Mitigates Pulmonary Fibrosis.
Prevention of Pulmonary Fibrosis via Trichostatin A (TSA) in Bleomycin Induced Rats.
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-? signalling in COVID-19 survivors.
TGF-?1 Stimulates HDAC4 Nucleus to Cytoplasm Translocation and NADPH Oxidase4-Derived Reactive Oxygen Species in Normal Human Lung Fibroblasts.
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Tubastatin ameliorates pulmonary fibrosis by targeting the TGF?-PI3K-Akt pathway.
[Effect and mechanism of inhibition of lipopolysaccharide-induced pulmonary fibrosis by butyric acid].
[Effect of histone deacetylase 2 and 4 activity on connective tissue disease associated pulmonary fibrosis in mice].
Rabies
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Radiculopathy
Immunohistochemical analysis of histone H3 acetylation in the trigeminal root entry zone in an animal model of trigeminal neuralgia.
Rectal Neoplasms
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Renal Insufficiency, Chronic
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.
Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis.
Treatment of chronic kidney diseases with histone deacetylase inhibitors.
Reperfusion Injury
Beneficial effects of histone deacetylase inhibition with severe hemorrhage and ischemia-reperfusion injury.
Cross-Talk Between Sirtuin 1 and High-Mobility Box 1 in Steatotic Liver Graft Preservation.
HDAC1 localizes to the mitochondria of cardiac myocytes and contributes to early cardiac reperfusion injury.
HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injury.
HDAC6 Inhibition Protects against OGDR-Induced Golgi Fragmentation and Apoptosis.
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity.
Histone deacetylase HDAC4 participates in the pathological process of myocardial ischemia-reperfusion injury via MEKK1/JNK pathway by binding to miR-206.
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy.
Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice.
Inhibited HDAC3 or Elevated MicroRNA-494-3p Plays a Protective Role in Myocardial Ischemia-Reperfusion Injury via Suppression of BRD4.
Inhibited histone deacetylase 3 ameliorates myocardial ischemia-reperfusion injury in a rat model by elevating microRNA-19a-3p and reducing cyclin-dependent kinase 2.
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Inhibition of histone deacetylase by butyrate protects rat liver from ischemic reperfusion injury.
Interference with long noncoding RNA SNHG3 alleviates cerebral ischemia-reperfusion injury by inhibiting microglial activation.
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury.
Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) Contributes to the Neuroprotective Effects of Histone Deacetylase Inhibitors In Retinal Ischemia-Reperfusion Injury.
Respiratory Distress Syndrome
Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review).
Respiratory Hypersensitivity
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
Retinal Degeneration
A Brain-Derived Neurotrophic Factor Mimetic Is Sufficient to Restore Cone Photoreceptor Visual Function in an Inherited Blindness Model.
Autophagy Induction by HDAC Inhibitors Is Unlikely to be the Mechanism of Efficacy in Prevention of Retinal Degeneration Caused by P23H Rhodopsin.
HDAC4 regulates neuronal survival in normal and diseased retinas.
Histone Deacetylase: Therapeutic Targets in Retinal Degeneration.
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities.
Retinitis
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
Retinitis Pigmentosa
A short N-terminal domain of HDAC4 preserves photoreceptors and restores visual function in retinitis pigmentosa.
Histone Deacetylase: Therapeutic Targets in Retinal Degeneration.
Inhibition of Epigenetic Modifiers LSD1 and HDAC1 Blocks Rod Photoreceptor Death in Mouse Models of Retinitis Pigmentosa.
Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic X. laevis Models of Retinitis Pigmentosa.
SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa.
Retinoblastoma
3-Methylcholanthrene, an AhR Agonist, Caused Cell-Cycle Arrest by Histone Deacetylation through a RhoA-Dependent Recruitment of HDAC1 and pRb2 to E2F1 Complex.
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro.
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma.
E2F-1 regulates the expression of a subset of target genes during skeletal myoblast hypertrophy.
Epigenetic control of trefoil factor family (TFF) peptide expression in human retinoblastoma cell lines.
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.
Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway.
Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription.
Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells.
Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
HPV E7 viral oncoprotein disrupts transcriptional regulation of L1Md retrotransposon.
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Knockdown of long non?coding RNA HCP5 suppresses the malignant behavior of retinoblastoma by sponging miR?3619?5p to target HDAC9.
Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism.
MicroRNA-101-3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9.
MicroRNA?936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway.
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Phosphorylation of Drosophila Brahma on CDK-phosphorylation sites is important for cell cycle regulation and differentiation.
pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus.
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells.
RbAp48 belongs to the histone deacetylase complex that associates with the retinoblastoma protein.
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression.
Retinoblastoma binding protein 4 represses HIV-1 long terminal repeat-mediated transcription by recruiting NR2F1 and histone deacetylase.
Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription.
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
Retinoblastoma protein recruits histone deacetylase to repress transcription.
Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
Retinoblastoma protein transcriptional repression through histone deacetylation of a single nucleosome.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease.
The double dealing of cyclin D1.
The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein.
The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity.
Transrepressive function of TLX requires the histone demethylase LSD1.
UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
[Histone deacetylase and retinoblastoma protein]
Rett Syndrome
HDAC6 Brain Mapping with [
Rhabdoid Tumor
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumour Growth Arrest and Multi-lineage Differentiation of Malignant Rhabdoid Tumours.
Suberoylanilide hydroxamic acid affects ?H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA.
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.
Rhabdomyolysis
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Rhabdomyosarcoma
Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma.
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-propylpentanamide, a Valproic Acid Aryl Derivative with activity against HeLa cells.
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma.
HDAC8 regulates canonical Wnt pathway to promote differentiation in skeletal muscles.
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines.
NIK is required for NF-?B-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways.
OBP?801, a novel histone deacetylase inhibitor, induces M?phase arrest and apoptosis in rhabdomyosarcoma cells.
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.
Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation.
The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
[Erratum] OBP?801, a novel histone deacetylase inhibitor, induces M?phase arrest and apoptosis in rhabdomyosarcoma cells.
Rhabdomyosarcoma, Alveolar
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Rhinitis
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.
Rhinitis, Allergic
Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis.
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
HDAC inhibitor sodium butyrate prevents allergic rhinitis and alters lncRNA and mRNA expression profiles in the nasal mucosa of mice.
Histone deacetylase 11 inhibits interleukin 10 in B cells of subjects with allergic rhinitis.
Regulation of Trek1 expression in nasal mucosa with allergic rhinitis by specific immunotherapy.
RGFP966, a selective HDAC3 inhibitor, ameliorates allergic and inflammatory responses in an OVA-induced allergic rhinitis mouse model.
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
ring-type e3 ubiquitin transferase deficiency
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
RNA Virus Infections
HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I.
Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6.
Sarcoma
A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.
Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
Clinical efficacy of vorinostat in a patient with leiomyosarcoma.
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma.
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
Correction: Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma.
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Discovery research to clinical trial: a ten year journey.
Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Histone deacetylase 1 and 2 in mesenchymal tumors.
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.
Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
p53-Mediated Molecular Control of Autophagy in Tumor Cells.
Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.
Searching for molecular targets in sarcoma.
Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Sarcoma, Avian
Characterization of the Phosphoproteome in SLE Patients.
Sarcoma, Clear Cell
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Sarcoma, Endometrial Stromal
Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Sarcoma, Ewing
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells.
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sarcoma, Synovial
Death by HDAC inhibition in synovial sarcoma cells.
Discovery research to clinical trial: a ten year journey.
EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
HDAC2 links ubiquitination to tumor suppression in synovial sarcoma.
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.
SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex.
Schistosomiasis
Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni.
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
Scleroderma, Systemic
Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
Histone deacetylase SIRT1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting TGF-ß signaling.
Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma.
Novel treatment approaches to fibrosis in scleroderma.
Seizures
An epigenetic intervention interacts with genetic strain differences to modulate the stress-induced reduction of flurazepam's antiseizure efficacy in the mouse.
Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex.
Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal none development.
Optimizing antiepileptic drug treatment in tumoral epilepsy.
Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex.
Seizure control by ketogenic diet-associated medium chain fatty acids.
The ketogenic diet increases Neuregulin 1 expression via elevating histone acetylation and its anti-seizure effect requires ErbB4 kinase activity.
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity.
Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons.
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival.
[Regulatory mechanism of MS275 on the p38 MAPK signaling pathway in rats with convulsion in the developmental stage].
Seminoma
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Sepsis
Citrullinated histone H3: a novel target for the treatment of sepsis.
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
Degradation of histone deacetylase 4 via the TLR4/JAK/STAT1 signaling pathway promotes the acetylation of high mobility group box 1 (HMGB1) in lipopolysaccharide-activated macrophages.
Effects of sodium butyrate on aversive memory in rats submitted to sepsis.
HDAC5 promotes intestinal sepsis via the Ghrelin/E2F1/NF-?B axis.
HDAC6 promotes sepsis development by impairing PHB1-mediated mitochondrial respiratory chain function.
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Histone deacetylase 2 is essential for LPS-induced inflammatory responses in macrophages.
Histone Deacetylase 6 Inhibition Improves Survival in a Swine Model of Lethal Hemorrhage, Polytrauma and Bacteremia.
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Histone deacetylase III as a potential therapeutic target for the treatment of lethal sepsis.
Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis.
Histone Deacetylase Inhibitors Attenuate Acute Lung Injury During Cecal Ligation and Puncture-Induced Polymicrobial Sepsis.
Histone Deacetylase Inhibitors: A Novel Strategy In Trauma And Sepsis.
Histone deactylase gene expression profiles are associated with outcomes in blunt trauma patients.
Host gene expression analysis in Sri Lankan melioidosis patients.
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2.
Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis.
Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review).
Selective histone deacetylase 6 inhibition prolongs survival in a lethal two-hit model.
Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle.
Sirt1 restrains lung inflammasome activation in a murine model of sepsis.
The Novel HDAC8 Inhibitor WK2-16 Attenuates Lipopolysaccharide-Activated Matrix Metalloproteinase-9 Expression in Human Monocytic Cells and Improves Hypercytokinemia In Vivo.
Sepsis-Associated Encephalopathy
Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy.
Severe Acute Respiratory Syndrome
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Shock, Septic
Bioinformatic analysis of pivotal genes associated with septic shock.
Creating a prosurvival phenotype through a histone deacetylase inhibitor in a lethal two-hit model.
HDAC6 Mediates Macrophage iNOS Expression and Excessive Nitric Oxide Production in the Blood During Endotoxemia.
Histone deacetylase 2 is essential for LPS-induced inflammatory responses in macrophages.
Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock.
Modulation of Acetylation: Creating a Pro-survival and Anti-Inflammatory Phenotype in Lethal Hemorrhagic and Septic Shock.
Selective inhibition of histone deacetylase 6 promotes survival in a rat model of hemorrhagic shock.
Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock.
Sialadenitis
Epigallocatechin gallate stimulates the neuroreactive salivary secretomotor system in autoimmune sialadenitis of MRL-Fas(lpr) mice via activation of cAMP-dependent protein kinase A and inactivation of nuclear factor ?B.
Sick Sinus Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Skin Diseases
Histone Deacetylase 1 Reduces Lipogenesis by Suppressing SREBP1 Transcription in Human Sebocyte Cell Line SZ95.
Regulation of the Glycerol Transporter, Aquaporin-3, by Histone Deacetylase-3 and p53 in Keratinocytes.
Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1.
Sleep Deprivation
Role of epigenetic regulatory enzymes in animal models of mania induced by amphetamine and paradoxical sleep deprivation.
Small Cell Lung Carcinoma
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Smear Layer
Release of bio-active dentine extracellular matrix components by histone deacetylase inhibitors (HDACi).
Smith-Magenis Syndrome
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Spasms, Infantile
Embryonic forebrain transcriptome of mice with polyalanine expansion mutations in the ARX homeobox gene.
sphingosine kinase deficiency
SPHK1 deficiency protects mice from acetaminophen-induced ER stress and mitochondrial permeability transition.
Spinal Cord Injuries
Age-dependent autophagy induction after injury promotes axon regeneration by limiting NOTCH.
Author Correction: HDAC3 inhibition ameliorates spinal cord injury by immunomodulation.
Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury.
Diversified transcriptional responses of myeloid and glial cells in spinal cord injury shaped by HDAC3 activity.
Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science.
HDAC3 inhibition ameliorates spinal cord injury by immunomodulation.
HDAC3 Inhibition Promotes Alternative Activation of Macrophages but Does Not Affect Functional Recovery after Spinal Cord Injury.
HDAC6 Regulates the Chaperone-Mediated Autophagy to Prevent Oxidative Damage in Injured Neurons after Experimental Spinal Cord Injury.
HDAC8 Inhibition Reduces Lesional Iba-1+ Cell Infiltration after Spinal Cord Injury without Effects on Functional Recovery.
Histone deacetylase 6 inhibition restores autophagic flux to promote functional recovery after spinal cord injury.
Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.
Ketogenic Metabolism Inhibits Histone Deacetylase (HDAC) and Reduces Oxidative Stress After Spinal Cord Injury in Rats.
miR-27a promotion resulting from silencing of HDAC3 facilitates the recovery of spinal cord injury by inhibiting PAK6 expression in rats.
PP4-dependent HDAC3 dephosphorylation discriminates between axonal regeneration and regenerative failure.
Systemic administration of valproic acid stimulates overexpression of microtubule-associated protein 2 in the spinal cord injury model to promote neurite outgrowth.
Valproic acid attenuates microgliosis in injured spinal cord and purinergic P2X4 receptor expression in activated microglia.
Valproic acid improves outcome after rodent spinal cord injury: Potential roles of histone deacetylase inhibition.
Spinocerebellar Ataxias
Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach.
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Spondylitis, Ankylosing
Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1? expression in peripheral blood mononuclear cells.
Squamous Cell Carcinoma of Head and Neck
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Azacitidine, as a DNMT inhibitor decreases hTERT gene expression and telomerase activity more effective compared with HDAC inhibitor in human Head and neck squamous cell carcinoma cell lines.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.
Effect of resveratrol on cancer progression through the REG ? expression pathway in head and neck cancer cells.
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63?mediated tight junction molecules and p21?mediated growth arrest.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma.
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Role of anoctamins in cancer and apoptosis.
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
ST Elevation Myocardial Infarction
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Starvation
A hormone-dependent module regulating energy balance.
A metabolic throttle regulates the epigenetic state of rDNA.
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4).
AMPK-Dependent Phosphorylation of HDAC8 Triggers PGM1 Expression to Promote Lung Cancer Cell Survival under Glucose Starvation.
Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
HDAC6 regulates lipid droplet turnover in response to nutrient deprivation via p62-mediated selective autophagy.
Large-scale analysis of mRNA translation states during sucrose starvation in arabidopsis cells identifies cell proliferation and chromatin structure as targets of translational control.
LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation.
MFN1 deacetylation activates adaptive mitochondrial fusion and protects metabolically challenged mitochondria.
MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4.
Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth.
Passport control for foreign integrated DNAs: An unexpected checkpoint by class II HDAC4 revealed by amino acid starvation.
Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome.
Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms.
The Histone Deacetylase Gene Rpd3 Is Required for Starvation Stress Resistance.
The histone deacetylase HDA19 controls root cell elongation and modulates a subset of phosphate starvation responses in Arabidopsis.
Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility.
Status Epilepticus
Expression of class II HDACs in two mouse models of temporal lobe epilepsy.
Stomach Neoplasms
4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
4-phenylbutyric acid promotes migration of gastric cancer cells by histone deacetylase inhibition-mediated IL-8 upregulation.
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity.
Association of NDRG1 Gene Promoter Methylation with Reduced NDRG1 Expression in Gastric Cancer Cells and Tissue Specimens.
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer.
CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner.
Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs.
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1.
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma.
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-?B-dependent and Notch-independent mechanism.
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Expression of the clustered NeuAc?2-3Gal? O-glycan determines the cell differentiation state of the cells.
Expression profile of class I histone deacetylases in human cancer tissues.
Expression profile of histone deacetylase 1 in gastric cancer tissues.
HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
High-throughput screening of genome fragments bound to differentially acetylated histones.
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer.
Histone deacetylase 1 expression in gastric cancer.
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.
Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression.
Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell.
Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Inhibited HDAC3 promotes microRNA-376c-3p to suppress malignant phenotypes of gastric cancer cells by reducing WNT2b.
Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.
Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78.
LncRNA HRCEG, regulated by HDAC1, inhibits cells proliferation and epithelial-mesenchymal-transition in gastric cancer.
Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation [Retraction].
Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation.
LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer.
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
MiR-330-3p inhibits gastric cancer progression through targeting MSI1.
MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway.
miR-543 promotes gastric cancer cell proliferation by targeting SIRT1.
Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial.
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.
Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer.
RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.
Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.
RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs.
SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer.
Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a.
Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.
Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells.
Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
[Effect of siRNA targeting HDAC1 gene on proliferation, apoptosis, histone acetylation, and histone metylation in gastric cancer cells in vitro].
[Effects of sodium butyrate on proliferation of human gastric cancer cells and expression of p16 gene]
[The progress study of HDAC2 function in diseases].
[The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines]
Stomatitis
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Stroke
?lass II histone deacetylases in the post-stroke recovery period-expression, cellular, and subcellular localization-promising targets for neuroprotection.
APOL1, CDKN2A/CDKN2B, and HDAC9 polymorphisms and small vessel ischemic stroke.
Association between Histone Deacetylase 9 Gene Polymorphism and Stroke in Chinese Han Population.
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke.
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke.
Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke.
Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke.
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Delayed Treatment with Histone Deacetylase Inhibitors Promotes Stroke Recovery.
Early Histone Deacetylase Inhibition Mitigates Ischemia/Reperfusion Brain Injury by Reducing Microglia Activation and Modulating Their Phenotype.
Emerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications.
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Expression of Class I Histone Deacetylases in Ipsilateral and Contralateral Hemispheres after the Focal Photothrombotic Infarction in the Mouse Brain.
Expression of Histone Deacetylases HDAC1 and HDAC2 and Their Role in Apoptosis in the Penumbra Induced by Photothrombotic Stroke.
Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.
GWAS-linked hot loci predict short-term functional outcome and recurrence of ischemic stroke in Chinese population.
HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis.
HDAC2 (Histone deacetylase 2): A critical factor in environmental enrichment-mediated stroke recovery.
HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage.
HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury.
HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke.
HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury.
HDAC9 gene is associated with stroke risk in a Chinese population.
HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke.
HDAC9 Polymorphisms Predict Susceptibility, Severity, and Short-Term Outcome of Large Artery Atherosclerotic Stroke in Chinese Population.
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
HDAC9, TWIST1 and FERD3L gene expression in asymptomatic stable and unstable carotid plaques.
Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development.
Histone deacetylase expression in white matter oligodendrocytes after stroke.
Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage.
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.
Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke.
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Inhibition of Histone Deacetylase 3 (HDAC3) Mediates Ischemic Preconditioning and Protects Cortical Neurons against Ischemia in Rats.
Inhibition of histone deacetylase 3 by MiR-494 alleviates neuronal loss and improves neurological recovery in experimental stroke.
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
MS-275, a Class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
Novel Protective Effects of Histone Deacetylase Inhibition on Stroke and White Matter Ischemic Injury.
Nuclear translocation of histone deacetylase 4 induces neuronal death in stroke.
OCT4B-190 protects against ischemic stroke by modulating GSK-3?/HDAC6.
Opening a New Time Window for Treatment of Stroke by Targeting HDAC2.
Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of ?-phenyl tropolone, HPOB, and sodium valproate.
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Role of Phosphorylated HDAC4 in Stroke-Induced Angiogenesis.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia.
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Stroke Induces Nuclear Shuttling of Histone Deacetylase 4.
The association between HDAC9 gene polymorphisms and stroke risk in the Chinese population: A meta-analysis.
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke.
The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome.
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
The Neuroprotective Effect of the HDAC2/3 Inhibitor MI192 on the Penumbra After Photothrombotic Stroke in the Mouse Brain.
The relationship between the prognosis of children with acute arterial stroke and polymorphisms of CDKN2B, HDAC9, NINJ2, NAA25 genes.
Therapeutic Application of Histone Deacetylase Inhibitors for Stroke.
Valproic acid increases white matter repair and neurogenesis after stroke.
Subarachnoid Hemorrhage
Astrocytic histone deacetylase 2 facilitates delayed depression and memory impairment after subarachnoid hemorrhage by negatively regulating glutamate transporter-1.
Enhancement of Autophagy by Histone Deacetylase Inhibitor Trichostatin A Ameliorates Neuronal Apoptosis After Subarachnoid Hemorrhage in Rats.
Inhibition of HDAC4 Attenuated JNK/c-Jun-Dependent Neuronal Apoptosis and Early Brain Injury Following Subarachnoid Hemorrhage by Transcriptionally Suppressing MKK7.
Superinfection
Differences in Activation of HIV-1 Replication by Superinfection With HIV-1 and HIV-2 in U1 Cells.
Sweet Syndrome
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Synucleinopathies
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Tauopathies
A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline.
HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.
Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
TDP-43 Proteinopathies
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
Teratocarcinoma
Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A.
The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells.
Teratoma
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
HDAC1, a novel marker for benign teratomas.
Teratoma Growth Retardation by HDACi Treatment of the Tumor Embryonal Source.
Testicular Neoplasms
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.
Tetralogy of Fallot
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Thalassemia
Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia.
Thanatophoric Dysplasia
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Thrombocythemia, Essential
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Thrombocytopenia
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor.
Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.
Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia.
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Thrombosis
HDAC6 controls the kinetics of platelet activation.
Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk.
Synergistic Expression of Histone Deacetylase 9 and Matrix Metalloproteinase 12 in M4 Macrophages in Advanced Carotid Plaques.
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Thymoma
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis.
Thyroid Cancer, Papillary
Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.
Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.
MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAFV600E: An In Vitro Study.
Thyroid Carcinoma, Anaplastic
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer.
Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization.
HISTONE DEACETYLASE INHIBITION AFFECTS SODIUM IODIDE SYMPORTER (NIS) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.
Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells.
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.
Thyroid Neoplasms
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Epigenetics of thyroid cancer and novel therapeutic targets.
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC).
Expression and Biologic Significance of Adiponectin Receptors in Papillary Thyroid Carcinoma.
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells.
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.
Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
Inhibition of Growth in Medullary Thyroid Cancer Cells with Histone Deacetylase Inhibitors and Lithium Chloride.
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells.
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
New molecular targeted therapies in thyroid cancer.
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid.
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Targeting histone deacetylase in thyroid cancer.
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.
Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists.
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
Valproic acid downregulates NF-?B p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells.
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Tics
Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Tongue Neoplasms
Alterations of 63 hub genes during lingual carcinogenesis in C57BL/6J mice.
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Toxoplasmosis
An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes.
Histone deacetylase SIR2 in Toxoplasma gondii modulates functions of murine macrophages in vitro and protects mice against acute toxoplasmosis in vivo.
Tracheal Stenosis
Expression of histone deacetylase 2 in tracheal stenosis models and its relationship with tracheal granulation tissue proliferation.
Nintedanib ameliorates tracheal stenosis by activating HDAC2 and suppressing IL-8 and VEGF in rabbit.
Trauma, Nervous System
Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries.
Injury-induced HDAC5 nuclear export is essential for axon regeneration.
Triple Negative Breast Neoplasms
A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer.
A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase.
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Cytotoxic Activity of the Histone Deacetylase 3-Selective Inhibitor Pojamide on MDA-MB-231 Triple-Negative Breast Cancer Cells.
Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer.
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Reactivation of Estrogen Receptor ? by Vorinostat Sensitizes Mesenchymal-Like Triple-Negative Breast Cancer to Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor.
SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Targeting triple negative breast cancer with histone deacetylase inhibitors.
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker.
Trypanosomiasis, African
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
Tuberculosis
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice.
Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.
Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells.
Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages.
Transcription Repressor Protein ZBTB25 Associates with HDAC1-Sin3a Complex in Mycobacterium tuberculosis-Infected Macrophages, and Its Inhibition Clears Pathogen by Autophagy.
Tuberculosis, Pulmonary
Histone H3K14 hypoacetylation and H3K27 hypermethylation along with HDAC1 up-regulation and KDM6B down-regulation are associated with active pulmonary tuberculosis disease.
Tuberous Sclerosis
Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.
Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex.
Urea Cycle Disorders, Inborn
Acute effects of phenylbutyrate on glutamine, branched-chain amino acid and protein metabolism in skeletal muscles of rats.
Clinical and experimental applications of sodium phenylbutyrate.
Uremia
DNA methylation profiling reveals differences in the three human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation.
Ureteral Obstruction
Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-? and EGFR signaling pathways in obstructive nephropathy.
Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.
Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis.
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling.
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction.
Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.
Urinary Bladder Neoplasms
A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Apoptosis of bladder cancer by sodium butyrate and cisplatin.
Cancer-testis antigen expression in bladder cancer.
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.
Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer.
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.
FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines.
HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest.
Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Histone Deacetylase Inhibitors and Bladder Cancer.
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer.
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Induction of caspase mediated apoptosis and down-regulation of nuclear factor-?B and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction.
Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.
MAGE-A9 mRNA and protein expression in bladder cancer.
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.
miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.
p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation.
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Potential of histone deacetylase inhibitors for bladder cancer treatment.
Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity.
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential.
Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction.
Simvastatin-romidepsin combination kills bladder cancer cells synergistically.
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer.
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells.
Valproic Acid Decreases Urothelial Cancer Cell Proliferation and Induces Thrombospondin-1 Expression.
Urinary Retention
Histone Deacetylase 6 Regulates Bladder Architecture and Host Susceptibility to Uropathogenic Escherichia coli.
Urogenital Neoplasms
Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells.
Urologic Neoplasms
Manipulating the epigenome for the treatment of urological malignancies.
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Uterine Cervical Neoplasms
Acetylation of intragenic histones on HPV16 correlates with enhanced HPV16 gene expression.
Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells.
CDH1 and SNAI1 are regulated by E7 from human papillomavirus types 16 and 18.
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Cytotoxic effects of peanut phenolics possessing histone deacetylase inhibitory activity in breast and cervical cancer cell lines.
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Effect of downregulated histone deacetylase 2 expression on cell proliferation and cell cycle in cervical cancer.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Epigenetics of cervical cancer. An overview and therapeutic perspectives.
Erratum to Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4- phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract.
Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis.
HDAC1/DNMT3A-Containing Complex Is Associated with Suppression of Oct4 in Cervical Cancer Cells.
HDAC6 suppresses microRNA-199a transcription and augments HPV-positive cervical cancer progression through Wnt5a upregulation.
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.
Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.
Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus.
Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.
HPV16 activates the promoter of Oct4 gene by sequestering HDAC1 from repressor complex to target it to proteasomal degradation.
Integrated Analysis of ceRNA Regulatory Network Associated With Tumor Stage in Cervical Cancer.
Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway.
Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors.
N-(2'-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Inhibits HDAC1 and Increases the Translocation of HMGB1 Levels in Human Cervical Cancer Cells.
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
PKCepsilon is essential for gelsolin expression by histone deacetylase inhibitor apicidin in human cervix cancer cells.
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.
Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor.
Sevoflurane Enhances Proliferation, Metastatic Potential of Cervical Cancer Cells via the Histone Deacetylase 6 Modulation In Vitro.
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.
Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer.
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer.
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
Valproic acid exhibits different cell growth arrest effect in three HPV-positive/negative cervical cancer cells and possibly via inducing Notch1 cleavage and E6 downregulation.
Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1?/VEGF signals.
Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway.
Uveitis
Vorinostat Modulates the Imbalance of T Cell Subsets, Suppresses Macrophage Activity, and Ameliorates Experimental Autoimmune Uveoretinitis.
Vaccinia
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Varicella Zoster Virus Infection
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Vascular Calcification
Deacetylation of cGAS by HDAC1 regulates vascular calcification by promoting autophagy.
HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype.
MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification.
New Aspects of Vascular Calcification: Histone Deacetylases and Beyond.
Salt-inducible kinase induces cytoplasmic histone deacetylase 4 to promote vascular calcification.
The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells.
Trichostatin A, an HDAC Class I/II Inhibitor, Promotes Pi-Induced Vascular Calcification Via Up-Regulation of the Expression of Alkaline Phosphatase.
Vascular Diseases
Cross-talk between SIRT1 and p66Shc in vascular diseases.
HDAC4 regulates vascular inflammation via activation of autophagy.
HDAC9 complex inhibition improves smooth muscle-dependent stenotic vascular disease.
Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases.
SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication.
Splicing of Histone Deacetylase 7 Modulates Smooth Muscle Cell Proliferation and Neointima Formation Through Nuclear {beta}-Catenin Translocation.
Vascular System Injuries
Angiogenic Factor With G Patch and FHA Domains 1 Is a Novel Regulator of Vascular Injury.
HDAC6 inhibition prevents TNF-?-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.
Vasculitis
Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis.
Ventilator-Induced Lung Injury
Histone deacetylase inhibitors trichostatin A and suberoylanilide hydroxamic acid attenuate ventilator-induced lung injury.
Ventricular Dysfunction, Left
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Vesicular Stomatitis
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-?B-dependent autophagy.
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.
Viremia
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.
Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
Virus Diseases
A novel class of anthraquinone-based HDAC6 inhibitors.
ATXN3 Positively Regulates Type I IFN Antiviral Response by Deubiquitinating and Stabilizing HDAC3.
Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes.
Cellular defence or viral assist: the dilemma of HDAC6.
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Corrigendum to "Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity" [Mol. Immunol. 136 (2021) 55-64].
Diverse roles of HDAC6 in viral infection: Implications for antiviral therapy.
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.
HDAC8: a multifaceted target for therapeutic interventions.
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection.
In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-X(L).
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Influenza A virus-induced caspase-3 cleaves the histone deacetylase 6 in infected epithelial cells.
Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity.
Overexpression of Hdac6 enhances resistance to virus infection in embryonic stem cells and in mice.
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and ?-catenin.
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Small RNA Profiling of Influenza A Virus-Infected Cells Identifies miR-449b as a Regulator of Histone Deacetylase 1 and Interferon Beta.
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFN? generation.
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Trichostatin-A enhances adaptive immune responses to DNA vaccination.
Virus-induced differential expression of nuclear receptors and coregulators in dendritic cells: implication to interferon production.
Waldenstrom Macroglobulinemia
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia.
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia.
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
Warts
Genome-wide identification of methylated CpG sites in nongenital cutaneous warts.
West Nile Fever
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Williams Syndrome
A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development.
Wilms Tumor
Gene Expression Profile and Functional Analysis of Alzheimer's Disease.
Histone deacetylase 5 promotes Wilms' tumor cell proliferation through the upregulation of c-Met.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Wiskott-Aldrich Syndrome
Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.